

45th Annual Congress of the Canadian Neurological Sciences Federation



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA




June 8-11 juin, 2010

Ministère du tourisme du Québec / Bourdeau, Jacques

45e congrès annuel de la
Fédération des sciences
neurologiques du
Canada

final
program

programme
final



45th Annual Congress of the Canadian Neurological Sciences Federation: Epilepsy Industry Co-developed Symposium

Wednesday, June 9, 2010

12:00 pm – 1:30 pm

Québec City, Québec

The Treatment of Epilepsy: What should we expect?

Agenda

Introduction and welcome

Frederick Andermann, O.C., M.D., F.R.C.P.(C)

Professor of Neurology and Pediatrics,
McGill University

Director, Epilepsy Service,
Montreal Neurological Hospital & Institute
Montreal, Québec

Diagnostic imaging in epilepsy

Andrea Bernasconi, M.D.

Associate Professor of Neurology
Montreal Neurological Institute
Montreal, Québec

New therapies in the treatment of epilepsy

Imad Najm, M.D.

Neurological Institute
Director, Epilepsy Center
Cleveland, Ohio

Epilepsy management in the pediatric population

Mary Connolly, M.B., F.R.C.P.(C)

Clinical Professor of Pediatrics (Neurology),
BC Children's Hospital and UBC
Vancouver, British Columbia

Panel discussion

Lunch will be served



Canadian
Neurological Society



Société
canadienne de neurologie

This activity is an Accredited Group Learning Activity (Section 1)
as defined by the Maintenance of Certification activity of
The Royal College of Physicians and Surgeons of Canada
and approved by the Canadian Neurological Society.
This activity is accredited for 1.5 MOC hours.



THE EPILEPSY COMPANY™

WELCOME MESSAGE

Dear Colleagues,

Welcome to the 45th Congress of the Canadian Neurological Sciences Federation. Congress educational content is now more than ever a reflection of what delegates and CNSF Members have indicated as their Continuing Professional Development needs as determined through our various evaluations.

Some examples of features or topics that have been implemented in direct response to feedback from participants include:

1. The Canadian Stroke Network Congress will immediately precede the CNSF Congress from June 6-8, 2010.
2. Topic specific review sessions designed for residents, as well as for non-residents with an interest in upgrading knowledge on that topic. The topics in 2010 are epilepsy and neurovascular surgery. New topics will be addressed annually thereafter.
3. The Neuromuscular Diseases and Headache Courses return to the Program, along with the Neuro-oncology Course, which returns for the first time since 2006.
4. Abstract submissions were again very high so expect to see quality Platform and Digital Mini-poster presentations, in an ever improving format.
5. Dr. James Orbinski is joining us this year as the Distinguished Guest Lecturer.

During this Congress there will be opportunities for you to:

1. Network with colleagues, mentors and friends.
2. Rejuvenate your practice with additional knowledge and skill.
3. Stimulate your thinking.
4. Earn Section 1 MOC Credits.

Please tell us how we are doing by completing the Session Specific Evaluation Forms and the Overall Congress Evaluation, available on-line and in your registration gift. It is important that you provide us this feedback so we can continue to improve and better meet your professional development needs.

Yours truly,



George Elleker
President, CNSF



Michael Hill
Chair, Scientific Program Committee

Please visit the following web sites for further information on the Congress and the Province of Quebec.

www.cnsfederation.org

www.bonjourquebec.com

CNSF Executive Committee

The Executive Committee oversees the affairs of the organization, making decisions on behalf of the Board between full board meetings and serves as a liaison between the Board and the Chief Executive Officer. The CNSF President, two Vice-Presidents, and Chief Executive Officer (non-voting) serve on the Executive Committee.

George Elleker, CNSF President

Garth Bray, CNSF Vice-President

Derek Fewer, CNSF Vice-President

Dan Morin, CNSF Chief Executive Officer

Scientific Program and Professional Development Committees

The Scientific Program and Professional Development Committees are responsible for planning all aspects of the annual CNSF Congress, which is an accredited learning activity approved for Section I credits as defined by the Royal College of Physicians and Surgeons of Canada.

The committees oversee and coordinate: the Congress's educational courses, industry co-developed symposia and workshops; abstract adjudication; program structure; short and long-term objectives and curricula.

Dr. Michael Hill (Chair, SPC)

**Dr. Robert Loch Macdonald
(Vice Chair, SPC)**

Dr. Colin Chalk (Chair, PDC)

Dr. Ron Pokrupa (Vice Chair, PDC)

Dr. Cecil Hahn (SPC)

Dr. Seyed Mirsattari (SPC)

Dr. Shobhan Vachhrajani (SPC, PDC)

Dr. George Elleker (SPC, PDC)

Dr. Jeanne Teitelbaum (SPC)

Dr. Derek Fewer (SPC)

Dr. Chris White (SPC)

Dr. Trevor Steve (SPC, PDC)

Dr. Eric Massicotte (SPC)

Dr. Peter Smith (CAN Representative)

Dr. Michelle Demos (SPC)

Dr. Vijay Ramaswamy (SPC, PDC)

Dr. Dhany Charest (PDC)

Dr. Garth Bray (PDC)

Dr. Jose Martin del Campo (PDC)

Dr. Bev Prieur (PDC)

Dr. Rudolf Arts (PDC)

Mr. Dan Morin

Ms. Lisa Bicek

Mr. Brett Windle

GENERAL MEETING INFORMATION

MEETING LOCATION AND REGISTRATION

MEETING SITE

Le Centre des congrès de Québec
1000, boul. René-Lévesque Est
Québec City, QC G1R 2B5

DELEGATE & EXHIBITOR REGISTRATION – ON SITE

Registration Desk

Le Centre des congrès de Québec

Tuesday, June 8	07:00 – 18:30
Wednesday, June 9	06:00 – 18:30
Thursday, June 10	07:00 – 18:30
Friday, June 11	07:00 – 13:30

CANADIAN NEUROLOGICAL SCIENCES FEDERATION'S FUTURE CONGRESS SITES

June 14-17, 2011	Vancouver, British Columbia
June 5-8, 2012	Ottawa, Ontario

QUESTIONS?

Advance Group, Conference Management

Attention: Canadian Neurological Sciences Federation

Suite 101 - 1444 Alberni Street

Vancouver, BC, Canada V6G 2Z4

Phone: (604) 688-9655 (Extension 2)

Fax: (604) 685-3521

E-mail: cnsinfo@advance-group.com for registration only.

Canadian Neurological Sciences Federation

709 – 7015 Macleod Trail SW

Calgary, AB, Canada T2H 2K6

Tel: (403) 229-9544 Fax: (403) 229-1661

E-mail: brett-windle@cnsfederation.org

REGISTRATION DETAILS

Full Registration

- Includes all sessions of the 2010 Annual Congress from Tuesday, June 8, 2010 through Friday, June 11, 2010 and the Exhibitors' Reception on Wednesday June 9, 2010.

One-Day Registration

- Includes all sessions for the day registered. Note: Wednesday One-Day Registrants can attend the Exhibitors' Reception on June 9, 2010.

Badges

- Delegates must wear their badges at all times to gain entry to Congress Courses, Scientific Sessions and evening events.

SOCIAL EVENTS

SPONSORS' AND EXHIBITORS' RECEPTION

Wednesday, June 9, 2010 - 17:00-19:30

Le Centre des congrès de Québec – Room 200AB

Wine & hors d'oeuvres. Cash bar. **Must have badges for entry.**

(This is not a dinner)

IMPORTANT NOTICE

CNSF 2010 Congress delegates who register and stay at the Quebec City Hilton for a minimum of three consecutive nights during the CNSF Congress June 8th to 11th are eligible for a draw for:

- a free two nights stay
- one buffet breakfast for 2 people
- one dinner for 2 people at the Hilton's Allegro restaurant (table d'hôte menus, no alcohol)

This prize must be taken between July 1st 2010 and March 31st, 2011.

This prize is not redeemable for cash.

Connection procedure to the wireless Internet network (no charge)

1. Select the « Code Centre des congrès » wireless network.
2. Launch the Internet browser.
3. Read and accept the terms and conditions by entering one of the following access codes: AU12N, AU98J, AU42X.
4. For any configuration or connectivity problems, please dial 1 888 236-8312 first.

We acknowledge the financial support of the Government of Canada through the Department of Canadian Heritage Official Languages Support Programs Branch.



Canadian
Heritage

Nous reconnaissons l'appui financier du gouvernement du Canada par l'entremise du ministère du Patrimoine canadien Direction générale des programmes d'appui aux langues officielles.

Patrimoine
canadien

TABLE OF CONTENTS / TABLE DES MATIÈRES

Table of Contents

Message from the President.....	1
General Meeting Information	2
Daily Events Calendar	
Scientific Sessions / Social Events	6
Business Meetings.....	8
Scientific Sessions - Meetings at a Glance	11
Plenary Guest Speakers.....	12
Maintenance of Certification - How to Obtain CME Credits	14
Meeting Level Map.....	15
Board Photos	16
Exhibition Hall and Booth Assignments.....	17
Detailed Scientific Program	
Tuesday, June 8, 2010	18
Wednesday, June 9, 2010.....	26
Thursday, June 10, 2010.....	34
Friday, June 11, 2010.....	36
Winners of the 2010 Society Prizes	46
Platform Sessions	47
Poster Sessions	55



Table des matières

Accreditation FRCPC ou FRCSC - Comment obtenir des crédits CME	14
Message du Président.....	67
Reseignements D'ordre Général	68
Programme des Activités	
Programme scientifique / Activités sociales.....	69
Réunions	71
Programme scientifique	
Mardi 8 juin 2010	72
Mercredi 9 juin 2010	80
Jeudi 10 juin 2010.....	88
Vendredi 11 juin 2010	90

Co-developed Symposium

CURRENT VIEWS ON THE PATHOPHYSIOLOGY OF SLEEP AND THE INTERRELATIONSHIP WITH PAIN

Wednesday, June 9, 2010; 12:00-1:30 pm • Quebec City Convention Centre • Room 205 BC
Quebec City, Quebec

Symposium conjoint

PERSPECTIVES ACTUELLES SUR LA PHYSIOPATHOLOGIE DU SOMMEIL ET SON INTERRELATION AVEC LA DOULEUR

Le mercredi 9 juin 2010; 12 h - 13 h 30 • Centre des congrès de Québec • Salle 205 BC
Québec (Québec)

FACULTY

Angela Genge, MD, FRCP(C)
Director, Clinical Research Unit
Director, ALS Clinic
Montreal Neurological Institute and Hospital

André Lalonde, MD
General Practitioner
Polyclinique Concorde Laval
Sacré-Coeur Hospital, Pain Clinic

CONFÉRENCIERS

Angela Genge, MD, FRCP(C)
Directrice, Unité de recherche clinique
Directrice, Clinique de sclérose latérale amyotrophique
Institut et hôpital neurologiques de Montréal

André Lalonde, MD
Omnipraticien
Polyclinique Concorde Laval
Hôpital du Sacré-Coeur,
clinique de la douleur

LEARNING OBJECTIVES

Following this educational session participants will be better able to:

- Understand sleep physiology and pathophysiology
- Identify methods used to measure sleep
- Recognize the interrelationship between pain and sleep
- Know the impact of pain medication on sleep

OBJECTIFS D'APPRENTISSAGE

À la suite de cette séance, les participants seront en mesure :

- de comprendre la physiologie et la physiopathologie du sommeil;
- de déterminer les méthodes utilisées pour évaluer le sommeil;
- de reconnaître la relation étroite et réciproque entre la douleur et le sommeil;
- de discerner les retombées d'un traitement médical de la douleur sur le sommeil.

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification activity of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Neurological Society. This activity is accredited for 1.5 MOC hours.

Cette activité est une activité de formation collective agréée au titre de la section 1 conformément au programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Ce programme a été revu et approuvé par la Société canadienne de neurologie. Les participant(e)s peuvent obtenir jusqu'à un maximum de 1.5 crédits.

This event is co-developed by the Canadian Neurological Society and Pfizer Canada Inc.
Cet événement est coparrainé par la Société canadienne de neurologie et Pfizer Canada Inc.



Sleep Talk Live • Conférence sur le sommeil



CLARK'S

AUDIO VISUAL SERVICES LTD.



CONTACT CLARK'S AV FOR A FULL LIST OF AUDIO VISUAL SERVICES, INCLUDING...

AV Equipment Rentals | Staging/Gala Events | Multilingual
Simultaneous Interpretation Services | Audience Response
Systems | Large Venue Audio, Video and Lighting Systems |
Registration Support Services | Digital Signage | Multi-Venue/
Room Networking | Online File Management Services

www.clarksav.com

1910 Ontario St. Vancouver B.C. V5T 4G6
Phone. +1.604.877.8558 Toll Free. +1.800.667.1819

World Class Audio Visual Services



Conference Management by ADVANCE-GROUP

Advance Group is proud to be the Professional Congress Organizer of the CNSF Annual Congress since 2005.

We are recognized as one of Canada's **leading** professional conference organizers.

With years of **proven experience**, we provide a comprehensive range of Conference Planning, Site Selection and Accommodation services.

Our broad spectrum of work includes:

- Small Corporate Meetings
- Annual Association Conferences
- Large International Congresses

For more information, please visit: www.advance-group.com or phone us at **604.688.9655**.



* Tuesday, June 8, 2010

- 07:45-17:00 **Advances in the Neurobiology of Disease**
Room 206B
- 07:50-17:30 **Epilepsy Review Course for Neuroscience Residents**
Room 204AB
- 08:00-17:00 **Neurosurgery Resident Review Course - Neurovascular Disease**
Room 301AB
- 08:30-17:00 **ALS Strategies for Quality of Life/Quality Care** *Quebec Hilton - Beauport Room*
- 08:30-17:00 **Child Neurology Day**
Room 206A
- 12:00-13:30 **Stroke Co-Developed Symposium**
Room 2000D
- 18:00-20:00 **Epilepsy Video Session**
Room 206B
- 18:00-20:00 **Movement Disorders SIG**
Room 207
- 18:00-20:00 **Headache SIG**
Room 2101
- 18:00-20:00 **Neuromuscular Diseases SIG**
Room 206A

Wednesday, June 9, 2010

- 06:30-08:00 **Headache Co-Developed Symposium**
Room 204AB
- 08:00-10:00 **Grand Opening Plenary - Scientific & Technical Advances in the Clinical Neurosciences** *Room 200C*
- 10:15-11:45 **Chair's Select Plenary Presentation**
Room 200C
- 12:00-13:30 **Epilepsy Co-Developed Symposium**
Room 204AB
- 12:00-13:30 **Neuropathic Pain Co-Developed Symposium**
Room 205BC
- 13:30-17:00 **Headache Course**
Room 205BC
- 13:30-17:00 **Stroke Course**
Room 204AB
- 13:30-17:00 **Neurovascular Surgery Course**
Room 201BC
- 13:30-17:00 **Epilepsy Course - Epilepsy Management - From Sci-fi to Reality** *Room 202*
- 13:30-17:00 **Neuro-oncology Course**
Room 203
- 13:30-17:00 **Multiple Sclerosis Course - Update for the MS Professional**
Room 205A
- 17:00-19:30 **Sponsors and Exhibitors Reception**
Room 200AB

All Scientific Sessions are held at the Quebec City Convention Centre (QCC) unless otherwise stated.

ABBREVIATION GUIDE

Annual General Meeting (AGM); Canadian Association of Child Neurology (CACN); Canadian Neurological Sciences Federation (CNSF); Canadian Journal of Neurological Sciences (Journal); Canadian Neurological Society (CNS); Canadian Neurosurgical Society (CNSS); Canadian Society of Clinical Neurophysiologists (CSCN); Neurological Sciences Foundation of Canada (NSFC).
Bold type shows scientific program events. Non-bold shows business and other events.



Thursday, June 10, 2010

- 08:30-10:00 **Plenary Session - CNS, CSCN & CACN**
Room 200C
- 08:30-10:00 **Plenary Session - CNSS**
Room 204AB
- 10:00-10:15 Break/Exhibit Viewing
Room 200AB
- 10:15-12:30 **Platform Sessions (6 simultaneous)**
 - **MS** *Room 200C*
 - **General Neurology & Dementia** *Room 201BC*
 - **Neuromuscular & Neuro-oncology** *Room 202*
 - **Pediatric Neurology** *Room 203*
 - **Stroke Prevention & Treatment 1** *Room 204A*
 - **Stroke Recovery & Rehabilitation** *Room 205A*
- 12:30-14:00 Lunch/Exhibit Viewing/Digital Mini-platforms
Room 200AB
- 14:00-16:30 **Platform Sessions (6 simultaneous)**
 - **Spine** *Room 200C*
 - **Epilepsy** *Room 201BC*
 - **General Neurosurgery & Neuroradiology** *Room 202*
 - **Trauma, Critical Care & Treatment 2** *Room 203*
 - **Stroke Prevention & Treatment 2** *Room 204A*
 - **Stroke Health Serv. Research & Acute Treatment**
Room 205A
- 16:30-18:30 Digital Poster and Exhibit Viewing
Room 200AB

Friday, June 11, 2010

- 08:00-08:15 Journal Editors' Report/Reviewer of the Year
Award Presentation *Room 200C*
- 08:15-08:30 CBANHC Report *Room 200C*
- 08:30-09:30 **Distinguished Guest Lecture:**
James Orbinski *Room 200C*
- 09:30-09:45 Currently Active Canadian Clinical Trials
Room 200C
- 09:45-10:15 Break/Exhibit Viewing/Digital Mini-platforms
Room 200AB
- 10:15-12:00 **Grand Rounds** *Room 200C*
- 12:00-13:30 Lunch/Exhibit Viewing/Digital Mini-platforms
Room 200AB
- 13:30-17:00 **Neuro-ophthalmology Course**
Room 202
- 13:30-17:00 **Interventional Neuroradiology Course -
Difficult Aneurysms** *Room 201B*
- 13:30-17:00 **What's New in Neurosurgery?**
Room 203
- 13:30-17:00 **Neurocritical Care Course**
Room 204B
- 13:30-17:00 **Neuromuscular Diseases Course**
Room 204A
- 13:30-17:00 **Spine Course - Controversies in Spinal
Neurosurgery** *Room 201C*
- 13:30-17:00 **What's New in Neurology?**
Room 200C
- 13:30-17:00 **EEG Course** *Room 205A*

Educational Objectives for the 2010 Congress:

By the end of the Congress, delegates will have affirmed and/or gained additional knowledge, skills and attitudes to enhance the care of their patients with diseases of the nervous system through:

- Discussing advances in the management of acute and chronic neurological and neurosurgical disorders.
- Discussing new findings in neurological and neurosurgical disorders.
- Describing advances in neurological disorders and/ or neurosurgical techniques.
- Identifying areas where there are gaps in learning not realized before attending the Congress and extending this professional learning after the Congress to the enhanced care of patients.

Monday, June 7, 2010

15:00 CNSF and NSFC Board Meeting
Plaines - QH

Tuesday, June 8, 2010

07:00-08:15 CACN Council Meeting
Lauzon - QH

12:00-13:00 CNS Residents Meeting
Lauzon - QH

12:00-13:00 CSCN EMG Section Meeting
Portneuf - QH

12:00-13:00 CNS Council Meeting
Sainte-Foy - QH

12:00-16:00 Royal College Specialty Committee Neurology
Courville - QH

13:00-14:00 CSCN EEG Section Meeting
Portneuf - QH

16:00-17:30 CSCN Council Meeting
Portneuf - QH

17:00-18:00 CNSS Council Meeting
Sainte-Foy - QH

17:00-18:00 CACN Annual General Meeting
206A - QCC

17:30-18:30 CNSS Resident's Meeting
Courville - QH

Wednesday, June 9, 2010

06:45-07:45 CNS International Development Committee
Lauzon - QH

Thursday, June 10, 2010

07:00-08:00 Canadian Headache Society Annual General Meeting
Portneuf - QH

07:00-08:00 Journal Editorial Board
Sainte-Foy - QH

07:30-08:30 CNSF Affiliates Meeting
Lauzon - QH

07:30-08:30 CNSS Annual General Meeting
Plaines - QH

09:00-17:00 MS Investigators Group Meeting
Courville - QH

12:45-13:45 CNS Annual General Meeting
204A - QCC

13:30-14:30 CNSF Advocacy Committee Meeting
Sainte-Foy - QH

17:00-18:00 CSCN Annual General Meeting
Sainte-Foy - QH

17:00-20:00 Canadian Network of MS Clinics Meeting
Portneuf - QH

17:00-19:00 CNSF SPC/PDC Committee Meeting
204A - QCC

Friday, June 11, 2010

07:00-08:30 Royal College Specialty Comm Neurosurgery
Lauzon - QH

12:00-13:30 Canadian Neuromuscular Group Meeting
Sainte-Foy - QH

12:00-13:30 CNSF/NSFC Board Meeting
Courville - QH

12:00-13:30 Canadian Pediatric Neuromuscular Research Group
Lauzon - QH

12:00-13:30 Canadian Neurocritical Care Society Meeting
Portneuf - QH

All Business Meetings are held at the Quebec Hilton (QH) unless otherwise stated.
Business Meetings are sponsored by The Advance Group.

2010 SPONSORS

The Canadian Neurological Sciences Federation is pleased to recognize those Sponsors who have already committed to supporting the 2010 Congress. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provided educational grants to the Annual Congress, this year in Quebec City, Quebec, June 8-11, 2010.

PLATINUM



MERCK

Merck Frosst Canada Ltd., Kirkland, Quebec



THE EPILEPSY COMPANY™

GOLD



**Boehringer
Ingelheim**



TEVA CANADA INNOVATION
E-CPD CO-FOUNDING SPONSOR



E-CPD CO-FOUNDING SPONSOR

SILVER



We Innovate Healthcare



BRONZE



**Neurological Sciences Foundation
of Canada (NSFC)**



ELEKTA



**NSFC - CNS - Don Paty
Fund**

SUPPORTERS

**Synthes Canada
Medtronic of Canada**

**Actelion Pharmaceuticals
Canada Microsurgical**

STROKE PREVENTION IN ATRIAL FIBRILLATION

Emerging Trends



Program Chair

Ariane Mackey, MD, FRCPC
Neurologist
Director, Neurovascular Research Centre
CHA, Hôpital de l'Enfant-Jésus
Associate Professor of Medicine
Université Laval
Quebec City, Quebec

Program Faculty

John Eikelboom, MBBS, FRCPC
David J. Gladstone, MD, PhD, FRCPC
Philip Teal, MD, FRCPC

Co-Developed Symposium
Tuesday, June 8, 2010 | 12:00–1:30 pm | Room: 2000 D

Canadian Neurological Sciences Federation 45th Annual Congress
Centre des congrès de Québec | Quebec City, Quebec

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification (MOC) activity of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Neurological Society. This activity is accredited for 1.5 MOC hours.

This event is co-developed by the Canadian Neurological Society and Boehringer Ingelheim (Canada) Ltd.



SCIENTIFIC SESSIONS - MEETING AT A GLANCE

Tuesday June 8, 2010

- 07:50-17:30
Epilepsy Review Course
page 18
- 07:45-17:00
Advances in the
Neurobiology of Disease
page 20
- 08:00-17:00
Neurosurgery Resident
Review Course
page 21
- 08:30-17:00
ALS Strategies for Quality of
Life/Quality Care
page 22
- 08:30-17:00
Child Neurology Day
page 23
- 12:00-13:30
Stroke Co-Developed
Symposium
page 24
- 18:00-20:00
Epilepsy Video Session
page 24
- 18:00-20:00
Movement Disorders SIG
page 24
- 18:00-20:00
Headache SIG
page 25
- 18:00-20:00
Neuromuscular Diseases
SIG
page 25

Wednesday June 9, 2010

- 06:30-08:00
Headache Co-Developed
Symposium
page 26
- 08:00-10:00
Grand Opening Plenary -
Scientific & Technical
Advances in the Clinical
Neurosciences
page 26
- 10:15-11:45
Chair's Select Plenary
Presentation
page 27
- 12:00-13:30
Epilepsy Co-Developed
Symposium
page 27
- 12:00-13:30
Neuropathic Pain Co-
Developed Symposium
page 27
- 13:30-17:00
Headache Course
page 28
- 13:30-17:00
Stroke Course
page 29
- 13:30-17:00
Neurovascular Surgery
Course
page 30
- 13:30-17:00
Epilepsy Course
page 31
- 13:30-17:00
Neuro-oncology Course
page 32
- 13:30-17:00
Multiple Sclerosis Course
page 33

Thursday June 10, 2010

- 08:30-10:00
Plenary Session: CNS,
CSCN and CACN
page 34
- 08:30-10:00
Plenary Session: CNSS
page 34
- 10:15-12:30
Platform Sessions
(6 simultaneous)
page 35
- 12:30-14:00
Exhibit Viewing and Digital
Mini-Platforms
page 35
- 14:00-16:30
Platform Sessions
(6 simultaneous)
page 35
- 16:30-18:30
Digital Poster and Exhibit
Viewing
page 35
- Friday
June 11, 2010**
- 08:00-08:15
Reviewer Award Presentation
and Journal Report
page 36
- 08:15-08:30
CBANHC Report
page 36
- 08:30-09:30
Distinguished Guest Lecturer
- James Orbinski
page 36
- 09:30-09:45
Currently Active Canadian
Clinical Trials
page 36

Friday June 11, 2010 *Continued*

- 09:45-10:15
Exhibit Viewing/Orbinski
Book Signing
page 37
- 10:15-12:00
Grand Rounds
page 37
- 12:00-13:30
Exhibit Viewing/Digital
Mini-Platforms
page 37
- 13:30-17:00
Neuro-ophthalmology Course
page 38
- 13:30-17:00
Interventional Neuroradiology
Course
page 39
- 13:30-17:00
What's New in
Neurosurgery?
page 40
- 13:30-17:00
Neurocritical Care Course
page 41
- 13:30-17:00
Neuromuscular Diseases
Course
page 42
- 13:30-17:00
Spine Course
page 43
- 13:30-17:00
What's New in Neurology
page 44
- 13:30-17:00
EEG Course
page 45

PLENARY GUEST SPEAKERS

Josep Dalmau

Dr. Josep Dalmau received his M.D. and Ph.D. from the Autònoma University of Barcelona, Spain, where he also completed an internship in Internal Medicine and a residency in Neurology. He trained in Neuro-oncology at the Memorial Sloan-Kettering Cancer Center in New York where he was appointed to the faculty at the completion of his fellowship. Dr. Dalmau is currently Professor of Neurology at the University of Pennsylvania, and the Director of the Neuro-oncology Laboratory. In addition to funding by the National Institutes of Health, Dr. Dalmau has received grants and awards from the Charles A. Dana Foundation, the McKnight Neuroscience of Brain Disorders, the American Cancer Society, and the European and Japanese Neurological Societies. Dr. Dalmau is recognized for his research in paraneoplastic diseases and related autoimmune disorders of the nervous system. His recent work focuses on the identification and characterization of a novel group of disorders associated with antibodies against neuronal cell surface receptors or ion channels that result in alterations of memory, behavior, cognition and dementia.



Ziya L. Gokaslan

Ziya L. Gokaslan was born on April 07, 1959 in Washington, D.C. (USA). He later returned to Turkey with his family where he completed his medical education at the Medical Faculty of Istanbul University. In 1984, Dr. Gokaslan returned to the U.S. and worked as the Clinical Director of Sleep Disorders Center of the Department of Psychiatry for 1 ½ years. He then entered General Surgery Residency under Dr. Michael E. DeBakey in 1985. After one year of internship, he joined Department of Neurosurgery of Baylor College of Medicine as Clinical Neurotrauma Research Fellow. In 1988, he became a Neurosurgery

Resident under Dr. Robert G. Grossman and completed his training at the Baylor College of Medicine in Houston in 1993. He was, then, accepted into Neurosurgery/Orthopaedic Spine Surgery Fellowship Training under Drs. Paul Cooper and Thomas Errico at the New York University Medical Center in New York. After the completion of his Fellowship Training in Spinal Surgery, Dr. Gokaslan returned to Houston and joined the faculty of Department of Neurosurgery as Assistant Professor at the University of Texas, MD Anderson Cancer Center under Dr. Raymond Sawaya. That is where Dr.



Gokaslan specialized in the surgical treatment of spinal neoplasms, published extensively on the topic and developed novel surgical approaches in managing these tumors.

In 2000, Dr. Gokaslan became the Director of Neurosurgical Spinal Oncology Section and, in 2002, he was appointed as Deputy Chairman of the Department of Neurosurgery and was promoted to Associate Professor. In 2002, Dr. Gokaslan was recruited to Johns Hopkins University, Department of Neurosurgery and became the Director of the Spine Division, Vice-Chairman, and Professor of Neurosurgery, Oncology, and Orthopaedic Surgery under Dr. Henry Brem. Later that year, he was awarded the Donlin M. Long Professorship at Johns Hopkins.

Dr. Gokaslan's clinical practice focuses on the radical surgical treatment of both primary and metastatic spinal tumors, sacral neoplasms and spinal cord tumors. He developed many novel approaches for resection of pancost tumors, spinal neoplasms, as well as sacral tumors, including total sacrectomy and complex spinal and pelvic reconstruction.

His basic research focuses on the development of new animal models to study the pathophysiology of neoplastic spinal cord compression and to define the roles of proteolytic enzymes in tumor invasion and to devise novel therapeutic approaches to spinal tumors.

Anthony E. Lang

Dr. Lang trained in Internal Medicine and Neurology at the University of Toronto. He then undertook postgraduate training in Movement Disorders at Kings College Hospital and the Institute of Psychiatry in London, England under the late Professor David Marsden. He returned to Toronto in 1982 and shortly thereafter initiated the Movement Disorders Clinic at the Toronto Western Hospital which has developed into the largest Movement Disorders Clinic in Canada and one of the most reputable units in the world for the investigation, assessment and treatment of patients with movement disorders.

Dr. Lang's research has included clinical studies of poorly recognized neurological disorders, clinical trials of new therapeutic modalities and collaborative basic and clinical studies involving molecular biology, neurophysiology, neuropsychology and imaging. He has published over 390 peer reviewed papers, many in important medical journals including the New England Journal of Medicine, the Lancet, Nature Medicine, the Annals of Neurology, Brain, etc. Dr. Lang was one of the founding members and initial Executive Committee members of the Parkinson Study Group (PSG). He served on the Steering Committee of the first large scale neuroprotective therapies study in Parkinson's disease (the DATATOP trial) carried out by the PSG, and funded by NIH and has served on many other Steering Committees for PSG studies since then. Dr. Lang has served on the Movement Disorders Society (MDS) International Executive Committee and as Treasurer from 1988-1992 and Secretary from 1996-1998. He served as the MDS President from January 2007- June 2009 and is the current Past President. He served as CoEditor-in-Chief of the international journal Movement Disorders between 1996 and 2003 inclusive.

Dr. Lang is Professor and Director of the Division of Neurology at the University of Toronto, Director of the Movement Disorders Center at the Toronto Western Hospital, the Jack Clark Chair for Parkinson's Disease Research at the University of Toronto and was the recipient of the 2005 Research Award for the Department of Medicine at the University of Toronto and the Donald Calne Lectureship from Parkinson Society Canada in 2008. Dr. Lang is a Fellow of the American Academy of Neurology and was the recipient of the AAN Movement Disorders Research Award in 2004.



Stephan A. Mayer

Stephan A. Mayer, MD, is Professor of Neurology and Neurological Surgery at Columbia University College of Physicians & Surgeons in New York City, and is Director of the Neurological Intensive Care Unit at NewYork-Presbyterian Hospital/ Columbia University Medical Center. He is a graduate of Brown University, received his medical degree from Cornell University Medical College in New York, and did his

postgraduate medical training in neurology and neurological intensive care at the Neurological Institute of New York. Dr. Mayer has published more than 500 journal articles, books, case reports, book chapters, and abstracts. He was principal investigator of the FAST Trial, a worldwide multicenter clinical trial evaluating ultra-early hemostatic therapy for brain hemorrhage, and is principal investigator of the NIH-funded New York Presbyterian Hospital hub of the Neurological Emergencies Treatment Trials (NETT) network. His work in helping to organize therapeutic hypothermia for victims of cardiac arrest in New York City was recently featured in the book *Cheating Death*, by CNN medical correspondent Dr. Sanjay Gupta.



James T. Rutka

Born in Toronto, and educated at Princeton University (1975-1977), and Queen's University Medical School (1977-1981), Dr. Rutka did an internship at McGill University (1981-1982) before entering the University of Toronto Neurosurgery Training Program in 1982. His training included a research fellowship at the Brain Tumor Research Centre, the University of California San Francisco where he obtained his PhD in Experimental Pathology (1984-1987). Upon conclusion of his neurosurgical residency 1989, Dr. Rutka did a post-doctoral research fellowship in molecular immunology at Juntendo University, Tokyo (1990).

Dr. Rutka assumed his appointment in the Department of Surgery, Division of Neurosurgery in 1990, and has been on the surgical staff at the Hospital for Sick Children in the Division of Pediatric Neurosurgery since that time. Dr. Rutka's primary research and clinical interests relate to the science and surgery of human brain tumors. His laboratory interests lie in the molecular biology of human brain tumors - specifically in the determination of the mechanisms by which brain tumors grow and invade. His recent clinical and research interests have centred on the surgical treatment of epilepsy in children. He has over 300 peer review publications. He is on the editorial boards of the *Journal of Neurosurgery* and *Neurosurgery*. He is Professor of Neurosurgery at the University of Toronto. He is Co-Director of the Arthur and Sonia Labatt Brain Tumor Research Centre at the University of



Toronto in 1998. In 1999, Dr. Rutka was appointed Chairman of the Division of Neurosurgery at the University of Toronto, and sits in the Dan Family Chair of Neurosurgery. In 2004, he was honoured with the Grass Award from the Society of Neurological Surgeons. In 2005, he received the Farber Award from the AANS/CNS Section on Tumors for longstanding contributions to neuro-oncology research. In 2006, Dr. Rutka was made a member of the International Order of Smile. In 2009 he was the Honored Guest at the Annual Meeting of the Congress of Neurological Surgeons, and in May 2010 he was installed as President of the American Association of Neurological Surgeons.

John Stewart

Dr. John Stewart is a 4th generation Manitoban, but lived in other countries for a long time before returning to Canada. He studied physiology at University College, London, UK, then graduated in medicine from the University of the West Indies in Jamaica.

He did postgraduate studies in Internal Medicine and Neurology in the UK, then worked at the University of Nairobi, Kenya. He returned to Canada, doing further training in Neurology at McGill University. He then spent the next 25 years at McGill developing his special interests in peripheral neuropathies and disorders of the autonomic nervous system. He is the author of "Focal Peripheral Neuropathies", the 4th edition of which has recently been published. Dr. Stewart is emeritus professor, McGill University.

Five years ago he changed his career to that of a community neurologist working in North Vancouver and associated with Lions Gate Hospital. He maintains his interest in disorders of the peripheral nervous system, particularly focal peripheral neuropathies.



G. Campbell Teskey

Cam Teskey completed an undergraduate honors degree in 1983 and a M.Sc. degree in 1985 from the University of Western Ontario. He then returned to U.W.O. as an NSERC-funded PhD student in Dr. Peter Cain's laboratory. His Ph.D. thesis examined the role of the immediately early gene *c-fos* following seizures. He defended his PhD in 1989 and then moved to Dr. Ron Racine's laboratory at McMaster University for an NSERC-, and then Epilepsy Canada-funded post-doctorate fellowship. His post-doctorate research focused on the response properties of neurons following electrical stimulation and seizures. In July of 1992 he took an Assistant Professor position at the University of Calgary and in 2002 he was promoted to Full Professor. His primary appointment is in the Department of Cell Biology and Anatomy, with a joint appointment in the Department of Psychology.

Cam Teskey's main research focus is on the neurobiology of motor maps and their relationship to behaviour. His lab has described many alterations in motor maps that are associated with the motor performance deficits in rats. Intracortical microstimulation within motor neocortex results in forelimb movements and the topography of these movements (motor maps) are organized much like Penfield's homunculus in people. He has shown that neocortical motor maps of the rat forelimb are dramatically (2 times) larger following repeated seizures. These larger maps can arise from seizures elicited in the corpus callosum or hippocampus as long as the epileptiform activity propagates to the frontal neocortex. The increased size of the maps is linearly related to the number of seizures in the neocortex and the altered expression of the maps is highly persistent without significant loss of size at least 5 weeks following the last seizure. These seizure-induced larger motor maps are quantifiable, robust, persistent, plastic, and related to alterations in motor performance. The alterations in motor map expression we have observed in rats are similar to the documented changes in movement representations in people with epilepsy.



HOW TO OBTAIN CME CREDITS

Maintenance of Certification / Maintien du certificat

The 45th Annual Congress of the Canadian Neurological Sciences Federation is an accredited learning activity approved by the CNS and the CNSS, as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The Royal College of Physicians and Surgeons of Canada established the Maintenance of Certification program on January 1, 2001. Participation in this program is a requirement for admission to and renewal of Fellowship and for the use of the designations FRCPC and FRCSC.

The 2010 Congress has been approved for Section 1 under the Maintenance of Certification program. This means each attendee is assigned one credit per hour in education sessions. Breaks, lunch, and the poster sessions are excluded.

As Fellows are responsible for keeping track of their hours of participation in educational activities, they should keep a copy of this meeting program and their registration form for future reference. Certificate of Attendance Forms will be issued upon completion of the Overall Congress Evaluation on-line through a link we will be providing to all delegates, or by completing the hard copy we will have in the delegates portfolio distributed at the Congress and faxed it to the CNSF Secretariat at 1-403-229-1661. The deadline for completion and submission is July 2, 2010.

For more information about the Maintenance of Certification Program, please refer to the Royal College website <http://www.rcpsc.medical.org> or e-mail Lisa at the CNSF secretariat office at lisa-bicek@cnsfederation.org.

Le 45^e congrès annuel de la Fédération des sciences neurologiques du Canada est une activité éducative agréée, approuvée par la SNC et la SCNCH selon la définition du programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

Le Collège royal des médecins et chirurgiens du Canada a institué le maintien du certificat le 1^{er} janvier 2001.

Participer à ce programme est obligatoire pour l'obtention ou le renouvellement du titre d'Associé et pour utiliser les mentions FRCPC et FRCSC.

Le congrès 2010 a été approuvé comme activité de la Section 1 du programme de maintien du certificat. Ce qui veut dire que chaque participant reçoit un crédit pour chaque heure de séance éducative. Les pauses, les déjeuners et les présentations affichées n'en font pas partie.

Comme c'est la responsabilité des Associés de tenir une comptabilité de leurs heures de participation aux activités de formation, ils doivent garder une copie du programme de ce congrès et le formulaire d'inscription en vue d'une utilisation ultérieure. Des attestations d'assiduité ne vous seront délivrées que lorsque vous aurez rempli en ligne l'évaluation générale du congrès en utilisant un lien que nous indiquerons à tous les délégués, ou bien lorsque vous aurez rempli la feuille que vous trouverez dans le cartable distribué à tous les délégués au congrès et que vous l'aurez envoyée par télécopie au secrétariat de la FSNC au 1-403-229-1661. Date-limite pour remplir et soumettre l'évaluation: 2 juillet 2010.

Pour plus de renseignements sur le programme de maintien du certificat, veuillez consulter le site web du Collège royal à <http://www.rcpsc.medical.org> ou envoyer un courriel au secrétariat de la FSNC à lisa-bicek@cnsfederation.org

CME Hours

Breaks, lunch and poster sessions are excluded

DATE: TUESDAY, JUNE 8TH, 2010

Epilepsy Review Course for Neuroscience Residents	8.0
Neurosurgery Resident Review Course: Neurovascular Disease	7.5
Advances in the Neurobiology of Disease	7.5
ALS	6.0
Child Neurology Day	6.0
Stroke (Co-developed)	1.5
Epilepsy Video Session	2.0
Movement Disorders (SIGs)	2.0
Headache (SIGs)	2.0
Neuromuscular Diseases (SIGs)	2.0

DATE: WEDNESDAY, JUNE 9TH, 2010

Grand opening Plenary	2.0
Headache (Co-developed)	1.5
Epilepsy (Co-developed)	1.5
Neuropathic Pain (Co-developed)	1.5
Headache	3.5
Stroke	3.5
Neurovascular Surgery	3.5

Epilepsy	3.5
Neuro-oncology	3.5
Multiple Sclerosis	3.5

DATE: THURSDAY, JUNE 10TH, 2010


Plenary Session – CNS, CACN, CSCN (Neurology)	1.0
Plenary Session – CNSS (Neurosurgery)	1.0
Platform Session - Morning	2.0
Platform Session - Afternoon	2.0

DATE: FRIDAY, JUNE 11TH, 2010

Distinguished Lecturer - Dr. James Orbinski	1.0
Grand Rounds	1.5
Neuro-ophthalmology	3.5
Interventional Neuroradiology	3.5
What's New in Neurosurgery	3.5
Neurocritical Care	3.5
Neuromuscular Diseases	3.5
Spine	3.5
What's New in Neurology	3.5
EEG	3.5



MEETING LEVEL MAP



CENTRE
DES CONGRÈS
DE QUÉBEC

Level 2



Elevator



Escalator



Multimedia room



Washrooms
Wheel chair accessible



Ticket sales



Infirmary



Audio control room
and simultaneous
interpretation



Cloakroom



Mobile TV Units



Information



Security



Internet café



Stairway



Freight elevator




Washrooms

* Registration area is near the Level 4 Main Entrance

The Canadian Neurological Sciences Federation (CNSF) and Neurological Sciences Foundation of Canada (NSFC)

2009 – 2010 Board of Directors and Committee Chairs



George Elleker
• CNSF President
• NSFC President
• CSCN Past President



Garth Bray
• CNSF Vice-President
• NSFC Vice-President
• CNS Member



Derek Fewer
• CNSF Vice-President
• NSFC Vice-President
• CNSS Past President



Mary Connolly
• CNSF Board Member
• NSFC Board Member
• CACN President



Sharon Whiting
• CNSF Board Member
• NSFC Board Member
• CACN Vice-President



J. Max Findlay
• CNSF Board Member
• NSFC Board Member
• CNSS President



Chris Wallace
• CNSF Board Member
• NSFC Board Member
• CNSS Vice-President



Lyle Weston
• CNSF Board Member
• NSFC Board Member
• CNS President



Sarah Kirby
• CNSF Board Member
• NSFC Board Member
• CNS Vice-President



Ming Chan
• CNSF Board Member
• NSFC Board Member
• CSCN President



Seyed Mirsattari
• CNSF Board Member
• NSFC Board Member
• CSCN Vice-President



Trevor Steve
• CNSF Board Member
• NSFC Board Member
• Residents' Rep. CNS



Shobhan Vachrajani
• Residents' Rep. CNSS



Vijay Ramaswamy
• Residents' Rep. CACN



Andrew Kirk
• CNSF/NSFC
Past President
- Non-voting



Dan Morin
• CEO
Non-voting



G. Bryan Young
• Journal Editor-in-Chief
• CNS & CSCN Member



Michael Hill
• CNSF Scientific Program
Committee Chair
• CNS Member



Colin Chalk
• CNSF Professional
Development Committee Chair
• CNS Member




Richard Riopelle
• CBANHC Chair

Legend:

CNSF - Canadian Neurological Sciences Federation; NSFC - Neurological Sciences Foundation of Canada; CNS - Canadian Neurological Society;
CNSS - Canadian Neurosurgical Society; CSCN - Canadian Society of Clinical Neurophysiologists; CACN - Canadian Association of Child Neurology;
CBANHC - Canadian Brain and Nerve Health Coalition

EXHIBITION HALL AND BOOTH ASSIGNMENTS



Actelion 203
Allergan 210
Athena Diagnostics 201
Bioness 101
Biovail Pharma 414
Boehringer Ingelheim 300, 301, 302
Canada Microsurgical Ltd. 103, 105
Cardinal Healthcare 216
Carl Zeiss Canada 416
Elekta 200
Genzyme 402
Grass Technologies 313

Guide Dogs Canada 115
Imris 400
Johnson & Johnson Medical Products 211, 213, 215
KEGO Corporation 112
King Medical 214
Leica Microsystems 311
Medtronic of Canada Ltd. 308, 310, 312
Merck Frosst Canada Ltd. 202, 204
Merz Pharma 217
Natus 212
NHCC 113

Pfizer Canada 307, 309
Roche 305
Roxon Medi-Tech Ltd. 303
Santhera Pharma 404
Scotiabank 111
Stryker 412
Talecris Biotherapeutics 410
Teva Neuroscience 205, 304
UCB Pharma 306, 116, 118
Zimmer 117

Epilepsy Review Course for Neuroscience Residents

Room 204AB 07:50-17:30

This educational activity is generously sponsored by UBC Canada Inc. who have not had input to the activity's speaker selection, program or content

Chair: Jose Martin Del Campo

Course Outline: A comprehensive review of the most relevant aspects of epilepsy from the pathophysiological and therapeutic perspectives.

Learning Objectives: At the end of this session, participants will be able to:

1. Review the neurobiology of epilepsy, including mechanisms of seizures, role of kindling in the development of epilepsy, and fundamental effects of antiepileptic agents on epileptogenesis.
2. Identify benign versus malignant epilepsy syndromes that occur in children, their EEG characteristics, and clinical prognosis.
3. Outline evidence-based antiepileptic treatment options with regard to efficacy, pharmacokinetic profile, drug interactions, and risk of adverse effects. Participants will also be able to propose the place in therapy for emerging antiepileptic agents in development based on available evidence.
4. Recognize clinical features, underlying causes, and EEG patterns of status epilepticus and identify conventional and experimental treatment options that reduce morbidity and mortality.
5. Discuss psychiatric comorbidities of epilepsy as they relate to clinical course and choice of medication therapies.
6. Differentiate true seizure types from those of physiologic or psychogenic origin, somatization disorder, and panic disorder.
7. Outline alternatives to traditional anticonvulsant treatment that may augment the clinical plan in the "pharmacoresistant" patient, including ketogenic diet, vagal nerve stimulation, and acupuncture. Introduce the concept of deep brain stimulation and the early study results.
8. Consider impact of CT, MRI, fMRI, MRS, MSI, SPECT, and PET findings on epilepsy and other relevant neurological abnormalities as they relate to diagnosis, treatment, and presurgical planning.
9. Describe current surgical options for the treatment of epilepsy and the role of the neurologist in the presurgical workup.
10. Develop appropriate treatment plans for the female patient with epilepsy that consider impact of hormones, pregnancy, and risk for long-term adverse events such as osteoporosis.
11. Outline semiological pitfalls that complicate epilepsy diagnosis in the elderly and discuss pharmacokinetic changes of aging that impact clinical drug treatment.
12. Evaluate the child with seizures and epilepsy with regard to etiology, prognosis and treatment.

Target Audience: Neuroscience residents.

Learning Format: Seminar, Discussion Group

Epilepsy Review Course for Neuroscience Residents (continued)

07:50	Introduction <i>Jose Martin del Campo (Toronto, ON)</i>
08:00	What is Epilepsy? Basic Mechanisms <i>Warren Blume (London, ON)</i>
08:40	Epidemiology of Epilepsy and Approach to the First Seizure <i>Jorge Burneo (London, ON)</i>
09:20	Pharmacological Treatment <i>Alan Guberman (Ottawa, ON)</i>
10:00	Break

Epilepsy in Special Populations

10:15	Neonates <i>Rajesh RamachandranNair (Hamilton, ON)</i>
10:35	Infants and Children <i>Elizabeth Donner (Toronto, ON)</i>
10:55	Adolescents <i>Elizabeth Donner (Toronto, ON), Danielle Andrade (Toronto, ON)</i>
11:15	Women <i>Joseph Bruni (Toronto, ON)</i>
11:35	Elderly <i>Bernd Pohlmann-Eden (Halifax, NS)</i>
12:15	Lunch
13:30	Imaging in Epilepsy <i>Andrea Bernasconi (Montreal, QC)</i>
14:15	Management of the Pharmaco-Resistant Patient <i>Samuel Wiebe (Calgary, AB)</i>
15:00	Status Epilepticus <i>G. Bryan Young (London, ON)</i>
15:45	Break

Epilepsy Comorbidities

16:00	Psychiatric <i>Sherese Ali (Toronto, ON)</i>
16:30	Non-epileptic Seizures <i>Alan Guberman (Ottawa, ON)</i>
17:00	Cognitive <i>Mary Lou Smith (Mississauga, ON)</i>
17:25	Evaluations

Advances in the Neurobiology of Disease Room 206B 07:45-17:00

This educational activity is generously sponsored by NSFC - CNS Don Paty Fund who have not had input to the activity's speaker selection, program or content

- Chairs:** Peter Smith, Zelma Kiss
- Course Outline:** The first part of the course will review basic and emerging concepts in neurobiology and their relationship to contemporary clinical practice. The last four lectures will expand on these concepts by focusing on the basal ganglia, their role in degenerative disease and dyskinesias.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Understand how current new and emerging concepts of glial cell function, molecular neurobiology and biostatistics impact the understanding and management of neurological disease.
 2. Explain the current understanding of the anatomy and pharmacology of the basal ganglia and their interactions with thalamus.
 3. Understand the role of basal ganglia in degenerative disease and dyskinesias.
- Target Audience:** General (including neurology / neurosurgery residents).
- Learning Format:** Seminar, Discussion Group
- 07:45 Introduction
Zelma Kiss (Calgary, AB), Peter Smith (Edmonton, AB)
- 08:00 **Basic Principles of Glial Cell Biology**
Jasna Kriz (Quebec City, QC)
- 09:00 **Basic Principles of Molecular Biology; From DNA to Gene Therapy**
Josephine Nalbantoglu (Montreal, QC)
- 10:00 Discussion & Break
- 10:15 **Principles of Biostatistics**
Sam Wiebe (Calgary, AB)
- 11:15 **Basal Ganglia; Overview of Anatomy**
Martin Parent (Quebec City, QC)
- 12:15 Break
- 13:30 **Basal Ganglia Thalamic Relationships**
Abbas Sadikot (Montreal, QC)
- 14:30 **Basal Ganglia; Pharmacology and Degenerative disease**
Francesca Cicchetti (Quebec City, QC)
- 15:30 Discussion
- 15:45 **Basic Science and Clinical Relevance of Dyskinesias**
Pierre Blanchet (Montreal, QC)
- 16:45 Discussion and evaluations

Neurosurgery Resident Review Course: Neurovascular Disease**Room 301AB 08:00-17:00***This educational activity is generously sponsored by J&J / Codman who have not had input to the activity's speaker selection, program or content*

- Chairs:** J. Max Findlay, Shobhan Vachhrajani
- Course Outline:** A topical review of the salient anatomy, physiology, and most common clinical conditions and their current management as required by practicing neurosurgeons and neurosurgery residents.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Describe the development, anatomy, and physiology of the vasculature of the central nervous system.
 2. Efficiently diagnose common surgical neurovascular diseases.
 3. Be versed in evidence-based, most current management paradigms for common surgical neurovascular diseases.
 4. Apply the knowledge learned to problem solve clinical neurovascular cases that might be encountered in a general neurosurgical practice.
- Target Audience:** Neurosurgical residents in their 5th year of residency, practicing neurosurgeons seeking a review of topics in neurovascular surgery.
- Learning Format:** Seminar, Discussion Group, Simulation

- 08:00 Introduction
Shobhan Vachhrajani (Toronto, ON)
- 08:10 **Embryology and Anatomy**
J. Max Findlay (Edmonton, AB), Gary Redekop (Vancouver, BC)
- 09:25 Questions and discussion
- 09:30 **Physiology**
Mel Boulton (London, ON)
- 09:55 Questions, discussion & break
- 10:15 **Carotid Disease**
Cian O'Kelly (Edmonton, AB)
- 10:45 Questions and discussion
- 10:50 **Aneurysms**
Tim Darsaut, (Edmonton, AB), R. Loch Macdonald (Toronto, ON), John Wong (Calgary, AB)
- 11:50 Questions and discussion
- 12:00 Lunch
- 13:30 **AVMs**
Julian Spears (Toronto, ON)
- 14:10 Questions and discussion
- 14:15 **Other Vascular Malformations**
Robert Willinsky (Toronto, ON)
- 14:55 Questions and discussion
- 15:00 **Medical and Surgical Aspects of Stroke**
Ian Fleetwood (Halifax, NS)
- 15:25 Questions, discussion and break
- 15:35 **Mock Exam Scenarios**
*J. Max Findlay, (Edmonton, AB), Christopher Wallace (Toronto, ON),
Genevieve Milot (Quebec City, QC)*
- 16:55 Questions and evaluations

ALS Strategies for Quality of Life/Quality Care Hilton Hotel, Beauport Room 08:30-17:00

Chair: David Cameron

Course Outline: Interactive full day sessions with patients, caregivers, allied health professionals, neurologists, physiatrists, community support agencies: a comprehensive review of current topics in ALS including diagnosis and research, management and advocacy.

Learning Objectives: At the end of this session, participants will be able to:

1. Describe the current clinical and pathophysiological features of ALS.
2. Identify and apply strategies to improve the function and quality of life for people with ALS.
3. Demonstrate an understanding of research initiatives and findings in ALS.

Target Audience: Patients, caregivers, allied health professionals, neurologists, physiatrists and community support agencies.

Learning Format: Seminar, Discussion Group

08:30 Registration
09:00 **ALS Canada – Mandate & Research Activities**
David Cameron, (Toronto, ON)

Session I Plenary Presentations -Chair: Ian Grant (Halifax, NS)

09:10 **Pathogenesis and Passive Immunization Approaches to Therapy**
Jean-Pierre Julien (Quebec City, PQ)
09:35 **CALS Consortium and Clinical Trials – An Update**
Lorne Zinman (Toronto, ON)
10:00 Question and answer session
10:20 Break

Session II Presentations -Chair: Charles Kreiger (Vancouver, BC)

10:40 **The Genetics of ALS**
Guy Rouleau (Montreal, QC)
11:00 **End of Life Care in ALS**
Wendy Johnston (Edmonton, AB)
12:00 Question and answer session
12:15 Lunch break

Session III Breakout Sessions

13:30 **A. Francophone Session: Patients, Caregivers and Healthcare Professionals:**
Moderators: David Cameron - ALS Canada (Toronto, ON)
Claudine Cook - ALS Quebec (Montreal, QC)
i) **ALS Quebec - Client Services Program - presenters TBD**
ii) **Clinic Presentation - presenters TBD**
B. Physicians and Researchers: Moderator: Ian Grant (Halifax, NS)
i) **Heat Shock Proteins and Proteasomes - How They Lead to Therapy Development**
Heather Durham (Montreal, QC)
ii) **Research With *in vivo* Imaging**
Jasna Kriz (Quebec City, QC)
14:30 Break

Session IV -Chair: David Cameron (Toronto, ON)

14:45 **Management of Pain in ALS**
Angela Genge (Montreal, QC)
15:30 Question and answer session
15:45 Concluding remarks and evaluations
David Cameron (Toronto, ON)



Child Neurology Day Room 206A 08:30-17:00

Chair: Cecil Hahn, Michelle Demos

Course Outline: This year's Child Neurology Day will address two themes: Cerebral Palsy and Emerging Concepts in Central Nervous System Autoimmunity. The morning sessions will explore the theme of Cerebral Palsy from the epidemiological, basic science and management perspectives. The afternoon session on Emerging Concepts in CNS Autoimmunity will address the pathophysiological basis, diagnosis and management of opsoclonus-myoclonus syndrome, CNS vasculitis and autoimmune encephalitis. Highlighting both sessions will be case presentations by child neurology trainees from across Canada.

Learning Objectives: At the end of this session, participants will be able to:

1. Explain current concepts of cerebral palsy, including insights gained from a provincial registry and from animal models.
2. Manage spasticity and movement disorders among children with cerebral palsy.
3. Explain current concepts in central nervous system autoimmunity.
4. Diagnose and manage children with opsoclonus-myoclonus syndrome, CNS vasculitis and autoimmune encephalitis.

Target Audience: Child neurologists, child neurology residents and fellows, neuroscientists, child neurology nurses and other allied health professionals caring for children with neurological disorders.

Learning Format: Seminar, Case Studies, Discussion Group

- | | |
|-------|---|
| 08:30 | Introduction
<i>Cecil Hahn (Toronto, ON), Michelle Demos (Vancouver, BC)</i> |
| 08:45 | Insights From a Provincial Cerebral Palsy Registry
<i>Michael Shevell (Montreal, QC)</i> |
| 09:20 | Discussion |
| 09:30 | Animal Models for Acquired Brain Injury
<i>Jerome Yager (Edmonton, AB)</i> |
| 10:05 | Discussion and break |
| 10:30 | Spasticity and Movement Disorders in Cerebral Palsy
<i>Chantal Poulin (Montreal, QC)</i> |
| 11:05 | Discussion |
| 11:15 | Case Presentations
TBA |
| 12:00 | Lunch |
| 13:30 | CNS Vasculitis and Inflammatory Brain Disorders
<i>Susanne Benseler (Toronto, ON)</i> |
| 14:05 | Discussion |
| 14:15 | Opsoclonus Myoclonus
<i>Juliette Hukin (Vancouver, BC)</i> |
| 14:35 | Discussion |
| 15:00 | Anti-NMDA Receptor Encephalitis in Children
<i>Josep Dalmau (Philadelphia, Pennsylvania, USA)</i> |
| 15:45 | Discussion |
| 16:00 | Case Presentations
TBA |
| 16:55 | Evaluations |

Stroke Co-Developed Symposium Room 2000D 12:00-13:30

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and Boehringer Ingelheim.

Epilepsy Video Session Room 206B 18:00-20:00

- Chair:** Richard McLachlan
- Course Outline:** A picture is worth a thousand words. This Course will demonstrate how video is useful for the diagnosis and classification of seizures.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Distinguish different seizure types using video.
 2. Differentiate seizures from other spells.
 3. Identify physical signs of seizures.
- Target Audience:** Residents, fellows and medical students, adult and pediatric neurologists, nurses and EEG technologists.
- Learning Format:** Case Studies, Discussion Group
- 18:00 **An Interesting Case**
Jorge Burneo (London, ON)
- 18:30 **Video is Useful for Seizures in Children**
Lionel Carmant (Montreal, QC)
- 19:00 **Seizure Semiology in Saskatoon**
Jose Tellez-Zenteno (Saskatoon, SK)
- 19:30 **Another Interesting Case; But Aren't They All**
Richard McLachlan (London, ON)

Movement Disorders SIG Room 207 18:00-20:00

This educational activity is generously sponsored by Allergan Inc. who have not had input to the activity's speaker selection, program or content

- Chairs:** Alex Rajput, David Grimes
- Course Outline:** The SIG will incorporate extensive videos and case histories to be used as the basis for updating delegates on a wide variety of movement disorders and their treatment. Participants will be encouraged to provide opinions on the diagnosis, differential diagnosis and therapies of the cases seen.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Using video examples, know the latest information on diagnosing common and uncommon movement disorders.
 2. Know what the current evidence based treatment options and therapy trends are in Parkinson's disease and other movement disorders.
 3. Know the treatment options that are currently under investigation.
- Target Audience:** Residents, general neurologists and movement disorders neurologists are most welcome and encouraged to participate in the discussions.
- Learning Format:** Case Studies, Discussion Group

Headache SIG Room 2101 18:00-20:00

This educational activity is generously sponsored by Merck who have not had input to the activity's speaker selection, program or content

- Chair:** Werner Becker
- Course Outline:** The Headache SIG will open with a brief overview of advances in headache over the past year. Detailed discussion of the management of headache in the emergency department, and the diagnosis and management of headache due to decreased CSF pressure will follow.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Discuss significant advances in headache management over the previous year.
 2. Provide optimal management in patients with migraine / headache presenting to the ER.
 3. Diagnose and manage patients with headache secondary to decreased CSF pressure / CSF hypovolemia.
- Target Audience:** Adult neurologists, paediatric neurologists, headache specialists, neurology/neurosurgery residents; all interested individuals are welcome.
- Learning Format:** Seminar, Discussion Group
- 18:00 **A Short Summary of Advances in Headache Over the Past Year**
 Werner Becker (Calgary, AB)
- 18:10 Discussion
- 18:15 **The Management of Headache in the Emergency Department**
 Elizabeth Leroux (Montreal, QC)
- 19:00 Discussion
- 19:15 **The Diagnosis and Management of Headache Attributed to Spontaneous Low CSF Pressure**
 Farnaz Amoozegar (Calgary, AB)
- 19:45 Discussion

Neuromuscular Diseases SIG Room 206A 18:00-20:00

- Chairs:** Kristine Chapman
- Course Outline:** This is an interactive session, with group discussion of challenging neuromuscular cases. Written summary of the cases will be provided at the end. Ideas for collaborative research / initiatives may be discussed.
- Learning Objectives:** At the end of this session, participants will:
1. Have discussed 6-8 challenging neuromuscular cases.
 2. Shared ideas for collaborative research / initiatives in neuromuscular disease.
 3. Have acquired knowledge about new developments in neuromuscular disease.
- Target Audience:** Neurologists, physiatrists and residents with an interest in diseases of the peripheral nervous system.
- Learning Format:** Case Studies, Discussion Group

Headache Co-Developed Symposium Room 204AB 06:30-08:00

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and Merck.

Grand Opening Plenary

Scientific & Technical Advances in the Clinical Neurosciences Room 200C 08:00-10:00

This educational activity is generously sponsored by NSFC who have not had input to the activity's speaker selection, program or content

- Learning Objectives:** At the end of this plenary session, participants will have gained knowledge on:
- 1) Recent advances in pediatric epilepsy surgery
 - 2) Changing concepts of Parkinson's disease and how, with advances in treatment and in early disease recognition, the clinical nature of Parkinson's disease will no longer be the disorder that James Parkinson first described."
 - 3) Synaptic autoimmunity and new disorders of memory, cognition, movement disorders and psychosis
- Learning Format:** Plenary

- 08:00 Welcome & Introduction
George Elleker
- 08:10 **Penfield Lecture - Recent Advances in Pediatric Epilepsy Surgery:**
Penfield Would be Proud
James Rutka (Toronto, ON)
- 08:45 **Richardson Lecture - Not James Parkinson's Disease**
Anthony Lang (Toronto, ON)
- 09:20 **Tibbles Lecture - Synaptic Autoimmunity and New Disorders of Memory, Cognition, Movement Disorders and Psychosis**
Josep Dalmau (Philadelphia, Pennsylvania, USA)

Chair's Select Plenary Presentation
Room 200C 10:15-11:45

Chair's Select Plenary Presentations are the best of the abstracts submitted to the 2010 Congress.

Epilepsy Co-Developed Symposium
Room 204AB 12:00-13:30

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and UCB Canada Inc.

Neuropathic Pain Co-Developed Symposium
Room 205BC 12:00-13:30

This event is an accredited group learning activity (Section 1) as defined by the Maintenance of Certification (MOC) program of the Royal College of Physicians and Surgeons of Canada. It is co-developed by the Canadian Neurological Society and Pfizer Canada.

Headache Course Room 205BC 13:30-17:00

This educational activity is generously sponsored by Merck who have not had input to the activity's speaker selection, program or content

Chair: Jonathan Gladstone

Course Outline: This course will provide attendees with an overview of the state of the art in headache medicine, combining the expertise of adult neurologists, a pediatric neurologist, neuroradiologist and neurosurgeon. The Course will begin with an overview of what's new in headache medicine. Next, there will be a "hot topics" session where the pathophysiology of aura will be reviewed and the emerging literature on the relationship between migraine, aura, estrogen & stroke will be reviewed. Attention will then be turned to the pediatric population and an overview of clinical advances and clinical challenges in kids and teenagers with headache will be presented. This will be followed by practical clinical pearls in neuro-imaging of the patient with headache. Finally, the last portion of the afternoon will highlight the emerging neurosurgical treatment options for the patient with intractable disabling headache.

Learning Objectives: At the end of this session, participants will:

1. Gain an appreciation for what's new in headache medicines in 2010, and will be able to integrate these advances into their clinical practice.
2. Solidify their understanding of current concepts in the pathophysiology of migraine and the relationships between migraine, auras, hormones and stroke risk.
3. Increase their comfort level with diagnosing and managing kids and teenagers with a range of headache disorders.
4. Be able to utilize recent advances in headache neuro-imaging to assist in the diagnosis of their headache patients.
5. Gain an appreciation for the emerging neurosurgical options for treatments of their intractable headache patients.

Target Audience: Neurologists, neurology residents, nurses, neuroradiologists and neurosurgeons.

Learning Format: Seminar, Discussion Group

- | | |
|-------|---|
| 13:30 | Introduction
<i>Jonathan Gladstone (Toronto, ON)</i> |
| 13:45 | What's New in Headache Medicine in 2010
<i>Werner Becker (Calgary, AB)</i> |
| 14:05 | Discussion |
| 14:20 | Hot Topics in Headache Pathophysiology – Migraine, Aura & Stroke – What is the Link?
<i>Elizabeth Leroux (Montreal, QC)</i> |
| 14:40 | Discussion |
| 14:55 | Clinical Pearls in the Diagnosis and Management of Kids and Teens with Headache
<i>Joseph Dooley (Halifax, NS)</i> |
| 15:15 | Discussion & break |
| 15:45 | Imaging the Patient with Headache – What to Order & How to Interpret the Results
<i>Richard Farb (Toronto, ON)</i> |
| 16:05 | Discussion |
| 16:20 | Emerging Neurosurgical Options for the Patient with Intractable, Disabling Headache
<i>Zelma Kiss (Calgary, AB)</i> |
| 16:40 | Discussion and evaluations |

Stroke Course Room 204AB 13:30-17:00

This educational activity is generously sponsored by Boehringer Ingelheim who have not had input to the activity's speaker selection, program or content

- Chair:** Ariane Mackey
- Course Outline:** To provide an update on two selected stroke topics: Carotid Stenosis Management and Atrial Fibrillation and Stroke Prevention
- Learning Objectives:** At the end of this session, participants will be:
1. Able to choose appropriate carotid imaging for patients with carotid disease.
 2. Able to make appropriate decisions concerning carotid revascularization.
 3. Familiar with the recommendations concerning the search for arrhythmias in acute stroke (telemetry, Holter).
 4. Updated on appropriate stroke prevention treatment for patients with atrial fibrillation.
- Target Audience:** Neurologists, stroke neurologists, neurology residents, neurosurgery residents, neuroradiologists, vascular neurosurgeons and interventional neuroradiologists.
- Learning Format:** Seminar, Discussion Group
- 13:30 Introduction
Ariane Mackey (Quebec City, QC)
- 13:45 **Non-Invasive Angiography For Carotid Disease: From Technology to Clinical Relevance**
Daniel Roy (Montreal, QC)
- 14:05 **Carotid Stenosis: When Should We Revascularize?**
Jeff Minuk (Montreal, QC)
- 14:30 **Carotid Stenosis: Stent vs. Surgery. The CREST Results and What's Next?**
Frank Silver (Toronto, ON)
- 14:55 Panel discussion and break
- 15:45 **Atrial Fibrillation-Related Strokes: Optimizing Diagnosis and Prevention**
David Gladstone (Toronto, ON)
- 16:05 **RE-LY and Athena: What's the Bottom Line?**
Theodore Wein (Montreal, QC)
- 16:30 Panel discussion and evaluations

Neurovascular Surgery Course Room 201BC 13:30-17:00

- Chair:** R. Loch Macdonald
- Course Outline:** The course will provide an update on current management of some surgically-relevant aspects of neurovascular disease, focusing on carotid stenosis, subarachnoid hemorrhage, intracerebral hemorrhage and brain vascular malformations.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Explain the indications for and methods of treatment of carotid stenosis.
 2. Describe some techniques for treatment of brain vascular malformations.
 3. Know how to manage in the intensive care unit intracerebral and subarachnoid hemorrhage.
 4. Manage common spinal vascular malformations.
- Target Audience:** Neurosurgery residents, fellows and faculty.
- Learning Format:** Seminar, Discussion Group
- 13:30 Introduction
R. Loch Macdonald (Toronto, ON)
- 13:45 **Carotid Stenosis: Indications and Management Post-CREST**
Julian Spears (Toronto, ON)
- 14:05 Discussion
- 14:20 **Brain Arteriovenous Malformations: Surgical Treatment**
Ian Fleetwood (Halifax, NS)
- 14:40 Discussion
- 14:55 **Update on Management of Subarachnoid and Intracerebral Hemorrhage**
Stephan Mayer (New York, New York, USA)
- 15:15 Discussion
- 15:30 Break
- 15:45 **Spinal Vascular Malformations**
Mel Boulton (London, ON)
- 16:05 Discussion
- 16:20 **Postcourse Quiz: How Would You Treat this Neurovascular Patient?**
R. Loch Macdonald (Toronto, ON)
- 16:40 Discussion and evaluations

Epilepsy Course - Epilepsy Management - From Sci-fi to Reality**Room 202 13:30-17:00***This educational activity is generously sponsored by UBC Canada Inc. who have not had input to the activity's speaker selection, program or content*

- Chair:** S. Nizam Ahmed
- Course Outline:** To introduce the audience to cutting edge research and technology that holds the promise for a newer generation of investigations and treatment for epilepsy.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Understand the potential role of nanotechnology in neurological diseases.
 2. Understand the role and goal of a modern / next generation neurophysiology laboratory.
 3. Understand the role of computational neuroscience research in epilepsy management.
 4. Introduce and reinforce the concept of "Global Treatment Strategies" in the care of epilepsy patients.
 5. Understand the concept of minimally invasive surgery for medically intractable epilepsy.
- Target Audience:** Neurologists, epileptologists, neurosurgeons, basic scientists and neurophysiologists.
- Learning Format:** Seminar, Discussion Group
- 13:30 Introduction
S. Nizam Ahmed (Edmonton, AB)
- 13:45 **The Potential Role of Nanotechnology in Epilepsy Care**
Mark Saltzman (New Haven/Yale, Connecticut, USA)
- 14:05 Discussion
- 14:20 **From High-Tech Patient-Specific Epilepsy Therapies, to Global Therapies For All**
Sam Wiebe (Calgary, AB)
- 14:40 Discussion
- 14:55 **The Role and Goal of a Futuristic Neurophysiology Lab**
G. Bryan Young (London, ON)
- 15:15 Discussion and break
- 15:45 **Treating Epilepsy Via Adaptive Neurostimulation**
Joelle Pineau (Montreal, QC)
- 16:05 Discussion
- 16:20 **Minimally Invasive Surgery for Medically Intractable Epilepsy**
Matthew Wheatley (Edmonton AB)
- 16:40 Discussion and evaluations

Neuro-oncology Course Room 203 13:30-17:00

This educational activity is generously sponsored by Elekta who have not had input to the activity's speaker selection, program or content

Chair: David Eisenstat

Course Outline: The Neuro-oncology Course will provide an update on the advances in diagnostic and therapeutic approaches to the patient with a malignant glioma. The course will be of interest to trainees and practitioners in neuropathology, neurology, neurosurgery and pediatric neurology.

Learning Objectives: At the end of this session, participants will be able to:

1. Identify patients with a potential diagnosis of a malignant glioma and recommend further diagnostic and staging investigations.
2. Differentiate low grade from high grade gliomas and appreciate emerging molecular diagnostic approaches.
3. Explain the rationale for current surgical, radiation and medical (chemotherapy) management approaches for adults and children with malignant gliomas.
4. Introduce and reinforce the concept of "Global Treatment Strategies" in the care of epilepsy patients.
5. Assess emerging multidisciplinary treatment strategies for malignant gliomas for adults and children.

Target Audience: Neurologists, pediatric neurologists, neurosurgeons, neuropathologists, radiation oncologists, medical and pediatric oncologists.

Learning Format: Seminar, Discussion Group

- | | |
|-------|---|
| 13:30 | Introduction
<i>David Eisenstat (Winnipeg, MB)</i> |
| 13:45 | Radiation Therapy for Glioma: Where Have We Been, Where Are We Going and How Are We Going to Get There?
<i>Arjun Sahgal (Toronto, ON)</i> |
| 14:05 | Molecular Diagnostics and Neuropathology of Gliomas
<i>Stephen Yip (Vancouver, BC)</i> |
| 14:20 | Discussion |
| 14:40 | Advances and Controversy in Surgical Neuro-oncology
<i>Rolando Del Maestro (Montreal, QC)</i> |
| 14:55 | Discussion |
| 15:15 | Targeted Therapies for Malignant Gliomas - A Clinical Trialist's Perspective
<i>James Perry (Toronto, ON)</i> |
| 15:45 | Discussion and break |
| 16:05 | Discussion |
| 16:20 | The Past, Present and Future Treatment of Malignant Gliomas in Children
<i>David Eisenstat (Winnipeg, MB)</i> |
| 16:40 | Discussion and evaluations |

Multiple Sclerosis Course - Update for the MS Professional
Room 205A 13:30-17:00

Chair: Francois Emond

Course Outline: This course, targeting the MS professional, aims to discuss four hot topics in the field of MS and to present up-to-date evidence and clinical acumen for each of those. Experts in the field will present the latest on clinical trials, natalizumab and PML, MS mimics, and chronic cerebrospinal venous insufficiency, with discussion periods allowing the audience to interact directly with the speakers on those important yet controversial subjects.

Learning Objectives: At the end of this session, participants will be able to:

1. Discuss the various up-and-coming MS treatments, according to evidence from the recent or ongoing clinical trials, and present those treatments to their patients.
2. Safely manage MS patients treated with Natalizumab according to the most recent evidence, diagnose early an eventual case of PML, and apply up-to-date management principles for this disease.
3. Integrate a recommended "MS workup" in their practice, in order to accurately differentiate the disease from its mimics on clinical and paraclinical grounds.
4. Discuss how the CCSVI hypothesis can be integrated with the bulk of accumulated physiopathological knowledge in MS, and discern the next steps in the research about this entity.

Target Audience: MS neurologists, MS fellows, MS nurses, neurologists with an interest in MS, senior neurology residents.

Learning Format: Seminar, Discussion Group

- | | |
|-------|---|
| 13:30 | Introduction
<i>Francois Emond (Quebec, QC)</i> |
| 13:35 | Update on New Therapeutics and Clinical Trials
<i>Mark S. Freedman (Ottawa, ON)</i> |
| 14:05 | Discussion |
| 14:20 | Update on Natalizumab and PML
<i>Pierre Duquette (Montreal, QC)</i> |
| 14:50 | Discussion |
| 15:05 | Break |
| 15:20 | Diagnostic Challenges: MS Mimics
<i>François Emond (Quebec, QC)</i> |
| 15:50 | Discussion |
| 16:05 | Chronic Cerebrospinal Venous Insufficiency: What's the Evidence? What's Coming Up?
<i>E. Mark Haacke (Detroit, Michigan, USA)</i> |
| 16:35 | Discussion and evaluations |

Plenary Session - CNS, CSCN and CACN Neurology Room 200C 08:30-10:00

Learning Objectives: At the end of this session, participants will have gained knowledge on:

1. Motor and sensory map changes with epilepsy.
2. Focal Peripheral Neuropathies.

Learning Format: Plenary

08:30 Welcome & Introduction

Lyle Weston

08:40 **Gloor Lecture - Motor and Sensory Map Changes with Epilepsy: Implications for Interictal Behavioural Co-Morbidities**

Cam Teskey (Calgary, AB)

09:20 **Focal Peripheral Neuropathies: A 25 Year Update in 25 Minutes**

John Stewart (Vancouver, BC)

Plenary Session - CNSS Neurosurgery Room 204AB 08:30-10:00

Learning Objectives: At the end of this session, participants will have gained knowledge on:

1. Understanding the mechanisms and recovery of the comatose human brain.
2. The surgical management of spinal neoplasms.

Learning Format: Plenary

08:30 Welcome & Presentation of CNSS Lifetime Achievement Award to Charles Tator

J. Max Findlay

08:40 **Inside the Black Box: Illuminating the Comatose Human Brain**

Stephan Mayer (New York, New York, USA)

09:20 **Surgical Management of Spinal Neoplasms**

Ziya Gokaslan (Baltimore, Maryland, USA)

Break - Exhibit Viewing Room 200AB 10:00-10:15

Visit the Exhibit Hall and show our industry supporters that their continued presence and financial support of your Congress matters to you! Whether you've had a chance to visit or not, stop in and let our Sponsors & Exhibitors know that you value their support.



**Platforms - Six Simultaneous Sessions
10:15-12:30**

MS	Room 200C	Moderator: Mark Freedman
General Neurology & Dementia	Room 201BC	Moderator: TBA
Neuromuscular & Neuro-oncology	Room 202	Moderator: Mike Nicolle, James Perry
Pediatric Neurology	Room 203	Moderator: Cecil Hahn
Stroke Prevention & Treatment 1	Room 204A	Moderator: Matthew Hogan
Stroke Recovery & Rehabilitation	Room 205A	Moderator: Adam Kirton

**Lunch - Exhibit Viewing - Digital Mini-Platforms
Room 200AB 12:30-14:00**

Buffet Lunch will be available in the Exhibit Hall

**Platforms - Six Simultaneous Sessions
14:00-16:30**

Spine	Room 200C	Moderator: Ramesh Sahjpaul
Epilepsy	Room 201BC	Moderator: Seyed Mirsattari
General Neurosurgery & Neuroradiology	Room 202	Moderator: R. Loch Macdonald
Trauma, Critical Care & Neurosurgery	Room 203	Moderator: Jeanne Teitelbaum
Stroke Prevention & Treatment 2	Room 204A	Moderator: TBA
Stroke Health Serv. Research & Acute Treatment	Room 205A	Moderator: Theodore Wein

**Digital Poster and Exhibit Viewing
Room 200AB 16:30-18:30**

Remember to introduce yourself to our industry supporters in the Exhibit Hall whenever you have a moment to spare! Their contributions to the CNSF and the Congress allow us to continue to independently provide the quality Congress content you expect.

Reviewer of the Year Presentation and the Journal Editors' Report

Room 200C 08:00-08:15

G. Bryan Young presenting the Reviewer of the Year Award and his Annual Journal Report

CBANHC Report

Room 200C 08:15-08:30

Chair Richard Riopelle presenting the Annual CBANHC Report

Distinguished Guest Lecture

Room 200C 08:30-09:30

James Orbinski

This educational activity is generously sponsored by Neurological Sciences Foundation of Canada who have not had input to the activity's speaker selection, program or content



Dr. Orbinski is a veteran of many of the world's most disturbing and complex humanitarian emergencies. He accepted the Nobel Peace Prize on behalf of Medecins Sans Frontieres (Doctors Without Borders) in 1999.

A brilliant and mesmerizing orator, Orbinski offers a compelling look at the ravages of genocide and civil war, the role of humanitarianism, and the conflict that arises from combining humanitarian assistance with a political agenda.

Orbinski is an outspoken and passionate speaker who is deeply committed to the core principles of volunteerism and impartiality, with a belief that everyone deserves both medical assistance and the recognition of his or her humanity.

08:30 **Welcome & Introduction**

George Elleker

Currently Active Canadian Clinical Trials

Room 200C 09:30-09:45

09:30 **Phase III Randomized, Placebo-Controlled Trial of Minocycline in Early Suspected MS (Clinically Isolated Syndromes)**

Luanne Metz (Calgary, AB)

09:37 **Endothelin Antagonists for Subarachnoid Hemorrhage: CONSCIOUS 2 and 3 Randomized Trials**

Loch Macdonald (Toronto, ON)

Break - Exhibit Viewing
Room 200AB 09:45-10:15

This is your last opportunity to visit the Exhibit Hall and show our industry supporters that their continued presence and financial support of your Congress matters to you! Whether you've had a chance to visit or not, stop in and let our Sponsors & Exhibitors know that you value their support.

Book Signing - James Orbinski
Room 200AB 09:45-10:15

*Dr. Orbinski will be signing copies of his book, **An Imperfect Offering: Humanitarian Action in the Twenty-first Century**, in the Exhibit Hall after his lecture. Copies of the book are available for purchase.*

Grand Rounds
Room 200C 10:15-12:00

Chairs: Philippe Major (Montreal, QC), Martin Savard (Quebec City, QC), Genevieve Milot (Quebec City, QC)

Learning Objectives: At the end of this session, participants will have:

1. Discussed challenging case studies in general neurology, neurosurgery and child neurology.
2. Analyzed / diagnosed challenging case studies in general neurology, neurosurgery and child neurology.

Learning Format: Case Studies, Discussion Group

CNS Case Presenter - Nicolas Chrestian

Case Title: Doctor, Please Temperate Your Psychiatric Diagnosis

CNSS Case Presenter - TBA

Case Title: TBA

CACN Case Presenter - Sébastien Perreault

Case Title: One Flew Over the Cuckoo's Nest

Lunch - Exhibit Viewing - Digital Mini-Platforms
Room 200AB 12:00-13:30

Buffet Lunch will be available in the Exhibit Hall

Neuro-ophthalmology Course Room 202 13:30-17:00

- Chair:** William Fletcher
- Course Outline:** The 2010 Neuro-ophthalmology Course will focus on common clinical problems that fall under the purview of the neurologist but often pose diagnostic difficulties. The course will cover 5 topics: interpretation of visual fields, ischemia of retina and optic nerve, idiopathic intracranial hypertension, orbital disease and supranuclear eye-movement disorders. A half-hour discussion period at the end of the session will be supplemented by presentation of interesting cases.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Interpret visual field defects caused by neurological disease.
 2. Diagnose ischemia of retina and optic nerve and giant cell arteritis.
 3. Recognize and manage idiopathic intracranial hypertension.
 4. Investigate and diagnose orbital conditions that present to the neurologist.
 5. Analyze and localize supranuclear eye-movement disorders.
- Target Audience:** General neurologists, neurology residents and other neurologist interested in increasing their neuro-ophthalmological knowledge and skills.
- Learning Format:** Seminar, Discussion Group
- | | |
|-------|---|
| 13:30 | Introduction
<i>William Fletcher (Calgary, AB)</i> |
| 13:35 | Visual Fields for the Neurologist
<i>Jason Barton (Vancouver, BC)</i> |
| 14:00 | Discussion |
| 14:05 | Idiopathic Intracranial Hypertension
<i>Deborah Friedman (Rochester, NY, USA)</i> |
| 14:30 | Discussion |
| 14:35 | Ocular Ischemia for the Neurologist
<i>Edward Atkins (Saskatoon, SK)</i> |
| 15:00 | Discussion |
| 15:05 | Break |
| 15:20 | Orbital Disease for the Neurologist
<i>Francois Evoy (Sherbrooke, QC)</i> |
| 15:45 | Discussion |
| 15:50 | Supranuclear Eye-Movement Disorders
<i>William Fletcher (Calgary, AB)</i> |
| 16:20 | Panel discussion and interactive case presentations |
| 16:55 | Evaluations |

Interventional Neuroradiology Course - Difficult Aneurysms
Room 201B 13:30-17:00

- Chairs:** Alain Weill
- Course Outline:** To provide an update on diagnostic and endovascular management of difficult and complex aneurysms.
- Learning Objectives:** At the end of this session, participants will be able to:
1. Define, diagnose and discuss treatment plan for blister aneurysms.
 2. Choose the best imaging modality to diagnose recurrent aneurysm and discuss their treatment.
 3. Discuss treatment modalities of giant aneurysms.
 4. Manage anticoagulants antiagregant and thrombolytic drugs in haemorrhagic situations.
 5. Critique the new technology of flow diverter stent.
- Target Audience:** Neuroradiologists, vascular neurosurgeons, interventional neuroradiologists and stroke neurologists interested in aneurysms.
- Learning Format:** Seminar, Discussion Group
- 13:30 Introduction
Alain Weill (Montreal, QC)
- 13:45 **Blister Aneurysms: Definition, Diagnostic and Treatment**
Gary Redekop (Vancouver, BC)
- 14:05 Discussion
- 14:20 **Recurrent Aneurysms: Diagnostic and Treatment**
Robert Willinsky (Toronto, ON)
- 14:40 Discussion
- 14:55 **Giant Aneurysms: Treatments and Results**
Danna Iancu Gontard (Winnipeg, ON)
- 15:30 Break
- 15:45 **Flow Diverters: Limits and Complications**
Cian O'Kelly (Edmonton, AB)
- 16:05 Discussion
- 16:20 **Managing the Anticoagulants, Antiagregants and Thrombolytics Drugs in Difficult Situations**
Geneviève Milot (Quebec City, QC)
- 16:40 Discussion and evaluations

What's New in Neurosurgery? Room 203 13:30-17:00

Chair:	Pascale Lavoie
Course Outline:	This course will provide current updates, including new clinical recommendations concerning a variety of neurosurgical pathologies. Speakers will discuss the latest scientific evidence concerning the use of carotid artery stenting and management of spinal cord injury, the indication and efficacy of vertebroplasty, the latest advances in neuro-oncology and the endoscopic management of anterior cranial base and suprasellar lesions.
Learning Objectives:	At the end of this session, participants will be able to: 1. Recognize the indications of carotid artery stenting. 2. Discuss the efficacy of vertebroplasty. 3. Be aware of new evidence concerning spinal cord injury management. 4. Be aware of new advances in neuro-oncology. 5. Describe the indications and limitations of the expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions.
Target Audience:	General neurosurgeons and residents in neurosurgery.
Learning Format:	Seminar, Discussion Group
13:30	Introduction <i>Pascale Lavoie (Québec City, QC)</i>
13:45	What's New in Spine Surgery? <i>R. John Hurlbert (Calgary, AB)</i>
14:05	Discussion
14:20	Carotid Artery Stenting: The New Evidence <i>Genevieve Milot (Quebec City, QC)</i>
14:40	Discussion
14:55	What's New in Neuro-oncology? <i>David Macdonald (London, ON)</i>
15:15	Discussion
15:30	Break
15:45	Expanded Endoscopic Endonasal Approach for Anterior Cranial Base and Suprasellar Lesions: Indications and Limitations <i>Fred Gentili (Toronto, ON)</i>
16:05	Discussion
16:20	What's New in Epilepsy Surgery <i>Walter Hader (Calgary, AB)</i>
16:40	Discussion
16:55	Evaluations

Neurocritical Care Course Room 204B 13:30-17:00

Chair: Jeanne Teitelbaum, Draga Jichici

Course Outline: Through the use of case histories the participant will learn about utilization of ancillary testing in brain death, appropriate use of induced hypothermia for a variety of neurologic problems, how to prognosticate outcome after cardiac arrest, have an understanding of the newest guidelines for the management of ICH and SAH, have a better understanding of EEG monitoring in ICU and learn of new experimental techniques.

Learning Objectives: At the end of this session, participants will be able to:

1. Know about the current acceptable ancillary tests used in the neurological determination of brain death.
2. Know the indications, technique, complications and limitations of induced hypothermia in a number of neurologic disorders.
3. Know about the evidence on which the current guidelines for prognostication after cardiac arrest are based.
4. Know about the newest recommendations in the management of SAH and ICH, as well as the limitations of the guidelines.
5. Learn when and how to apply continuous EEG monitoring in ICU.

Target Audience: Neurologists, neurosurgeons, emergency physicians and intensive care physicians, as well as residents in these same fields.

Learning Format: Seminar, Discussion Group

- | | |
|-------|---|
| 13:30 | Introduction
<i>Draga Jichici (Hamilton, ON)</i> |
| 13:45 | Ancillary Tests in Brain Death
<i>Martin Savard (Quebec City, QC)</i> |
| 14:05 | Discussion |
| 14:20 | Induced Hypothermia: When and How to Use It
<i>Draga Jichici (Hamilton, ON)</i> |
| 14:40 | Discussion |
| 14:55 | Prognostication after Cardiac Arrest
<i>G. Bryan Young (London, ON)</i> |
| 15:15 | Discussion |
| 15:30 | Break |
| 15:45 | What is New in SAH and ICH
<i>Jeanne Teitelbaum (Montreal, QC)</i> |
| 16:05 | Discussion |
| 16:20 | Continuous EEG Monitoring in ICU
<i>Cecil Hahn (Toronto, ON)</i> |
| 16:40 | Discussion |
| 16:55 | Evaluations |

Neuromuscular Diseases Course Room 204A 13:30-17:00

Chair: Annie Dionne, Christopher White

Course Outline: The neuromuscular course will provide an update across a number of areas. The invited speakers will review what's new in peripheral nerve surgery; discuss controversies in entrapment neuropathies; reappraise hereditary myopathies; bring to light the new clinically relevant neuromuscular research of the last year.

Learning Objectives: At the end of this session, participants will be able to:

1. Identify patients who are most likely to benefit from peripheral nerve surgery and explain what those benefits may be.
2. Develop an approach to patients referred with potential uncommon or controversial peripheral nerve entrapment syndromes.
3. Discuss and apply recent findings in the scientific literature as they apply to patients with neuromuscular disease.
4. Evaluate appropriately patients with inherited myopathies.

Target Audience: Neurologists, neurosurgeons, residents and electromyographers.

Learning Format: Seminar, Discussion Group

- | | |
|-------|--|
| 13:30 | Introduction
<i>Christopher White (Calgary, AB), Annie Dionne (Montreal, QC)</i> |
| 13:35 | What's New and Exciting in Peripheral Nerve Surgery
<i>Rajiv Midha (Calgary, AB)</i> |
| 14:05 | Discussion |
| 14:15 | Controversial Entrapment Neuropathies
<i>John Stewart (Vancouver, BC)</i> |
| 14:45 | Discussion |
| 14:55 | Panel Discussion
<i>Rajiv Midha (Calgary, AB), John Stewart (Vancouver, BC)</i> |
| 15:10 | Break |
| 15:30 | Hereditary Myopathies: Old Order Revisited
<i>Sandrine Larue (Montreal, QC)</i> |
| 16:00 | Discussion |
| 16:15 | Update in Neuromuscular Disease - What's New
<i>Timothy Benstead (Halifax, NS)</i> |
| 16:45 | Discussion and evaluations |

Spine Course - Controversies in Spinal Neurosurgery

Room 201C 13:30-17:00

This educational activity is generously sponsored by J&J / Depuy Spine / Synthes who have not had input to the activity's speaker selection, program or content

Chair: Eric Massicotte

Course Outline: Three specific topics will be debated in order to facilitate discussion: Metastatic spine cancer; indications for decompression and stabilization, role of instrumented fusion for spondylolisthesis, and indications for use of biological agents.

Learning Objectives: At the end of this session, participants will be able to:

1. Discuss the indications for surgical intervention for metastatic spine cancer.
2. Appreciate the advantages of timing of these interventions.
3. Discuss the use of instrumented fusion techniques for lumbar spine decompression in the face of spondylolisthesis.
4. Discuss options available to patients with respect to biological agents.

Target Audience: All neuroscience healthcare professionals.

Learning Format: Case Studies, Discussion Group

- | | |
|-------|--|
| 13:30 | Introduction
<i>Eric Massicotte (Toronto, ON)</i> |
| 13:35 | Case presentation #1
<i>Eric Massicotte (Toronto, ON)</i> |
| 13:45 | Treatment option #1
<i>Brad Jacobs (Calgary, AB)</i> |
| 14:00 | Treatment option #2
<i>David Mercier (Quebec, QC)</i> |
| 14:15 | Discussion |
| 14:40 | Case presentation #2
<i>Eric Massicotte (Toronto, ON)</i> |
| 14:55 | Treatment option #1
<i>Ramesh Sahjpaul (Vancouver, BC)</i> |
| 15:10 | Treatment option #2
<i>Sean Christie (Halifax, NS)</i> |
| 15:25 | Discussion |
| 15:50 | Case presentation #3
<i>Eric Massicotte (Toronto, ON)</i> |
| 16:05 | Treatment option #1
<i>Ramesh Sahjpaul (Vancouver, BC)</i> |
| 16:20 | Treatment option #2
<i>Eric Massicotte (Toronto, ON)</i> |
| 16:35 | Discussion |
| 16:45 | Debate conclusion and evaluations |

What's New in Neurology Room 200C 13:30-17:00

Chair: Nicolas Dupré

Course Outline: The course will focus on new discoveries and promising therapeutic avenues in peripheral nerve injury, hereditary myopathies, and neurodegenerative disease such as ALS, frontotemporal dementias, hereditary ataxias and spastic parapareses.

Learning Objectives: At the end of this session, participants will be able to:

1. Initiate the diagnostic work up of a patient presenting with progressive ataxia or spastic paraparesis based on the latest genetic breakthroughs.
2. Integrate the recent knowledge in biology and genetics to their understanding of frontotemporal dementias.
3. Identify where current research in ALS will influence their clinical practice.
4. Understand where recent research in hereditary myopathies has allowed a better classification of these entities and where current research protocols will integrate with clinical practice.
5. Identify patients most susceptible to benefit from nerve repair procedures, and understand where late discoveries are enhancing technical approaches.

Target Audience: Neurologists with an interest in dementia, ALS, neuromuscular disorders, EMG, neurogenetics and neurodegenerative diseases; neuropathologists; neurosurgeons with an interest in trauma and nerve injury.

Learning Format: Seminar, Discussion Group

- | | |
|-------|--|
| 13:30 | Introduction
<i>Nicolas Dupré (Quebec City, QC)</i> |
| 13:45 | What's New in Neurogenetics
<i>Nicolas Dupré (Quebec City, QC)</i> |
| 14:05 | Discussion |
| 14:20 | What's New in Frontotemporal Dementia?
<i>Gabriel Leger (Montreal, QC)</i> |
| 14:40 | Discussion |
| 14:55 | What's New in ALS
<i>Jean-Pierre Julien (Quebec City, QC)</i> |
| 15:15 | Discussion and break |
| 15:45 | What's New in Muscular Dystrophies
<i>Jack Puymirat (Quebec City, QC)</i> |
| 16:05 | Discussion |
| 16:20 | What's New in Peripheral Nerve Surgery and Repair
<i>Line Jacques (Montreal, QC)</i> |
| 16:40 | Discussion and evaluations |

EEG Course Room 205A 13:30-17:00

Chair: Seyed Mirsattari

Course Outline: A review of the pathophysiology, waveform features, and treatment of common epileptiform EEG abnormalities in children and adults and how to differentiate them from common non-epileptic waveforms of metabolic origin such as trochaic waves or benign epileptiform variants.

Learning Objectives: At the end of this session, participants will:

1. Understand the pathophysiology of common epileptic EEG findings such as interictal epileptic spikes, focal seizures, generalized spikes and waves, generalized seizures, periodic lateralized epileptiform discharges (PLEDs), Rolandic and occipital spikes.
2. Become familiar with pattern recognition of common epileptic abnormalities such as interictal epileptic spikes, focal seizures, generalized spikes and waves, generalized seizures, PLEDs, PLEDs, plus, benign and malignant Rolandic and occipital spikes, plus triphasic waves and benign epileptiform variants.
3. Become familiar with the clinical significance and treatment of the above-mentioned waveforms.

Target Audience: Neurology and neurosurgery residents, practicing neurologists, EEG technologists, epilepsy fellows, and CNS nurses.

Learning Format: Seminar, Discussion Group

- | | |
|-------|---|
| 13:30 | Introduction
<i>Seyed Mirsattari (London, ON)</i> |
| 13:45 | Interictal Epileptic Spikes and Partial Seizures
<i>Richard Desbiens (Quebec City, QC)</i> |
| 14:05 | Discussion |
| 14:20 | Triphasic Waves, Generalized Spikes-and-Waves and Generalized Seizures
<i>Charles Deacon (Sherbrooke, QC)</i> |
| 14:40 | Discussion |
| 14:55 | Periodic Lateralized Epileptiform Discharges (PLEDS) and PLEDs plus
<i>Paolo Federico (Calgary, AB)</i> |
| 15:15 | Discussion and break |
| 15:45 | Benign and Malignant Rolandic and Occipital Spikes
<i>Mary Connolly (Vancouver, BC)</i> |
| 16:20 | Benign Epileptiform Variants
<i>Seyed Mirsattari (London, ON)</i> |
| 16:40 | Discussion and evaluations |

WINNERS OF THE 2010 SOCIETY PRIZES

THE PRESIDENT'S PRIZE CANADIAN ASSOCIATION OF CHILD NEUROLOGY

Electrocorticography and seizure outcomes in children with lesional epilepsy

Jennifer N. Gelinas

K.G. MCKENZIE PRIZE IN BASIC NEUROSCIENCE RESEARCH CANADIAN NEUROSURGICAL SOCIETY

2010 Prize Awarded to Two Recipients

Augmenting adult hippocampal neurogenesis using targeted brain stimulation:
implications for memory networks

Scellig Stone

Oligodendroglioma cell lines containing t(1;19)(q10;p10)

John Kelly

K.G. MCKENZIE PRIZE IN CLINICAL NEUROSCIENCE RESEARCH CANADIAN NEUROSURGICAL SOCIETY

Efficacy and active ingredients in an epidural analgesic paste after lumbar
decompression: a prospective randomized double-blind controlled trial

Roberto Diaz

THE HERBERT JASPER PRIZE CANADIAN SOCIETY OF CLINICAL NEUROPHYSIOLOGISTS

A descriptive analysis of prognostic indicators in patients with
non-convulsive status epilepticus in a tertiary hospital population

Chantelle Hrazdil

FRANCIS MCNAUGHTON MEMORIAL PRIZE CANADIAN NEUROLOGICAL SOCIETY

Cognitive impairment in ARCA-1, a newly discovered pure cerebellar ataxia syndrome

Robert Laforce

ANDRE BARBEAU MEMORIAL PRIZE CANADIAN NEUROLOGICAL SOCIETY

Molecular mechanisms associated with an increased seizure susceptibility
in adults after experimental febrile seizures in juveniles

Aylin Reid

PLATFORM AND POSTER PRESENTATION LEARNING OBJECTIVE:

At the end of the platform sessions and after reviewing the digital posters, participants will be aware of current research and advances in patient care of neuroscience patients in Canada.

TARGET AUDIENCE: ALL NEUROSCIENCE HEALTHCARE PROFESSIONALS

CHAIR'S SELECT PLENARY PRESENTATIONS

Chair: Michael Hill, Loch Macdonald June 9, 2010 Room 200C

- | | | |
|------|-------|--|
| A-01 | 10:15 | Cognitive impairment in ARCA-1, a newly discovered pure cerebellar ataxia syndrome
<i>R Laforce (Quebec)*, JP Buteau (Quebec), J Bouchard (Quebec), GA Rouleau (Montréal), B Lefebvre (Lévis), RW Bouchard (Quebec), N Dupré (Quebec)</i> |
| A-02 | 10:30 | Oligodendroglioma cell lines containing t(1;19)(q10;p10)
<i>JJ Kelly (Calgary)*, MD Blough (Calgary), O Stechishin (Calgary), M Perizzolo (Calgary), JA Chan (Calgary), D Demetrick (Calgary), RN Auer (Calgary), WJ Hader (Calgary), R Jenkins (Rochester), S Weiss (Calgary), J Cairncross (Calgary)</i> |
| A-03 | 10:45 | Efficacy and active ingredients in an epidural analgesic paste after lumbar decompression: a prospective randomized double-blind controlled trial
<i>RJ Diaz (Calgary)*, R Hurlbert (Calgary)</i> |
| A-04 | 11:00 | Meralgia paresthetica: topography of the sensory deficit
<i>JD Stewart (North Vancouver)*</i> |
| A-05 | 11:15 | Efficacy and safety of idebenone in children with Friedreich's ataxia: results of the 6-month US phase 3 study
<i>R Lynch (Philadelphia), S Perlman (Los Angeles), WT Andrews (Charlestown)*, T Meier (Liestal)</i> |
| A-06 | 11:30 | Treatment of acute ischemic stroke in Old World primates with the PSD-95 inhibitor NA-1
<i>DJ Cook (Toronto)*, L Teves (Toronto), M Tymianski (Toronto)</i> |
| A-07 | 11:45 | Untangling the mystery of poor clinical outcomes despite excellent recanalization: analysis of data from the Penumbra Pivotal Stroke Trial
<i>M Goyal (Calgary)*, BK Menon (Calgary), MD Hill (Calgary), AM Demchuk (Calgary)</i> |

MULTIPLE SCLEROSIS

Chair: Mark Freedman June 10, 2010 Room 200C

- | | | |
|------|-------|--|
| B-01 | 10:15 | HLA-DRB1 and pediatric multiple sclerosis
<i>G Disanto (Oxford), A Handel (Oxford), K Morrison (Oxford), GC Ebers (Oxford), D Sadovnick (Vancouver)*, B Banwell (Toronto), D Arnold (Montreal), A Bar-Or (Montreal)</i> |
| B-02 | 10:30 | 8-week interim analysis of the compliance with interferon beta 1a (Avonex® PS) administered intramuscularly (IM) every week (qW) to patients with relapsing-remitting multiple sclerosis (COMPASS) study
<i>M Oh (Burlington)*, J Otis (Burlington), T Napper (Burlington), L Krajewski (Burlington), VA Migounov (Mississauga), M Kremenichutzky (London)</i> |
| B-03 | 10:45 | Comparability of randomized controlled versus observational studies: findings from the Toronto observational study of natalizumab in multiple sclerosis
<i>KM Krysko (Toronto)*, PW O'Connor (Toronto)</i> |
| B-04 | 11:00 | Treatment of aggressive MS with high intensity immunoablation and autologous stem cell transplant (IA/ASCT) can stabilize or improve disease outcomes without compromising on patient related outcomes
<i>MJ Bowman (Ottawa), MS Freedman (Ottawa)*, HL Atkins (Ottawa)</i> |
| B-05 | 11:15 | Canadian Asians with multiple sclerosis (CAMS) study: comparison of clinical features in Canadian-born versus immigrant patients
<i>D Sadovnick (Vancouver)*, J Lee (Vancouver), T Traboulsee (Vancouver)</i> |
| B-06 | 11:30 | The impact of disease modifying therapies (DMTs) on the health-related quality of life (HRQL) of men with relapsing-remitting multiple sclerosis (RRMS)
<i>SA Warren (Edmonton)*, KV Turpin (Edmonton), WJ Hader (Saskatoon), KG Warren (Edmonton)</i> |
| B-07 | 11:45 | Quality of life, cognitive function and mood in young adults with pediatric-onset multiple sclerosis
<i>KM Krysko (Toronto)*, PW O'Connor (Toronto)</i> |

PLATFORM SESSIONS

- B-08 12:00 Modeling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying-drugs that delay disability progression**
MG Brown (Halifax), C Skedgel (Halifax), S Kirby (Halifax)*
- B-09 12:15 Monoclonal antibodies and progressive multifocal leukoencephalopathy: need for ongoing monitoring**
DL Keene (Ottawa), C Legare (Ottawa), S Semalulu (Ottawa), D Vu (Ottawa)*

GENERAL NEUROLOGY AND DEMENTIA

Chair: TBA June 10, 2010 Room 201BC

- C-01 10:15 Acquired mitochondrial toxicity in patients with adult-onset chronic progressive external ophthalmoplegia**
G Pfeffer (Vancouver), S Sirrs (Vancouver), HC Cote (Vancouver), MM Mezei (Vancouver)*
- C-02 10:30 Invasive investigation for insular epilepsy: opened micro-dissection of the Sylvian fissure (type 1) vs. combined Yale-Grenoble stereotactic implantation (type 2)**
A Bouthillier (Montréal), W Surbeck (Montréal), R Malak (Montréal), DK Nguyen (Montréal)*
- C-03 10:45 Central nervous system granulomas associated with anti-tumor necrosis factor alpha therapy**
J Hegedus (Halifax), J Wooff (Halifax), D Mosher (Calgary), C Maxner (Halifax)*
- C-04 11:00 Early clinical features differentiate cerebellar variant of multiple system atrophy and sporadic ataxia**
*AJ Lloyd-Smith (Vancouver), M Schulzer (Vancouver), SD Spacey (Vancouver)**
- C-05 11:15 Headache severity, comorbidities, and healthcare resource utilization (RU) among chronic migraine (CM) and episodic migraine (EM) in Canada**
WJ Becker (Calgary), AK Kawata (Bethesda), K Yeomans (Bethesda), SF Varon (Irvine), RB Lipton (Bronx), L Wells (Markham), A Blumenfeld (Encinitas)*
- C-06 11:30 Plastic change of neuromagnetic responses in auditory cortices over the course of music-supported motor rehabilitation program**
T Fujioka (Toronto), S Jamali (Toronto), JE Ween (Toronto), DT Stuss (Toronto), B Ross (Toronto)*
- C-07 11:45 Neuromagnetic sensory evoked response as a biomarker of cortical reorganization during stroke recovery**
*S Jamali (Toronto), B Ross (Toronto), JE Ween (Toronto), DT Stuss (Toronto), T Fujioka (Toronto)**
- C-08 12:00 A validation study of the diagnostic accuracy of the revised 2008 consensus criteria for the diagnosis of MSA-C in British Columbia**
KL Jack (Vancouver), SD Spacey (Vancouver)*
- C-09 12:15 Prevalence of overweight in patients with migraine: a population base study with a control group of healthy patients**
D Pahwa (Saskatoon), JF Tellez-Zenteno (Saskatoon), L Hernandez-Ronquillo (Saskatoon), G Garcia-Ramos (Mexico City), J Anang (Saskatoon)

NEUROMUSCULAR AND NEURO-ONCOLOGY

Chair: Mike Nicolle, James Perry June 10, 2010 Room 202

- D-01 10:15 Case series: vestibular schwannoma resection after radiation treatment**
CC Gillis (Vancouver), R Akagami (Vancouver)*
- D-02 10:30 Ependymoma stratification according to expression of the epidermal growth factor and the Y-box binding protein-1**
J Hukin (Vancouver), JH Law (Vancouver), S Yip (Vancouver), J Maguire (Vancouver), T Yamashita (London), C Fryer (Vancouver), A Singhal (Vancouver), M Sargent (Vancouver), T Ailon (Vancouver), G Hendson (Vancouver), C Hawkins (Toronto), SE Dunn (Vancouver)*
- D-03 10:45 Role of bone marrow derived progenitor cells in intracranial tumor neovascularization**
G Zadeh (Toronto), K Burrell (Toronto), A Guha (Toronto), R DaCosta (Toronto), R Hill (Toronto)*
- D-04 11:00 Hearing preservation following microsurgical resection of large vestibular schwannomas**
AD Malebranche (Vancouver), S Di Maio (Vancouver), B Westerberg (Vancouver), R Akagami (Vancouver)*
- D-05 11:00 Defining the optimal management of os odontoideum: results of a systematic review**
J Wilson (Toronto), MG Fehlings (Toronto)*
- D-06 11:30 Four cases of anti-N-methyl-D-aspartate receptor limbic encephalitis**
C Xia (Montreal), ML Jones (Montreal), A Yu (Montreal), A Al-Hashmi (Montreal), F Dubeau (Montreal)*

- D-07 11:45 Longterm follow-up in three patients with severe generalized myasthenia gravis treated with autologous stem cell transplant**
CE Pringle (Ottawa), HL Atkins (Ottawa)*
- D-08 12:00 The Canadian Neuromuscular Disease Registry (CNDR): study design and methodology**
L Korngut (Calgary), JK Mah (Calgary), A McCormick (Ottawa), CE Pearson (Toronto), J Puymirat (Quebec), S Venance (London), C Campbell (London)*
- D-09 12:15 A snapshot of an academic neuromuscular clinic**
SL Venance (London), E Lopes (London), J Verheyden (London), WJ Koopman (London), MW Nicolle (London)*

PEDIATRIC NEUROLOGY

Chair: Cecil Hahn June 10, 2010 Room 203

- E-01 10:15 Radial columnar cortical architecture: maturational arrest or cortical dysplasia?**
HB Sarnat (Calgary), L Flores-Sarnat (Calgary), W Hader (Calgary)*
- E-02 10:30 Survival curves in outcome of mild traumatic brain injury**
KM Barlow (Calgary), S Sandhu (Calgary), S Crawford (Calgary), D Dewey (Calgary)*
- E-03 10:45 The role 5-HT1A gene promoter polymorphism in post-concussion syndrome in children**
KM Barlow (Calgary), K Smith (Calgary), S Crawford (Calgary), S Sandhu (Calgary), D Dewey (Calgary), J Parboosingh (Calgary)*
- E-04 11:00 A decade of dystrophin mutations: preliminary report from the Canadian Paediatric Neuromuscular Group**
JK Mah (Calgary), K Selby (Vancouver), C Campbell (London), A Nadeau (Montreal), MA Tarnopolsky (Hamilton), A McCormick (Ottawa), JM Dooley (Halifax), HK Kolski (Edmonton), A Skalsky (Winnipeg), G Smith (Kingston), DJ Buckley (St. John), P Bridge (Calgary), PN Ray (Toronto), G Yoon (Toronto)*
- E-05 11:15 Patterns of neuroinflammation and cortical astrocyte loss in Rasmussen's encephalitis**
V Ramaswamy (Edmonton), D Sinclair (Edmonton), L Resch (Edmonton), F Maingat (Edmonton), ES Johnson (Edmonton), R Tang-Wai (Edmonton), M Wheatley (Edmonton), T Snyder (Edmonton), C Power (Edmonton), DW Gross (Edmonton)*
- E-06 11:30 DLX transcriptional regulation of GABAergic interneuron migration – relevance to neuronal migration disorders**
*TN Le (Winnipeg), DD Eisenstat (Winnipeg)**
- E-07 11:45 Functional magnetic resonance imaging (fMRI) in the localization of atypical language networks in pediatric epilepsy surgery candidates**
KP Fitzpatrick (Vancouver), I Jokic (Vancouver), MB Connolly (Vancouver), BH Bjornson (Vancouver)*
- E-08 12:00 Fetal hippocampal development: analysis by magnetic resonance imaging volumetry**
F Jacob (Edmonton), K Kim (San Francisco), P Habas (San Francisco), V Rajagopalan (San Francisco), J Corbett-Detig (San Francisco), C Studholme (San Francisco), OA Glenn (San Francisco)*
- E-09 12:15 Ketogenic diet is associated with a reduction in neutrophil count**
J Lee (Vancouver), L Huh (Vancouver), K Farrell (Vancouver)*

STROKE PREVENTION AND TREATMENT I

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Chair: Matthew Hogan June 10, 2010 Room 204A

- F-01 10:15 Effectiveness of NA-1, a PSD-95 Inhibitor, in a non-human primate model of embolic stroke**
DJ Cook (Toronto), L Teves (Toronto), M Tymianski (Toronto)*
- F-02 10:30 Public health surveillance of stroke in Canada: an overview**
S Dai (Ottawa), C Bancej (Ottawa), P Walsh (Ottawa), M Nichol (Ottawa), R Semenciw (Ottawa), A Bienek (Ottawa), P Lindsay (Ottawa)*
- F-03 10:45 Outcomes after carotid angioplasty and stenting in symptomatic octogenarians: the Calgary experience**
MA Almekhlafi (Calgary), PL Couillard (Calgary)*, A Pandya (Calgary), N Shobha (Calgary)*, W Morrish (Calgary), J Wong (Calgary), MD Hill (Calgary)*

PLATFORM SESSIONS

F-04	11:00	Stroke mortality: derivation and validation of a clinical risk score <i>G Saposnik (Toronto)*, M Mamdani (Toronto), R Raptis (Toronto), M O'Donnell (Hamilton), R Hall (Toronto), Y Liu (Toronto), J Tu (Toronto), P Austin (Toronto), MK Kapral (Toronto)</i>
F-05	11:15	Regional leptomeningeal collateral (rLMC) score on CT angiography: good inter-rater reliability and independent predictive utility in patients with acute ischemic strokes <i>BK Menon (Calgary)*, EE Smith (Calgary), J Modi (Calgary), R Bhatia (Calgary), TW Watson (Calgary), AM Demchuk (Calgary), M Goyal (Calgary)</i>
F-06	11:30	The ASPIRE approach for TIA risk stratification <i>SB Coutts (Calgary)*, T Jeerakathill (Edmonton), PN Sylaja (Calgary), MD Hill (Calgary)</i>
F-07	11:45	Final 2-year results of the Vascular Imaging of acute Stroke for Identifying predictors of clinical Outcome and recurrent ischemic events (VISION) study <i>SB Coutts (Calgary)*, MD Hill (Calgary), M Eliasziw (Calgary), K Fischer (Calgary), AM Demchuk (Calgary)</i>
F-08	12:00	Sleep apnea in patients with transient ischemic attack (TIA) and minor stroke <i>W Chan (Calgary)*, SB Coutts (Calgary), PJ Hanly (Calgary)</i>
F-09	12:15	Stroke prevention clinic referrals are associated with reduced mortality after stroke <i>F Webster (Toronto), G Saposnik (Toronto)*, M Kapral (Toronto), J Fang (Toronto), V Hachinski (London), C O'Callaghan (Toronto), R Lyons (Toronto), A Dishaw (Toronto)</i>

STROKE RECOVERY AND REHABILITATION

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Chair: Adam Kirton June 10, 2010 Room 205A

G-01	10:15	Hypothermic neuroprotection after global ischemia is not associated with neurogenesis in the CA1 of the hippocampus <i>G Silasi (Edmonton)*, F Colbourne (Edmonton)</i>
G-02	10:30	Cognitive changes in patients with metabolic syndrome after ischemic stroke <i>T Nasonova (Kyiv)*, V Krylova (Kyiv)</i>
G-03	10:45	Pontocerebellar diffusion MRI and cerebellar diaschisis in childhood stroke <i>A Kirton (Calgary)*, S Mah (Calgary), T Domi (Toronto), R Chen (Toronto), B O'Brien (Calgary), G deVeber (Toronto)</i>
G-04	11:00	The involvement of superior colliculi in post-stroke unilateral spatial neglect: a pilot project <i>T Ogourtsova (Montreal)*, N Korner-Bitensky (Montreal), A Ptito (Montreal), S Leh (Montreal), G Eskes (Halifax)</i>
G-05	11:15	Independence of limb position sense and motor impairments following stroke <i>SP Dukelow (Calgary)*, TM Herter (Kingston), SH Scott (Kingston)</i>
G-06	11:30	Effectiveness of Virtual Reality using Wii Gaming technology in STroke Rehabilitation (EVREST): a randomized clinical trial and proof of principle <i>G Saposnik (Toronto)*, T Robert (London), M Mamdani (Toronto), D Cheung (Toronto), KE Thorpe (Toronto), B McIlroy (Waterloo), J Willems (Toronto), J Hall (Toronto), LG Cohen (Bethesda), M Bayley (Toronto)</i>
G-07	11:45	Mini-Mental Status Exam lacks sensitivity to cognitive impairment associated with TIA and minor ischemic stroke <i>M Harnadek (London)*, R Chan (London), C Mayer (London), V Hachinski (London)</i>
G-08	12:00	Promoting health and enhancing recovery in stroke survivors using home care services: the effects and costs of a specialized interprofessional team approach to community-based stroke rehabilitation <i>MF Markle-Reid (Hamilton)*, C Orridge (Toronto), R Weir (Hamilton), G Browne (Hamilton), A Gafni (Hamilton), M Lewis (Toronto), M Walsh (Toronto), C Levy (Toronto), S Daub (Toronto), H Brien (Toronto), J Roberts (Hamilton), L Thabane (Hamilton)</i>
G-09	12:15	Withdrawn

SPINE

Chair: Ramesh Sahjpaul June 10, 2010 Room 200C

- H-01 14:00 Spinal cord stimulation is effective in management of complex regional pain syndrome (CRPS) I: fact or fiction**
K Kumar (Regina), S Rizvi (Regina)*
- H-02 14:15 Early experience with a novel percutaneous method of lumbar decompression**
JS Wilkinson (Saskatoon), SA Mann (Saskatoon), E Frangou (Saskatoon), DR Fourney (Saskatoon)*
- H-03 14:30 Comparison of minimally-invasive lumbar interbody fusion for primary and revision surgery**
MF Shamji (Ottawa), RE Isaacs (Durham)*
- H-04 14:45 Local anticytokine therapy reverses sensory and gait abnormalities in experimental disc herniation radiculopathy**
MF Shamji (Ottawa), KD Allen (Durham), M Gabr (Durham), M Sinclair (Durham), SB Adams (Durham), B Mata (Durham), L Jing (Durham), DL Nettles (Durham), WJ Richardson (Durham), LA Setton (Durham)*
- H-05 15:00 Randomized trial of bracing for stable thoracolumbar burst fractures**
MF Shamji (Ottawa), E Wai (Ottawa), D Young (Ottawa), G Johnson (Ottawa), C Agbi (Ottawa), R Reindl (Montreal)*
- H-06 15:15 Minimally invasive approach for the resection of spinal neoplasm**
FA Haji (London), A Cenic (Hamilton), L Crevier (Hamilton), N Murty (Hamilton), K Reddy (Hamilton)*
- H-07 15:30 Normal computed tomography measurements of the upper cervical spine in the pediatric population**
S Vachhrajani (Toronto), K Satyan (Houston), AV Kulkarni (Toronto), A Jea (Houston)*
- H-08 15:45 Anterior craniospinal reconstruction and stabilization: technical note and review of the literature**
DH Zhang (Hamilton), K Reddy (Hamilton)*
- H-09 16:00 Proton magnetic resonance spectroscopy of the motor cortex in cervical spondylotic myelopathy**
I Kowalczyk (London), R Bartha (London), N Duggal (London)*
- H-10 16:15 The use of heat sensation to detect neuronal activity in the dorsal horn of the human spinal cord at 3T with novel fMRI methods – a proof-of-concept pilot study**
DW Cadotte (Toronto), MG Fehlings (Toronto)*

EPILEPSY

Chair: Seyed Mirsattari June 10, 2010 Room 201BC

- I-01 14:00 Molecular mechanisms associated with an increased seizure susceptibility in adults after experimental febrile seizures in juveniles**
A Reid (Calgary), K Riazi (Calgary), GC Teskey (Calgary), QJ Pittman (Calgary)*
- I-02 14:15 Source localization of neuromagnetic spike-locked high frequency oscillations (40-120 Hz) in pediatric neocortical epilepsy**
IS Mohamed (Calgary), H Otsubo (Toronto), P Ferrari (Toronto), A Ochi (Toronto), C Snead (Toronto), DO Cheyne (Toronto)*
- I-03 14:30 Transition to seizure: a synaptic crescendo**
PL Carlen (Toronto), ZJ Zhang (Toronto), H Ye (Toronto), L Zhang (Toronto), D Shin (Albany), A Tonkikh (Toronto), D Serletis (Toronto), Valiante (Toronto)*
- I-04 14:45 Characterization of hippocampal atrophy in a rodent model of complex febrile seizure**
SA Gibbs (Montréal), B Chattopadhyaya (Montréal), O Clerk-Lamallice (Sherbrooke), PN Awad (Montréal), S Desgent (Montréal), G Di Cristo (Montréal), L Carmant (Montréal)*
- I-05 15:00 Safety and efficacy of depth electrode recording (SEEG) in epilepsy surgery: a five year review**
MB Wheatley (Edmonton), D Gross (Edmonton), BD Sinclair (Edmonton), N Ahmed (Edmonton)*
- I-06 15:15 Continuous EEG monitoring in a paediatric intensive care unit**
B Mc Coy (Toronto), R Sharma (Toronto), A Ochi (Toronto), C Go (Toronto), H Otsubo (Toronto), JS Hutchison (Toronto), CD Hahn (Toronto)*
- I-07 15:30 Epilepsy: when to think surgery?**
N Jette (Calgary), J Tellez-Zenteno (Saskatoon), W Hader (Calgary), S Macrodimitris (Calgary), L Hamiwka (Calgary), E Wirrell (Calgary), H Quan (Calgary), E Sherman (Calgary), J Burneo (London), A Metcalfe (Calgary), S Wiebe (Calgary), R Expert Panellists (Calgary)*
- I-08 15:45 Electrocorticography and seizure outcomes in children with lesional epilepsy**
JN Gelinas (Vancouver), AW Battison (Vancouver), MB Connolly (Vancouver), P Steinbok (Vancouver)*

PLATFORM SESSIONS

- I-09 16:00 Neuropsychological outcome following selective amygdalo-hippocampectomy: a single Canadian center cohort of 82 patients**
R Malak (Calgary), L Partlo (Calgary), EM Sherman (Calgary), TB Fay (Calgary), T Myles (Calgary), S Wiebe (Calgary), N Pillay (Calgary), W Hader (Calgary)*
- I-10 16:15 A descriptive analysis of prognostic indicators in patients with non-convulsive status epilepticus in a tertiary hospital population**
CT Hrazdil (Vancouver), R Alroughani (Vancouver), M Javidan (Vancouver)*

GENERAL NEUROSURGERY AND NEURORADIOLOGY

Chair: R. Loch Macdonald June 10, 2010 Room 202

- J-01 14:00 Risks and benefits of increased sample size in frameless stereotactic brain biopsy**
KH Au (Edmonton), BM Wheatley (Edmonton)*
- J-02 14:15 Patterns of tumor response and nonauditory morbidity following radiosurgery for vestibular schwannoma**
C Hayhurst (Toronto), E Monsalves (Toronto), M van Prooijen (Toronto), B Kim (Toronto), M Tsao (Toronto), C Menard (Toronto), G Zadeh (Toronto)*
- J-03 14:30 Augmenting adult hippocampal neurogenesis using targeted brain stimulation: implications for memory networks**
SS Stone (Toronto), K Zaslavsky (Toronto), CM Teixeira (Toronto), AM Lozano (Toronto), PW Frankland (Toronto)*
- J-04 14:45 Neuromodulation for cranio-facial pain syndromes: results of a Canadian referral centre**
KW MacDougall (London), AG Parrent (London)*
- J-05 15:00 Warfarin anticoagulation following surgical evacuation of chronic subdural hematoma**
KH Au (Edmonton), C Poon (Edmonton), K Butcher (Edmonton), M Chow (Edmonton)*
- J-06 15:15 Management of maternal hydrocephalus**
S Mohammed (Toronto), F Meffe (Toronto), M Cusimano (Toronto)*
- J-07 15:30 Treatment of positional plagiocephaly – survey of cosmetic and cognitive outcomes**
MF Shamji (Ottawa), M Vassilyadi (Ottawa), P Merchant (Ottawa), EC Fric-Shamji (Ottawa), E Ventureyra (Ottawa)*
- J-08 15:45 Symptomatic retethering of the spinal cord following section of a tight filum terminale**
RL Yong (Vancouver), T Habrock-Bach (Salt Lake City), M Vaughan (Vancouver), JR Kestle (Salt Lake City), P Steinbok (Vancouver)*
- J-09 16:00 Internal cerebral vein sign on CT angiography as a marker of ipsilateral cerebral hypoperfusion in carotid occlusions**
BK Menon (Calgary), J Modi (Calgary), S Sohn (Calgary), TW Watson (Calgary), M Hudon (Calgary), AM Demchuk (Calgary), M Goyal (Calgary)*
- J-10 16:15 Visual functional MRI in premature infants**
EJ Donner (Toronto), W Lee (Toronto), D Morris (Toronto), JG Sled (Toronto), H Whyte (Toronto), MJ Taylor (Toronto)*

TRAUMA, CRITICAL CARE AND NEUROSURGERY

Chair: Jeanne Teitelbaum June 10, 2010 Room 203

- K-01 14:00 An fMRI study of the default mode network connectivity in comatose survivors of cardiac arrest**
*L Norton (London), M Sharpe (London), B Young (London), S Mirsattari (London)**
- K-02 14:15 Acute management of acquired brain injury: an evidence-based review**
MJ Meyer (London), J Megyesi (London), J Meythaler (Detroit), M Murie-Fernandez (Navarre), J Aubut (London), N Foley (London), S Katherine (London), M Bayley (Toronto), S Marshall (Ottawa), R Teasell (London)*
- K-03 14:30 A critical look at phenytoin use for early post-traumatic seizure prophylaxis**
SP Debenham (Provo), S Behzad (Montreal), S Neeley (Provo), RS Saluja (Montreal), J Marcoux (Montreal)*
- K-04 14:45 Monitoring of cerebral oxygenation in traumatic brain injury (TBI) using Licox catheter in a tertiary trauma center: major therapeutic implications**
F Bernard (Montreal), V Brunette (Montreal), M Giroux (Montreal), J Giguère (Montreal)*
- K-05 15:00 Surgical activity of first year Canadian neurosurgical trainees: a cohort study**
FA Haji (London), S Ebrahim (Toronto), A Fallah (Toronto)*

K-06	15:15	Reducing radiation exposure to children with shunt treated hydrocephalus: follow-up CT scans with limited axial cuts <i>B Yarascavitch (Hamilton)*, T Gunnarsson (Hamilton)</i>
K-07	15:30	Establishing a high-resolution in-vivo imaging technique to examine the dynamic contribution of bone marrow derived endothelial progenitor cells to intracranial tumor vasculature <i>G Zadeh (Toronto)*, K Burrell (Toronto), A Guha (Toronto), R Hill (Toronto)</i>
K-08	15:45	Neurosurgery 2.0: the use of Web 2.0 applications in Neurosurgery <i>KH AalAli (Halifax)*, MA Alolama (Gothenburg), SD Christie (Halifax)</i>
K-09	16:00	Linear electrode for recording multiple high density local field potentials in the superior colliculus of monkey <i>R Levy (Calgary)*, DP Munoz (Kingston), RA Marino (Kingston)</i>
K-10	16:15	World's first patient-specific virtual reality open brain surgery <i>DB Clarke (Boucherville)*, RC D'Arcy (Halifax), R Brooks (Boucherville), D Jiang (Boucherville), F Ayres (Boucherville), S Ghosh-Hajra (Halifax), T Stevens (Halifax), J Hovdebo (Winnipeg), L Borgeat (Ottawa), P Massicotte (Ottawa), G Poirier (Ottawa), V Mora (Boucherville), J Marcotte (Boucherville), D Laroche (Boucherville), S Delorme (Boucherville), R Diraddo (Boucherville)</i>

STROKE PREVENTION AND TREATMENT II

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Chair: TBA June 10, 2010 Room 204A

L-01	14:00	Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke are associated with recurrent stroke <i>LC Gioia (Montreal), V Dubuc (Montreal), S Lanthier (Montreal), AY Poppe (Montreal)*</i>
L-02	14:15	Risk factors associated with silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke <i>LC Gioia (Montreal), S Lanthier (Montreal), AY Poppe (Montreal)*</i>
L-07	14:30	CTASI ASPECTS is superior to NCCT ASPECTS for predicting final infarct extent in patients with CT scans <90 minutes from onset <i>SP Bal (Calgary)*, R Bhatia (Calgary), N Shobha (Calgary), B Menon (Calgary), V Puetz (Dresden), I Dzialowski (Dresden), S Tymchuk (Calgary), T Watson (Calgary), P Barber (Calgary), S Coutts (Calgary), E Smith (Calgary), A Demchuk (Calgary)</i>
L-04	14:45	Management of pediatric intracranial arteriovenous malformations: experience with multimodality therapy <i>TE Darsaut (Montreal)*, R Guzman (Stanford), ML Marcellus (Stanford), MS Edwards (Stanford), L Tian (Stanford), HM Do (Stanford), SD Chang (Stanford), RP Levy (Stanford), JR Adler (Stanford), MP Marks (Stanford), GK Steinberg (Stanford)</i>
L-05	15:00	Timing of re-canalization may permit decreased surveillance after one year <i>Z Kaderali (Toronto)*, H Lee (Toronto), R Macdonald (Toronto), W Montanera (Toronto), T Marotta (Toronto), J Spears (Toronto)</i>
L-06	15:15	In-hospital strokes - the Calgary experience <i>N Shobha (Calgary)*, K Roy (Calgary), V Lam (Calgary), V Bohm (Calgary), A Cole-Haskayne (Calgary), M Suddes (Calgary), MD Hill (Calgary)</i>
L-03	15:30	Multiple Interventions for Neuroprotection Utilizing Thermal regulation in the Emergent treatment of Stroke: the MINUTES study <i>MM Siddiqui (Edmonton)*, M Saqqur (Edmonton), Y Ludwig (Edmonton), A Shuaib (Edmonton)</i>
L-08	15:45	The "Track Sign": delayed blood-pool phase contrast-enhanced MR angiography shows acute large vessel occlusion <i>RH Swartz (Toronto)*, FL Silver (Toronto), MD Vergouwen (Toronto), DJ Mikulis (Toronto), RI Farb (Toronto)</i>
L-09	16:00	Carotid angioplasty and stenting is safe in women <i>N Shobha (Calgary)*, M Almekhlafi (Calgary), A Pandya (Calgary), P Couillard (Calgary), WF Morrish (Calgary), JH Wong (Calgary), MD Hill (Calgary)</i>
L-10	16:15	Risk of carotid endarterectomy as it relates to patient presentation <i>JM Findlay (Edmonton)*, M Jacka (Edmonton)</i>

PLATFORM SESSIONS

STROKE HEALTH SERVICES RESEARCH AND ACUTE TREATMENT

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Chair: Theodore Wein June 10, 2010 Room 205A

M-01	14:00	Stroke and aphasia; overcoming the challenges of capacity evaluation <i>A Carling-Rowland (Toronto)*, S Black (Toronto), L McDonald (Toronto), A Kagan (Toronto)</i>
M-02	14:15	Factors predicting discharge home from inpatient rehabilitation after stroke <i>N Damiano (Ottawa)*</i>
M-03	14:30	Establishing best-practice for speech-language pathology in aphasia and cognitive communication rehabilitation post-stroke <i>R Graham (London)*, R Teasell (London), J Orange (London), N Korner-Bitensky (Montreal)</i>
M-04	14:45	The development of an e-collaborative platform to accelerate application of stroke best practices <i>L Poissant (Montréal)*, S Ahmed (Montreal), A Rochette (Montréal), I David (Montréal)</i>
M-05	15:00	CTA source images are flow weighted <i>M Sharma (Toronto)*, AJ Fox (Toronto), S Symons (Toronto), A Jairath (Toronto), RI Aviv (Toronto)</i>
M-06	15:15	Anesthetic considerations and the role of blood pressure management in the endovascular treatment of acute ischemic stroke <i>M Davis (Calgary), BK Menon (Calgary)*, L Baghhirzada (Calgary), C Herrera (Calgary), M Eesa (Calgary), M Goyal (Calgary), DP Archer (Calgary), MD Hill (Calgary)</i>
M-07	15:30	Recanalization rate and outcome based on site and severity of cerebrovascular dissection <i>SP Bal (Calgary)*, R Bhatia (Calgary), N Shobha (Calgary), B Menon (Calgary), J Modi (Calgary), T Watson (Calgary), M Goyal (Calgary), E Smith (Calgary)</i>
M-08	15:45	CTASI-ASPECTS is more predictive of final ASPECTS and neurological outcome than NCCT-ASPECTS in acute ischemic stroke caused by proximal vessel occlusions <i>SP Bal (Calgary)*, R Bhatia (Calgary), N Shobha (Calgary), B Menon (Calgary), V Puetz (Dresden), I Dzialowski (Dresden), S Tymchuk (Calgary), S Idris (Calgary), T Watson (Calgary), S Coutts (Calgary), P Barber (Calgary), E Smith (Calgary), A Demchuk (Calgary)</i>
M-09	16:00	Canadian unruptured aneurysm endovascular vs. surgery: the CURES trial <i>JM Findlay (Edmonton), T Darsault (Montreal)*, J Raymond (Montreal)</i>
M-10	16:15	Cost analysis and clinical outcomes for coiling versus clipping of intracranial aneurysms: two years of follow-up data <i>CB Martin-Gaspar (Hamilton)*, T Gunnarsson (Hamilton), P Klurfan (Hamilton)</i>

DIGITAL MINI-PLATFORM SESSIONS

GENERAL NEUROLOGY

Thursday - Poster Station #1 - Moderator: Trevor Steve
Exhibition Hall Room 200AB

- P-013 12:30 The utility of a customized application for a handheld device in training neurology residents: a proof of concept study**
JE Alfonsi (Toronto), L Lee (Toronto)*
- P-014 12:33 Susac syndrome: a rare cause of simultaneous subacute hearing loss, encephalopathy and visual disturbance**
R Altman (Montreal), A Al Salti (Montreal), J Jirsch (Montreal)*
- P-036 12:40 Cervical fusion as a treatment for Parkinson's induced head drop syndrome**
N Rasool (Halifax), SD Christie (Halifax), KL Schoffer (Halifax)*
- P-016 12:45 Migraine-related disability, work impact, and quality of life (QOL) among Canadians with chronic migraine (CM) and episodic migraine (EM)**
WJ Becker (Calgary), TK Wilcox (Bethesda), L Wells (Markham), A Blumenfeld (Encinitas), AK Kawata (Bethesda), SF Varon (Irvine), RB Lipton (Bronx)*
- P-017 12:50 Asperger's K.I.S.S.**
*ME Berry (Nelson)**
- P-042 12:55 Degeneration of the mid cingulate cortex in amyotrophic lateral sclerosis (ALS) detected in vivo with MR spectroscopy**
N Sudharshan (Edmonton), C Hanstock (Edmonton), B Hui (Edmonton), T Pyra (Edmonton), W Johnston (Edmonton), S Kalra (Edmonton)*
- P-019 13:00 Neuro cognitive and behavioral changes in a healthy 41 year-old male**
V Brunette (Montreal), J Boileau (Montreal)*
- P-020 13:05 Clinical and genetic characterization of a polymerase gamma (POLG) mitochondrial myopathy syndrome**
JL Bouchard (Quebec City), N Chrestian (Quebec City), N Dupré (Quebec City), D Brunet (Quebec City), LC Wong (Houston)*
- P-021 13:10 Botulinum type A (Botox) in the management of cervical dystonia: a seven-year retrospective review**
*JY Chu (Toronto)**
- P-022 13:15 In vivo imaging of TLR2 response: effects of gender and estrogen on microglial activation following brain ischemia**
*JY Chu (Toronto)**
- P-023 13:20 Brachial plexopathy complicating Epstein-Barr virus infection in an adult**
PJ Cordeau (Quebec), Y Wend (Quebec), J Kriz (Quebec)*
- P-024 13:25 Use of acyclovir in suspected herpes simplex encephalitis**
PS Hughes (Winnipeg), AC Jackson (Winnipeg)*
- P-025 13:30 Recovery of awareness after hyperacute hepatic encephalopathy with "flat" EEG – 3 cases and review of the literature**
G Hunter (London), GB Young (London)*
- P-026 13:35 Seizures after cardiac surgery – a toxic syndrome**
G Hunter (London), GB Young (London)*
- P-027 13:40 Medical therapies for botulism**
MR Keezer (Montreal), T Benstead (Halifax), C Chalk (Montreal)*
- P-028 13:45 Aphasia camp: a inclusive recreational case study**
LA Klaponski (Toronto), J Roadhouse (Brantford)*

GENERAL NEUROLOGY

Friday - Poster Station #1 - Moderator: TBA
Exhibition Hall Room 200AB

- P-029 12:10 Relationship between amyotrophic lateral sclerosis and occupation**
L Limenis (London), A Rowe (London), CL Shoesmith (London)*
- P-030 12:15 Mitochondrial myopathy with inflammation due to novel missense mutation in the cytochrome c oxidase I gene**
R Massie (Rochester), J Wang (Houston), LC Wong (Houston), M Milone (Rochester)*
- P-031 12:20 Repeated intracutaneous injections of botulinum toxin-type A for the treatment of Frey's syndrome after parotidectomy: a case report**
*SM Mirsattari (London)**
- P-032 12:25 Acute encephalopathy following a large amount of milk consumption**
F Moien-Afshari (Saskatoon), C Voll (Saskatoon)*

DIGITAL MINI-PLATFORM SESSIONS

P-033	12:30	Two modern cases of encephalitis lethargica, with an historical review <i>CE Pringle (Ottawa)*, DA Grimes (Ottawa), L McIntyre (Ottawa), P Cardinal (Ottawa)</i>
P-034	12:35	Abdominal pain in Parkinson's disease – off or on phenomenon of levodopa <i>A Rana (Toronto)*, O Syed (Toronto)</i>
P-035	12:40	Initial presentation of diabetic optic neuropathy and retinopathy to Neurology <i>Rana (Toronto)*, A Al-Shahrani (Toronto), S Zia (Toronto)</i>
P-015	12:45	Type 2 diabetes mellitus exacerbates neuropathy in patients with CMT1a <i>S Arora (Hamilton)*, S Baker (Hamilton)*</i>
P-037	12:50	Regaining mobility: VON Canada's SMART (Seniors Maintaining Active Roles Together) ® program <i>SV Schuehle (Kitchener)*</i>
P-038	12:55	Prolonged restricted diffusion white matter changes in carbon monoxide delayed encephalopathy: a case report <i>ME Sharp (Vancouver)*, JA Pettersen (Vancouver)</i>
P-039	13:00	Hematopoietic stem cell transplantation (HSCT) for adult-onset Krabbe disease: first report in the literature <i>ME Sharp (Vancouver)*, C Laule (Vancouver), S Sirrs (Vancouver)</i>
P-040	13:05	Withdrawn
P-041	13:10	Innovative web-based software to assist students in localizing neurologic lesions <i>E Lewis (Ottawa), M Strike (Ottawa)*, E Sell (Ottawa)</i>
P-018	13:15	Isolated phrenic nerve palsy caused by air bag deployment in motor vehicle collision <i>JG Boyd (Kingston)*, D Jichici (Hamilton), C Bolton (Kingston)</i>
P-043	13:20	Supranuclear ophthalmoplegia in Powassan encephalitis <i>P Trépanier (Québec)*, L Vilayvong (Québec), M Savard (Québec)*, C Claessens (Sainte-Anne-de-Bellevue)</i>
P-044	13:25	Whipple disease presenting with hypersomnia <i>C Xia (Montreal)*, M Keezer (Montreal), A Duquette (Montreal), A Lafontaine (Montreal)</i>

GENERAL NEUROSURGERY

Thursday - Poster Station #2 - Moderator: Christopher Wallace
Exhibition Hall Room 200AB

P-051	12:30	Unusual hyperdense posterior fossa epidermoid cyst: 2 case reports and review of the literature <i>QS Al Hinai (Montreal)*, N McLaughlin (Montreal), M Maleki (Montreal), D Sirhan (Montreal), M Cortes (Montreal)</i>
P-052	12:35	Evan's ratio evaluated <i>Sa Almenawer (Hamilton)*</i>
P-053	12:40	Misplaced extraventricular drains (EVD): reasons and consequences <i>AO Alobaid (Hamilton)*, D Jichici (Hamilton), A Yarascavitch (Hamilton), B Lo (Hamilton), P Klurfan (Hamilton), K Reddy (Hamilton)</i>
P-054	12:45	Minimally invasive tubular access for the resection of spinal and intracranial neoplasms <i>WA Alsunbul (Hamilton)*</i>
P-055	12:50	Craniotomy and direct catheterization for Onyx embolization of an inoperable arteriovenous malformation <i>MR Boulton (London)*, DA Steven (London), D Pelz (London), S Lownie (London)</i>
P-056	12:55	A Canadian case of a newly-characterized coronal synostosis syndrome (Muenke syndrome): the value of genetic testing versus clinical determination of diagnosis <i>A Ranger (London), N Chaudhary (London)*, J Rau (London), D Matic (London), S Goober (London), I Makar (London), V Siu (London)</i>
P-057	13:00	The rare complication of bowel perforation within 29 hours of a ventriculoperitoneal shunt insertion <i>N Chaudhary (London)*, A Ranger (London)</i>
P-061	13:05	Case report: spontaneous cervical spine cerebrospinal fluid leak <i>S Gul (Vancouver)*, K Chapman (Vancouver), M Heran (Vancouver), R Sahjpaul (Vancouver)</i>
P-073	13:10	Spontaneous resolution of Chiari malformation <i>JA Pugh (Edmonton)*, I Ho (Edmonton), V Mehta (Edmonton)</i>
P-058	13:15	Atypical presentations of spontaneous intracranial hypotension: case series <i>N Chaudhary (London)*, N Duggal (London), P Cooper (London), SP Lownie (London)</i>

P-063	13:20	Chondroblastoma of the temporal bone: case report and review of the literature <i>LP Hnenny (Saskatoon)*, DR Fourney (Saskatoon)</i>
P-064	13:25	Rosette-forming glioneuronal tumor of the fourth ventricle presenting in the lateral ventricle: case report <i>RR Janicki (Vancouver)*, A Singhal (Vancouver), G Hendson (Vancouver)</i>
P-065	13:30	Withdrawn
P-069	13:35	Intracerebral dermoid cyst removal through a transtuberculum/ transplanum endoscopic approach <i>N McLaughlin (Santa Monica)*, M Laroche (Montreal), F Lavigne (Montreal), MW Bojanowski (Montreal)</i>
P-070	13:40	Endoscopic endonasal transsphenoidal approach to cholesterol granuloma of the petrous apex: case report and review of the literature <i>N McLaughlin (Santa Monica)*, A Kassam (Santa Monica), DM Prevedello (Pittsburgh), R Carrau (Pittsburgh), K Shahlaie (Santa Monica), D Kelly (Santa Monica)</i>

GENERAL NEUROSURGERY

Friday - Poster Station #2 - Moderator: Charles Matouk
Exhibition Hall Room 200AB

P-059	12:10	<i>Streptococcus anginosus</i> subdural empyema secondary to otitis media: case report <i>N Chaudhary (London)*, S deRibaupierre (London), A Ranger (London)</i>
P-060	12:15	Rapid reversal of a severe acute subdural hemorrhage in a patient with myelodysplastic syndrome – spontaneous resorption or secondary to hemostasis correction? <i>N Chaudhary (London)*, A Leung (London), E Small (London), C Hsia (London)</i>
P-062	12:20	Fibro-osseous pseudotumor – case report and review of literature <i>FA Haji (London)*, M Alturkustani (London), A Parrent (London), J Megyesi (London), I Gulka (London), RR Hammond (London)</i>
P-071	12:25	Intrathecal baclofen pump treatment for cerebral palsy: a case of post-operative respiratory depression <i>JD Pearl (Saskatoon)*, AM Vitali (Saskatoon)</i>
P-072	12:30	Augmentation of routine craniotomy with titanium and methylmethacrylate for improved cosmesis in individuals with alopecia <i>C Pinkoski (London)*, MR Boulton (London)</i>
P-068	12:35	Acute paraplegia due to intramedullary arachnoid cyst <i>FB Maroun (St. John's)*, JC Jacob (St. John's), AE Engelbrecht (St. John's), GP Murray (St. John's), R Avery (St. John's), J Barron (St. John's), P Bartlett (St. John's), RV Heale (St. John's)</i>
P-074	12:40	Withdrawn
P-075	12:45	A rare presentation in an unusual location: supratentorial hemorrhagic hemangioblastoma <i>RW Ryan (Edmonton)*, L Resch (Edmonton), JM Findlay (Edmonton)</i>
P-076	12:50	Edward Archibald: a Canadian surgeon's role in the professionalization of neurosurgery <i>RW Ryan (Edmonton)*, W Feindel (Montreal), R Patterson (New York), MC Preul (Phoenix)</i>
P-077	12:55	Endoscopic endonasal resection of the odontoid process for basilar invagination in Chiari type I malformation <i>F Scholtes (Montreal)*, F Signorelli (Montreal), P Lessard (Montreal), F Lavigne (Montreal), MW Bojanowski (Montreal)</i>
P-078	13:00	Clinical impact of myelodysplasia (MD) and myeloproliferative disorders (MPD) in patients undergoing neurosurgical procedures <i>AH Wong (Liverpool)*, K Saeed (Liverpool), MK Lee (Liverpool), T Pigott (Liverpool), M Javadpour (Liverpool)</i>
P-079	13:05	Intraventricular cystic mature teratoma in adults: case series <i>A Ziadi (Montreal)*, R Rahme (Montreal), AG Weil (Montreal), R Moumdjian (Montreal)</i>
P-080	13:10	Growing “gauzoma” (gauze induced granuloma) following wrapping of an aneurysm <i>HA Engelbrecht (St. John's), FB Maroun (St. John's), GP Murray (St. John's), N Hache (St. John's)</i>
P-066	13:15	A case of ventriculoperitoneal shunt silicone allergy <i>BW Lo (Hamilton)*, F Saunders (Kingston), P Ellis (Kingston), R Pokrupa (Kingston), J Rossiter (Kingston)</i>
P-067	13:20	Apoptictiform onset of peri-meningioma intracerebral hemorrhage: a discussion on possible mechanisms <i>BW Lo (Hamilton)*, R Pokrupa (Kingston), P Ellis (Kingston), F Saunders (Kingston), S Ludwin (Kingston)</i>

DIGITAL MINI-PLATFORM SESSIONS

SPINE AND NEURO-ONCOLOGY

Thursday - Poster Station #3 - Moderator: Shoban Vachhrajani
Exhibition Hall Room 200AB

- P-081 12:30 A systematic review of pain following traumatic spinal cord injury – an instance of abhorrent plasticity?**
DW Cadotte (Toronto), MG Fehlings (Toronto)*
- P-082 12:35 Cervical spondylotic myelopathy following cervical decompression: a prospective cohort**
SA El-Zuway (Hamilton), E Kachur (Hamilton)*
- P-083 12:40 Does intra-operative EMG affect pedicle screw position?**
EM Frangou (Saskatoon), JR Tynan (Saskatoon), L Ogieglo (Saskatoon), L Hnenny (Saskatoon), D Fourney (Saskatoon)*
- P-084 12:45 Bilateral C5 palsy following multilevel cervical laminectomy and fusion: case report and review of the literature**
PA Gooderham (Vancouver), R Sahjpaul (Vancouver), J Stewart (Vancouver)*
- P-085 12:50 A case of mistaken identity: spinal epidural angiolipoma case report and review of literature**
FA Haji (London), YK Patel (London), L Ang (London), J Megyesi (London)*
- P-086 12:55 Operative versus nonoperative management of acute odontoid type II fractures in elderly patients: a meta-analysis**
*IU Haq (Thunder Bay)**
- P-087 13:00 A comparison of four quantitative methods to assess spine stenosis on magnetic resonance imaging in patients with cervical spondylotic myelopathy(CSM)**
AV Karpova (Toronto), MG Fehlings (Toronto), S Chua (Toronto), D Rabin (Toronto), S Craciunas (Toronto), SR Smith (Toronto)*
- P-088 13:05 Spinal cord compression due to neuroendocrine carcinoma, a rare case**
M Maleki (Montreal), CE Chatillon (Montreal), M Guiot (Montreal)*
- P-089 13:10 Spinal cord injury without initial MRI abnormality: case report**
M Schellenberg (Kingston), R Pokrupa (Kingston)**
- P-090 13:15 Lumbar microdiscectomy for symptomatic disc herniation: analysis of clinical, functional, and radiological outcomes in a cohort of 41 patients, with a special emphasis on instability and disability**
R Rahme (Montreal), R Bou-Nassif (Beirut), R Moussa (Beirut), J Maarrawi (Beirut), T Rizk (Beirut), G Nohra (Beirut), E Samaha (Beirut), N Okais (Beirut)*
- P-091 13:20 What happens to Modic changes following lumbar discectomy? Analysis of a cohort of 41 patients with a 3 to 5-year follow-up**
R Rahme (Montreal), R Bou-Nassif (Beirut), R Moussa (Beirut), J Maarrawi (Beirut), T Rizk (Beirut), G Nohra (Beirut), E Samaha (Beirut), N Okais (Beirut)*
- P-092 13:25 Siemens Arcadis Orbic C-arm and BrainLab for thoracolumbar instrumentation**
RL Sahjpaul (North Vancouver), S Gul (North Vancouver), J Padilla (North Vancouver)*
- P-093 13:30 Traumatic spinal injuries in children**
C Kim (Ottawa), M Vassilyadi (Ottawa), PJ Moroz (Ottawa)*
- P-094 13:35 Giant cystic intradural lumbosacral schwannoma: is stabilization necessary?**
JS Wilkinson (Saskatoon), SA Mann (Saskatoon), CA Robinson (Saskatoon), DR Fourney (Saskatoon)*
- P-095 13:40 Traumatic expulsion of the L4 vertebral body from the spinal column**
JS Wilkinson (Saskatoon), M Riesberry (Saskatoon), SA Mann (Saskatoon), DR Fourney (Saskatoon)*
- P-096 13:45 Effects of a novel Chinese herbal formula on traumatic spinal cord injury in rats**
DH Zhang (Hamilton), C Su (Hamilton), S Jiang (Hamilton), K Reddy (Hamilton), M Rathbone (Hamilton)*

SPINE AND NEURO-ONCOLOGY

Friday - Poster Station #3 - Moderator: TBA
Exhibition Hall Room 200AB

- P-123 12:10 Metastatic choriocarcinoma: a treatable cause of intracranial hemorrhage and status epilepticus**
Z Abu-Sharar (Vancouver), P Teal (), M Heran (), MB Connolly (Vancouver)*
- P-124 12:15 Evaluation of concomitant temozolomide and radiotherapy treatment in patients with glioblastoma multiforme in two Canadian tertiary care centers: retrospective population based cohort study**
IM Alnaami (Edmonton), V Mehta (Edmonton), S Gourishankar (Edmonton), A Murtha (Edmonton), S Walling (Halifax), A Senthilselvan (Edmonton)*
- P-125 12:20 Brain tumor stereotactic biopsy: fame-based or frameless?**
M D'Astous (Québec), M Labidi (Québec), M Caron-Cantin (Québec), D Petit (Québec), C Dubé (Chicoutimi), M Prud'homme (Québec), L Cantin (Québec)*

DIGITAL MINI-PLATFORM SESSIONS

P-126	12:25	Cavernous hemangiomas associated with primary brain tumours: case reports and etiological hypotheses <i>RW Dudley (Montreal)*, BL Godoy (Rio De Janeiro), M Guiot (Montreal), D Melanson (Montreal), J Hall (Montreal), R Leblanc (Montreal), R Del Maestro (Montreal)</i>
P-127	12:30	Clinicopathological implications of congenital brain tumours: 10-year experience at Hamilton Health Sciences <i>B Manoranjan (Hamilton)*, JP Provias (Hamilton)</i>
P-128	12:35	Hemostasis management during completely endoscopic removal of a highly vascular intraparenchymal cerebellar tumor: technique assessment <i>N McLaughlin (Santa Monica)*, D Kelly (Santa Monica), DM Prevedello (Pittsburgh), K Shahlaie (Santa Monica), A Kassam (Santa Monica)</i>
P-129	12:40	The endoscopic endonasal transmaxillary approach to pterygopalatine fossa schwannomas <i>N McLaughlin (Santa Monica)*, D Kelly (Santa Monica), C Griffiths (Santa Monica), DM Prevedello (Pittsburgh), R Carrau (Pittsburgh), K Shahlaie (Santa Monica), A Kassam (Santa Monica)</i>
P-130	12:45	Medulloblastoma and gorlin syndrome: an extraordinary case of survival without adjuvant therapy <i>L Rasmussen (Vancouver)*, S Rassekh (Vancouver), A Singhal (Vancouver), G Henderson (Vancouver), J Hukin (Vancouver)</i>
P-131	12:50	Intravascular large B-cell lymphoma masquerading as primary CNS angiitis <i>N Rasool (Halifax)*, L Shimon (Halifax), RJ Macaulay (Halifax), T Benstead (Halifax)</i>
P-132	12:55	Herpes encephalitis and glioblastoma multiform: a rare but serious occurrence <i>MA Riesberry (Saskatoon)*, F Moien Afshari (Saskatoon), C Boyle (Saskatoon), JF Tellez Zenteno (Saskatoon), K Meguro (Saskatoon)</i>
P-133	13:00	Subtotal resection of vestibular schwannomas: a retrospective review of one centre's experience <i>AD Tu (Vancouver)*, R Akagami (Vancouver)</i>
P-134	13:05	Gliomatosis cerebri presenting as bilateral thalamic glioma: case report and review of the literature <i>DH Zhang (Hamilton)*, K Reddy (Hamilton)</i>

STROKE PREVENTION AND TREATMENT I

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Thursday - Poster Station #4 - Moderator: TBA
Exhibition Hall Room 200AB

P-169	12:30	Radiation induced cavernous malformation of the brain: case report and review of the literature <i>FB Maroun (St. John's)*, K Hong (St. John's), JC Jacob (St. John's), N Hache (St. John's)</i>
P-145	12:35	Low sensitivity and specificity of Oxfordshire community stroke project classification: a prospective MRI study <i>N Asdaghi (Edmonton)*, M Saini (Edmonton), B Hameed (Edmonton), J McCombe (Edmonton), T Jeerakathil (Edmonton), D Emery (Edmonton), K Butcher (Edmonton)</i>
P-146	12:40	Acute perfusion and diffusion abnormalities predict early new MRI lesions after minor stroke and transient ischemic attack (TIA) <i>N Asdaghi (Edmonton)*, B Hameed (Edmonton), M Saini (Edmonton), T Jeerakathil (Edmonton), D Emery (Edmonton), K Butcher (Edmonton)</i>
P-147	12:45	Combined full dose IV tPA and IA therapy versus primary IA therapy in proximal vessel occlusions <i>R Bhatia (Calgary), N Shobha (Calgary), B Menon (Calgary), SP Bal (Calgary)*, P Kochar (Calgary), J Wong (Calgary), W Morrish (Calgary), M Hudon (Calgary), T Watson (Calgary), M Goyal (Calgary), A Demchuk (Calgary), M Hill (Calgary)</i>
P-148	12:50	Low rates of acute recanalisation with Intravenous tPA in proximal vessel occlusions <i>R Bhatia (Calgary), N Shobha (Calgary), B Menon (Calgary), SP Bal (Calgary)*, P Kochar (Calgary), T Watson (Calgary), M Goyal (Calgary), M Hill (Calgary), A Demchuk (Calgary)</i>
P-149	12:55	Risk factors with carotid intimal media thickness in elderly asymptomatic individuals subjects <i>V Bandaru (Hyderabad)*, S Kaul (Hyderabad)</i>
P-168	13:00	Case report of ruptured intrameatal anterior inferior cerebellar artery aneurysm & review of literature <i>BW Lo (Hamilton)*, R Pokrupa (Kingston), F Saunders (Kingston), P Ellis (Kingston), M Tymianski (Toronto)</i>
P-151	13:05	"Alien voice" auditory hallucinations as the presenting symptom of acute left middle cerebral artery (MCA) infarction <i>JG Boyd (Kingston)*, AY Jin (Kingston)</i>
P-152	13:10	Prognostic accuracy of the ICH score on initial evaluation of patients presenting with non-traumatic intracerebral hemorrhage: a systematic review and meta-analysis <i>D Agarwal (Rochester), A Surana (Jodhpur), S Chandra (Rochester)*</i>
P-153	13:15	Prognostic utility of ABCD2 score in transient ischemic attack: a systematic review and meta-analysis <i>D Agarwal (Rochester), A Surana (Jodhpur), S Chandra (Rochester)*</i>

DIGITAL MINI-PLATFORM SESSIONS

P-154	13:20	Canine aneurysms treated with endovascular flow-diverting stents: testing factors that may predict safety and efficacy <i>TE Darsaut (Montreal)*, I Salazkin (Montreal), G Gevry (Montreal), R Jean (Montreal)</i>
P-155	13:25	The cost of endovascular consumables for the interventional treatment of acute stroke at CHUM Notre-Dame hospital <i>TE Darsaut (Montreal)*, V St-Supéry (Montreal), A Weill (Montreal)</i>
P-156	13:30	Time until transfer to rehabilitation center after stroke <i>P Durand-Martel (Sherbrooke)*, F Evoy (Sherbrooke)</i>
P-157	13:35	Intraoperative angiography during microsurgical resection of arteriovenous malformations in children <i>M Ellis (Toronto)*, A Kulkarni (Toronto), J Drake (Toronto), J Rutka (Toronto), D Armstrong (), P Dirks (Toronto)</i>

STROKE PREVENTION AND TREATMENT I

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Friday - Poster Station #4 - Moderator: TBA
Exhibition Hall Room 200AB

P-158	12:10	Cavernoma of the third ventricle near the foramen of Monro <i>R Leblanc (Montreal), N Gelinhas-Phaneuf (Montreal)*</i>
P-159	12:15	Withdrawn
P-160	12:20	Towards optimal management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk <i>GW Hawryluk (Toronto)*, J Austin (Toronto), J Furlan (Toronto), C O'Kelly (Toronto), MG Fehlings (Toronto)</i>
P-161	12:25	Predicting complications of radiosurgery for arteriovenous malformation <i>C Hayhurst (Toronto)*, E Monsalves (Toronto), A Kulkarni (Toronto), M Schwartz (Toronto), C Menard (Toronto), G Zadeh (Toronto)</i>
P-162	12:30	Morphological changes in residual rat cortex after stroke <i>JM Karl (Lethbridge)*, M Alaverdashvili (Lethbridge), A Cross (Lethbridge), IQ Whishaw (Lethbridge)</i>
P-163	12:35	Exploring the link between stroke and amyloid deposition in subjects participating in the Alzheimer Disease Neuroimaging Initiative <i>K Klages (London)*, Y Choi (London), M Borrie (London), M Smith (London), L Pino (London), R Bartha (London), V Hachinski (London)</i>
P-164	12:40	Quicker and better recanalization in acute ischemic strokes: our initial experience with a self-expanding, fully retrievable stent <i>P Kochar (Calgary)*, BK Menon (Calgary), AA SENG (Calgary), AM Demchuk (Calgary), M Goyal (Calgary)</i>
P-165	12:45	International Study of Primary Angiitis of the Central nervous system (I-SPACE): a proposal <i>J Kovitz-Lensch (Lausanne)*, AY Poppe (Lausanne), R Swartz (Lausanne), A Demchuk (Calgary), J Putaala (Calgary), JM Ferro (Lisbon), I Crassard (Paris), A de Windt (Lille), C Odier (Lausanne), P Michel (Lausanne), S Lanthier (Lausanne)</i>
P-166	12:50	Progressive and diffuse intracranial artery stenoses in Majewski osteodysplastic primordial dwarfism type II – a management challenge <i>S Lanthier (Montreal)*, T Darsaut (Montreal), F Guilbert (Montreal), LC Gioia (Montreal), V Dubuc (Montreal), J Kovitz-Lensch (Montreal), AY Poppe (Montreal)</i>
P-167	12:55	Immunosuppressive therapy in cerebral amyloid angiopathy with lobar hyperintensities <i>S Lanthier (Montreal)*, AY Poppe (Montreal), SM Greenberg (Boston), SE Black (Toronto)</i>
P-150	13:00	Invasive cortical near infrared spectroscopy for quantitative assessment of cerebral blood flow <i>MR Boulton (London)*, J Cooper (London), K St. Lawrence (London)</i>
P-144	13:05	Progression of dural arterio-venous fistula: a case report and review of the literature <i>Q Al Hinaï (Montreal)*, N McLaughlin (Montreal), D Sirhan (Montreal), D Tampieri (Montreal)</i>
P-170	13:10	Familial cerebral cavernous angiomas diagnosed by susceptibility-weighted MRI <i>AP Masiowski (Saskatoon)*, EJ Atkins (Saskatoon)</i>
P-171	13:15	Pipeline embolization device reconstruction of ruptured intracranial aneurysms: report of two cases <i>C Matouk (Toronto)*, C O'Kelly (Toronto), M Ellis (Toronto), D Sarma (Toronto), B Gray (Toronto), J Spears (Toronto), W Montanera (Toronto), T Marotta (Toronto)</i>
P-172	13:20	Endovascular treatment of middle cerebral artery aneurysms: the St. Michael's Hospital experience <i>CC Matouk (Toronto)*, Z Kaderali (Toronto), LN de Tilly (Toronto), B Gray (Toronto), D Sarma (Toronto), W Montanera (Toronto), T Marotta (Toronto), J Spears (Toronto)</i>

STROKE PREVENTION AND TREATMENT II

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Thursday - Poster Station #5 - Moderator: TBA
Exhibition Hall Room 200AB

- P-174 12:30 Patients in high clinical grade following an aneurysmal subarachnoid hemorrhage: recent experience**
N McLaughlin (Santa Monica), P Lessard-Bonaventure (Montreal), MW Bojanowski (Montreal)*
- P-175 12:35 The impact antibiotic impregnated ventricular catheters on infection rates in patients with a subarachnoid hemorrhage**
N McLaughlin (Santa Monica), P St-Antoine (Montreal), MW Bojanowski (Montreal)*
- P-173 12:40 Covered carotid stents as an adjunct in the surgical treatment of carotid body tumors: a report of two cases and a review of the literature**
CM McDougall (Edmonton), I Alnaami (Edmonton), MM Chow (Edmonton)*
- P-176 12:45 Does presence of vascular risk factors and elapsed time from stroke onset affect leptomeningeal collateral (LMC) recruitment in acute ischemic stroke?**
BK Menon (Calgary), TW Watson (Calgary), J Modi (Calgary), M Goyal (Calgary), AM Demchuk (Calgary), EE Smith (Calgary)*
- P-177 12:50 Estimation of acute stroke patients' weight for tPA treatment can lead to dose overcalculation and increased risk of hemorrhagic transformation**
N Mohammed (Hamilton), DJ Sahlas (Hamilton), L Gould (Hamilton), McNicoll-Whiteman (Hamilton), F Naufal (Hamilton), W Oczkowski (Hamilton)*
- P-178 12:55 Clinical features, risk factors and outcome in 84 patients with cerebral venous sinus thrombosis**
JO Nadeau (Calgary), V Lam (Calgary), C Hinnell (Calgary), MD Hill (Calgary), SB Coutts (Calgary)*
- P-179 13:00 Self-reported health predicts stroke**
L Nobel (Montreal), L Nadeau (Montreal), N Mayo (Montreal)*
- P-202 13:05 Interim Analysis of an Ongoing Canadian Phase IV Prospective Observational Cohort Study of Health Utility in Patients Receiving Botulinum Toxin Type A (BOTOX®) Treatment for Approved Therapeutic Indications (MDs on BOTOX® UTILITY-MOBILITY)**
T Wein (Montreal), M Jog (London), R Beauchamp (Vancouver), R Miller (Halifax), M Bhogal (Markham), S Simonyi (Markham)*
- P-181 13:10 Timing of hemorrhagic and thromboembolic complications in anticoagulant-associated intracranial hemorrhage**
CC Poon (Edmonton), M Chow (Edmonton), K Au (Edmonton), K Butcher (Edmonton)*
- P-182 13:15 Disabling arterial stroke in two young women within 1 month of starting Yaz (drospirenone and ethinyl estradiol)**
AY Poppe (Montreal), Y Deschaintre (Montreal), V Dubuc (Montreal), LC Gioia (Montreal), S Lanthier (Montreal)*
- P-196 13:20 Quality of life following decompressive hemicraniectomy for malignant middle cerebral artery infarction**
AG Weil (Montreal), R Rahme (Montreal), R Moumdjian (Montreal), A Bouthillier (Montreal), MW Bojanowski (Montreal)*
- P-197 13:25 Acute subdural hematoma (aSDH) without subarachnoid hemorrhage from a ruptured callosomarginal artery aneurysm**
AG Weil (Montreal), M Laroche (Montreal), N McLaughlin (Montreal), P Lessard-Bonaventure (Montreal), MW Bojanowski (Montreal)*
- P-185 13:30 Aβ-related angiitis of the central nervous system: report of three cases and review of the literature**
H Rigby (Halifax), L Shimon (Halifax), A Easton (Halifax), V Bhan (Halifax)*
- P-187 13:35 Baseline NIHSS drives clinical decision making in basilar artery occlusion—Calgary experience**
N Shobha (Calgary), R Bhatia (Calgary), SP Bal (Calgary), G Kumarpillai (Calgary), S Tymchuk (Calgary), EE Smith (Calgary), MD Hill (Calgary), M Goyal (Calgary), AM Demchuk (Calgary)*
- P-191 13:40 Dural branches of proximal ACA: description of a rare embryological remnant**
F Signorelli (Montreal), F Scholtes (Montreal), P Lessard (Montreal), MW Bojanowski (Montreal)*

STROKE PREVENTION AND TREATMENT II

SUPPORTED BY AN EDUCATIONAL GRANT FROM HOFFMAN LA ROCHE

Friday - Poster Station #5 - Moderator: TBA
Exhibition Hall Room 200AB

- P-186 12:10 The proapoptotic BNIP3 is involved in autophagic neuronal death in stroke**
R Shi (Winnipeg), J Weng (Winnipeg), L Zhao (Winnipeg), J Kong (Winnipeg)*
- P-188 12:15 Ocular tilt reaction and medial thalamic infarction: a case report**
MM Siddiqui (Edmonton), F Ba (Edmonton)**

DIGITAL MINI-PLATFORM SESSIONS

P-189	12:20	Superficial siderosis as a manifestation of a dural arteriovenous fistula <i>F Signorelli (Montreal)*, N McLaughlin (Santa Monica), MW Bojanowski (Montreal)</i>
P-190	12:25	Surgery of ruptured anterior communicating artery aneurysms of very small size <i>F Signorelli (Montreal)*, F Scholtes (Montreal), P Lessard (Montreal), MW Bojanowski (Montreal)</i>
P-192	12:30	Risk of recurrent aneurysmal subarachnoid hemorrhage after incomplete endovascular coiling of ruptured intracranial aneurysms <i>MK Tso (Calgary)*, M Goyal (Calgary), ME Hudon (Calgary), WF Morrish (Calgary), JH Wong (Calgary)</i>
P-193	12:35	Retrospective review of the incidence and presentation of arterial venous malformations of the brain in Saskatchewan <i>Z Tymchuk (Saskatoon)*, J Zheng (Saskatoon), ME Kelly (Saskatoon)</i>
P-194	12:40	Treatment of a small P1/P2 posterior cerebral artery aneurysm using a flow diverting stent <i>Z Tymchuk (Saskatoon)*, D Fiorella (Stony Brook), ME Kelly (Saskatoon)</i>
P-195	12:45	Evaluation of timely accessibility to an outpatient stroke clinic at community hospital <i>T Stefurak (Toronto)*, O Veselskiy (Toronto)*, M Barta (Toronto)</i>
P-183	12:50	Outcome of severe arteriovenous malformation (AVM)-related intracranial hemorrhage: the importance of cisternal subarachnoid hemorrhage and early seizures <i>R Rahme (Montreal)*, AG Weil (Montreal), MW Bojanowski (Montreal)</i>
P-184	12:55	Early rerupture of cerebral arteriovenous malformations: beware the progressive hemispheric swelling <i>R Rahme (Montreal)*, AG Weil (Montreal), MW Bojanowski (Montreal)</i>
P-198	13:00	Nec-1 protects against delayed neuronal death in stroke through inhibition of the BNIP3 pathway <i>J Weng (Winnipeg)*, J Kong (Winnipeg)</i>
P-199	13:05	Prospective evaluation of early use of SILK versus pipeline flow-diverting stents <i>JH Wong (Calgary)*, M Goyal (Calgary), ME Hudon (Calgary), WF Morrish (Calgary)</i>
P-200	13:10	Gamma knife surgery for cerebral arteriovenous malformations (AVMs): results of treatment of 69 consecutive patients at a single centre <i>FA Zeiler (Winnipeg)*, J Nesbitt (Winnipeg), AM Kaufmann (Winnipeg), G Schroeder (Winnipeg), P McDonald (Winnipeg), D Fewer (Winnipeg), M West (Winnipeg)*</i>
P-201	13:15	A clinical toolkit to support acute stroke management using Telestroke in Ontario <i>L Zimmer (Chatham)*, L Kelloway (Hamilton)*</i>
P-180	13:20	Stroke units improve outcomes by following stroke best practices <i>W Oczkowski (Hamilton)*, A Shoamaneh (Hamilton), R Whiteman (Hamilton), L Gould (Hamilton)</i>

STROKE RECOVERY AND REHABILITATION & SYSTEMS CHANGE POLICY AND KNOWLEDGE TRANSLATION

Thursday - Poster Station #6 - Moderator: TBA

Exhibition Hall Room 200AB

P-203	12:30	Measuring emotional vitality in stroke survivors and their caregivers <i>SP Barbic (Montreal)*, LE Finch (Montreal), NE Mayo (Montreal)</i>
P-204	12:35	Medical aspect, communication and quality of life after Locked-In Syndrome – a review of twenty cases <i>N. Beaudoin (Montréal)*, L De Serres (Montréal)*, N Martel (Montréal), D Forte (Montréal), A Nicolaidis (Montréal)</i>
P-205	12:40	Memory rehabilitation in individuals with vascular cognitive impairment <i>S Blanchet (Quebec City)*, S Belleville (Montreal), L Noreau (Quebec City), P Fougereyrollas (Quebec City)</i>
P-206	12:45	A cohort study of personally valued activities and well-being <i>M Egan (Ottawa)*, C Dubouloz (Ottawa), CG Davis (Ottawa), L Kubina (Ottawa), D Kessler (Ottawa)</i>
P-207	12:50	Development of a clinically-oriented instrument to identify the biomechanical characteristics and strategies adopted by stroke subjects during the timed “up and go” test – Part I: content validity and reliability <i>C Faria (Belo Horizonte)*, LF Teixeira-Salmela (Belo Horizonte), GE Laurentino (Recife), S Nadeau (Montréal)</i>
P-208	12:55	Development of a clinically-oriented instrument to identify the biomechanical characteristics and strategies adopted by stroke subjects during the timed “up and go” test – Part II: criterion-related validity <i>C Faria (Belo Horizonte)*, S Nadeau (Montréal), GE Laurentino (Recife), PA Araújo (Belo Horizonte), LF Teixeira-Salmela (Belo Horizonte)</i>
P-209	13:00	Development of a clinically-oriented instrument to identify the biomechanical characteristics and strategies adopted by stroke subjects during the timed “up and go” test – Part III: construct validity and reliability of the final version <i>C Faria (Belo Horizonte)*, LF Teixeira-Salmela (Belo Horizonte), GE Laurentino (Recife), S Nadeau (Montréal)</i>

DIGITAL MINI-PLATFORM SESSIONS

P-210	13:05	Observation and treatment of coprophagic behavior in a stroke patient: a two-patient case study <i>C Forbes (Montreal)*, D Pina (Montreal), G Georgiana (Montreal), D Mona (Montreal), G Fabienne (Montreal), T Caterina (Montreal), M Susan (Montreal), L Carl (Montreal), T Alexander (Montreal), E Jessica (Montreal)</i>
P-212	13:10	Can vision be used to compensate for deficits in limb position sense following stroke? <i>T Herter (Kingston)*, M Bourque (Calgary), S Scott (Kingston), S Dukelow (Calgary)</i>
P-213	13:15	Advancing assessment and management of balance and mobility: integrating research in ‘everyday’ practice <i>EL Inness (Toronto)*, A Mansfield (Toronto), K Brunton (Toronto), L Biasin (Toronto), B Lakhani (Toronto), S Prajapati (Toronto), R Mileris (Toronto), M Bayley (Toronto), WE McIroy (Toronto)</i>
P-214	13:20	La prise en charge des soins et l’aide à domicile après la réadaptation auprès des personnes âgées victimes d’un accident vasculaire cérébral <i>G Kashindi (Ottawa)*</i>
P-215	13:25	“Virtual” home safety assessment after stroke in remote aboriginal communities <i>E Linkewich (Huntsville)*, K Harrington (Hamilton), A Oikonen (Hamilton)</i>
P-220	13:30	Increasing best-practice management of post-stroke unilateral spatial neglect <i>A Petzold (Laval)*, N Korner-Bitensky (Laval), S Ahmed (Laval), N Salbach (Montreal), A Menon (Montreal), F Kaizer (Laval), T Ogourtsova (Montreal)</i>
P-216	13:35	Neural correlates of semantic feature analysis in chronic aphasia: a multiple single-case study <i>K Marcotte (Montreal)*, B Damien (Montreal), M de Préaumont (Montreal), S Généreux (Montreal), M Hubert (Montreal), A Ansaldo (Montreal)*</i>
P-217	13:40	The effect of tPA administration on rehabilitation outcomes: does thrombolysis facilitate functional recovery? <i>MJ Meyer (London)*, M Murie-Fernandez (Navarre), R Hall (Toronto), Y Liu (Toronto), S Katherine (London), N Foley (London), R Teasell (London)</i>
P-211	13:45	Withdrawn

STROKE RECOVERY AND REHABILITATION & SYSTEMS CHANGE POLICY AND KNOWLEDGE TRANSLATION

Friday - Poster Station #6 - Moderator: TBA

Exhibition Hall Room 200AB

P-218	12:10	Withdrawn
P-219	12:15	Instrumented cane for treadmill walking post-stroke <i>CF Perez (Montreal)*, J Fung (Montreal)</i>
P-221	12:20	Withdrawn
P-222	12:25	Withdrawn
P-223	12:30	Withdrawn
P-224	12:35	Withdrawn
P-225	12:40	Withdrawn
P-226	12:45	Baseline characteristics of patients enrolled in a large ongoing Canadian phase IV prospective observational cohort study (MDs on BOTOX® UTILITY – MOBILITY) of botulinum toxin type A (BOTOX®) for approved therapeutic indications <i>T Wein (Montreal)*, M Jog (London), R Beauchamp (Vancouver), R Miller (Halifax), M Bhogal (Markham), S Simonyi (Markham)</i>

DIGITAL MINI-PLATFORM SESSIONS

P-227	12:50	Activation of indoleamine 2,3-dioxygenase in post-stroke depression patients <i>A Wong (Toronto)*, N Herrmann (Toronto), SE Black (Toronto), G Tennen (Toronto), D Gladstone (Toronto), F Gao (Toronto), R Aviv (Toronto), A Sniderman (Toronto), P Albert (Ottawa), K Lancot (Toronto)</i>
P-228	12:55	Use of eco-maps in evaluating community reengagement post stroke <i>SM Gray (Owen Sound)*, M Solomon (Owen Sound)</i>
P-229	13:00	Supporting the implementation of stroke care clinical practice guidelines through online self-directed learning <i>K Lumley-Leger (Ottawa)*, R McNeil (Vancouver), A Fisher (Ottawa), T Miller (Ottawa), S Draper (Ottawa)</i>
P-230	13:05	Withdrawn
P-231	13:10	An academic half-day in stroke prevention developed for the family medicine residency training program at the University of Toronto <i>DJ Sahlas (Hamilton)*, C Whitehead (Toronto), D Chan (Toronto), J Hopyan (Toronto), L Casaubon (Toronto), D Selchen (Toronto)</i>
P-232	13:15	Knowledge to action: implementation, process and outcomes in the use of Holter monitors for acute stroke patients <i>RM Sourial (Montreal)*, J Teitelbaum (Montreal), S Lussier (Montreal), S Boutin (Montreal)</i>
P-233	13:20	Withdrawn

NEURORADIOLOGY, TRAUMA / CRITICAL CARE & PEDIATRIC NEUROLOGY

Thursday - Poster Station #7 - Moderator: Vijay Ramaswamy

Exhibition Hall Room 200AB

P-097	12:30	The use of ketamine for refractory status epilepticus <i>AD Al-Otaibi (Toronto)*, B Mc Coy (Toronto), M Cortez (Toronto), JS Hutchison (Toronto), CD Hahn (Toronto)</i>
P-098	12:35	Functional implication of the cAMP pathway learning genes in downstream long-term memory and cognition <i>C Rosenfelt (Edmonton), A Nguyen (Edmonton), F Bolduc (Edmonton)*</i>
P-099	12:40	Intermediate-dose idebenone and quality of life in Friedreich ataxia <i>JF Brandsema (Toronto)*, G Yoon (Toronto), D Stephens (Toronto), J Hartley (Toronto)</i>
P-100	12:45	Failure to recognize inferior vermian hypoplasia in congenital ocular motor apraxia <i>L Capano (Calgary)*, JK Mah (Calgary), JT Lysack (Calgary), WA Fletcher (Calgary)</i>
P-101	12:50	Hemimegalencephaly in 2 newborns: role of fetal MRI, gestational age, and surgery <i>L Flores-Sarnat (Calgary)*, W Hader (Calgary), L Bello-Espinosa (Calgary), X Wei (Calgary), HB Sarnat (Calgary)</i>
P-102	12:55	Parkinsonian rigidity in Rett syndrome <i>P Humphreys (Ottawa)*, N Barrowman (Ottawa)</i>
P-103	13:00	Acute transverse myelitis in infancy: is there a relationship to immunization? <i>F Jacob (Edmonton), J Neilson (Edmonton)*, JY Yager (Edmonton)</i>
P-104	13:05	Hemiplegic migraine in the pediatric population: different phenotypes and associated neurological diseases <i>LH Rodan (Toronto)*, T Soman (Toronto)</i>
P-105	13:10	CAPOS syndrome: further delineation of phenotype and etiology <i>CD van Karnebeek (Vancouver)*, G Horvath (Vancouver), MK Demos (Vancouver)</i>
P-106	13:15	Creating a community based paediatric neurology teaching clinic <i>S Wendy (Rotherham)*</i>

NEURORADIOLOGY, TRAUMA / CRITICAL CARE & PEDIATRIC NEUROLOGY

Friday - Poster Station #7 - Moderator: Kesava Reddy

Exhibition Hall Room 200AB

P-139	12:10	Accurate insertion of external ventricular drains in ICU setting: a retrospective study <i>AA Al Jishi (Montreal)*, M Basamh (Montreal), D Sinclair (Montreal)</i>
P-140	12:15	Computed tomography versus magnetic resonance imaging of the brain in comatose intensive care unit patients <i>HM Algethamy (London)*, M Alzawahmah (London), S Mirsattari (London), G Young (London)</i>

DIGITAL MINI-PLATFORM SESSIONS

P-141	12:20	The predictive value of clinical and immunological factors in the development of pneumonia after traumatic brain injury <i>N Deis (Edmonton)*, D Kutsogiannis (Edmonton)</i>
P-142	12:25	Good functional recovery in a patient with severe anoxic encephalopathy with bilaterally absent N20 somatosensory evoked potentials <i>D Jichici (Hamilton)*, J Paulseth (Hamilton), L Morillo (Hamilton), B Lo (Hamilton), W Oczkowski (Hamilton)</i>
P-143	12:30	Early tracheostomy – effect on the outcome of severe head injury patients <i>RA Shah (Rawalpindi)*</i>
P-001	12:35	Intracranial blister aneurysms: ambiguity awaited truth. Report of two cases and review of literature <i>AA Al Jishi (Montreal)*, G Goel (Montreal), M Cortes (Montreal), D Tampieri (Montreal)</i>
P-002	12:40	Cerebral blood volume reversibility within tissue that progresses to infarction in patients with ischemic stroke: a CT perfusion study <i>CD d'Esterre (London)*, TY Lee (London)</i>
P-003	12:45	Decreased internal cerebral vein filling in acute ischemic stroke <i>E Klourfeld (Kingston)*, AY Jin (Kingston)</i>
P-006	12:50	Vessel wall imaging in patients with middle cerebral artery stenosis <i>MD Vergouwen (Toronto)*, FL Silver (Toronto), DJ Mikulis (Toronto), RH Swartz (Toronto)</i>
P-007	12:55	Mapping brain pH and brain ATP using multivoxel 31P MR spectroscopy: a preliminary study <i>R Wu (Shantou)*, Y Chen (Shantou), W Liu (Shantou), Q Qiu (Shantou), KG terBrugge (Toronto), D Mikulis (Toronto)</i>
P-008	13:00	Vision and oxygen inhalation affect mitochondrial activity: a 31p magnetic resonance spectroscopy study <i>R Wu (Shantou)*, H Wang (Shantou), KG terBrugge (Toronto), D Mikulis (Toronto)</i>
P-004	13:05	Role of CT in assessment of traumatic cerebral hemorrhage <i>A Rana (Toronto)*, B Al-Enazi (Toronto), S Zia (Toronto)</i>
P-005	13:10	Neurological and radiological manifestations of alkaptonuria <i>A Rana (Toronto)*, B Alenazi (Toronto), S Naqvi (Toronto), A Al-Shahrani (Toronto)</i>

DEMENTIA, MULTIPLE SCLEROSIS, EPILEPSY AND NEUROMUSCULAR

Thursday - Poster Station #8 - Moderator: TBA

Exhibition Hall Room 200AB

P-048	12:30	Post influenza vaccinations encephalomyelitis <i>A Rana (Toronto)*, S Naz (Toronto)</i>
P-045	12:35	What influences patient's choice of disease-modifying medication for multiple sclerosis? <i>F Moore (Montréal), H Bahig (Montréal)*</i>
P-046	12:40	The adherence and disability outcomes of disease-modifying therapies in relapsing-remitting multiple sclerosis: a ten year prospective open-label study <i>WJ Hader (Saskatoon)*</i>
P-047	12:45	Multiple sclerosis disease-modifying therapy physician prescribing practices in Ontario in 2008 <i>JJ Marriott (Toronto)*, M Mamdani (Toronto), G Saposnik (Toronto), T Gomes (Toronto), PW O'Connor (Toronto)</i>
P-049	12:50	Multiple sclerosis (MS) and pregnancy: a comparison study <i>D Sadovnick (Vancouver)*, M Dybalski (Vancouver), C Guimond (Vancouver), I Yee (Vancouver), P Duquette (Montreal)</i>
P-050	12:55	Canadian Asians with multiple sclerosis (CAMS) study: epidemiological and clinical correlates of phenotype <i>D Sadovnick (Vancouver), T Traboulsee (Vancouver)*, J Lee (Vancouver)</i>
P-009	13:00	An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis <i>B Jeynes (Hamilton)*, J Provias (Hamilton)</i>
P-010	13:05	The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study <i>R Laforce (Quebec)*, JP Buteau (Quebec), N Paquet (Sherbrooke), L Verret (Quebec), M Houde (Quebec), RW Bouchard (Quebec)</i>
P-011	13:10	The impact of the anticholinergic load on development of delirium in elderly <i>G Laforce (Montréal)*, G Paquin-Lanthier (Montréal), M Beausoleil (Montréal), C Chayer (Montréal)</i>
P-012	13:15	A subacute amnesic syndrome caused by spontaneous intracranial hypotension successfully treated with prednisone <i>Y Nadeau (Toronto)*</i>
P-135	13:20	Endogenous neural stem/progenitor cell proliferation and differentiation with a novel biomaterial <i>MJ Coyle (Ottawa)*, U Shanmugalingam (Ottawa), H Westwick (Ottawa), X Cao (Ottawa), EC Tsai (Ottawa)</i>

DIGITAL MINI-PLATFORM SESSIONS

- P-136 13:25 A young patient with an unusual myopathy**
K Koochesfahani (Saskatoon), J Tellez-Zenteno (Saskatoon)*
- P-137 13:30 Non-inflammatory necrotizing myopathy responsive to steroids**
L Shimon (Halifax), I Grant (Halifax)*
- P-138 13:35 Screening for late onset acid maltase deficiency in a neuromuscular clinic**
SL Venance (London), WJ Koopman (London)*

DEMENTIA, MULTIPLE SCLEROSIS, EPILEPSY AND NEUROMUSCULAR

Friday - Poster Station #8 - Moderator: Seyed Mirsattari
Exhibition Hall Room 200AB

- P-117 12:10 Familial hemiplegic migraine and epilepsy: a case report**
BW Lo (Hamilton), D Jichici (Hamilton), M Meade (Hamilton), W Oczkowski (Hamilton)*
- P-107 12:15 Thalamic deep brain stimulation for the treatment of Dravet syndrome: short and long-term seizure control**
DM Andrade (Toronto), C Hamani (Toronto), A Lozano (Toronto), RA Wennberg (Toronto)*
- P-108 12:20 The relationship between the epileptic focus and fMRI language patterns in children with epilepsy**
O Bar-Yosef (Toronto), H Otsubo (Toronto), S Chuang (Toronto), D Morris (Toronto), W Logan (Toronto), EJ Donner (Toronto)**
- P-109 12:25 MEG source localization for epileptogenic zone in children with porencephalic cyst**
O Bennett-Back (Toronto), A Ochi (Toronto), E Widjaja (Toronto), C Go (Toronto), J Rutka (Toronto), J Drake (Toronto), C Snead (Toronto), H Otsubo (Toronto)*
- P-110 12:30 EEG findings in a cohort of patients with new-onset seizures**
JG Burneo (London), E Sandison (London)*
- P-111 12:35 Generalized nonconvulsive status epilepticus with reactive alpha rhythm**
E Cote-Mantha (Quebec), M Savard (Quebec)*
- P-112 12:40 Appraising content of specific health measures in childhood epilepsy: an important step in questionnaire selection**
N Fajed (Hamilton), O Kraus de-Camargo (Hamilton), GM Ronen (Hamilton)*
- P-113 12:45 N complexes: an under-recognized normal EEG variant that needs to be distinguished from generalized spike-waves**
A Guillemette (Sherbrooke), C Deacon (Sherbrooke), J Reiher (Sherbrooke)*
- P-114 12:50 Functional activity of generalized spike-and-wave discharges in the GBL rat model: an EEG-fMRI study**
R Hutchison (London), L Leung (London), JS Gati (London), SM Mirsattari (London)*
- P-115 12:55 The effective and ethical use of voluntary induction of psychogenic drop attacks in a patient with idiopathic generalized epilepsy**
MR Keezer (Montreal), A Wilner (Montreal), F Andermann (Montreal)*
- P-116 13:00 Effectiveness and safety of vagus nerve stimulation for intractable epilepsy**
S Kennedy (Saskatoon), JF Tellez Zenteno (Saskatoon)*
- P-118 13:05 Late onset epilepsy: a case of historic proportions**
*RS McLachlan (London)**
- P-119 13:10 A benign variant of TLE with long follow-up**
*MA Smith (London)**
- P-120 13:15 Evaluation of an extended French Canadian pedigree with idiopathic generalised epilepsy**
N Sudharshan (Edmonton), P Cossette (Edmonton), D Gross (Edmonton)*
- P-121 13:20 Early somatosensory symptoms suggest insular seizures and predict poor outcome in temporal lobe epilepsy surgery**
AG Weil (Montreal), W Surbeck (Montreal), R Rahme (Montreal), P Cossette (Montreal), N Giard (Montreal), J Saint-Hilaire (Montreal), A Bouthillier (Montreal), D Nguyen (Montreal)*
- P-122 13:25 Epilepsy surgery for pharmacoresistant temporal lobe epilepsy at Notre Dame Hospital**
W Surbeck (Montreal), AG Weil (Montreal), R Rahme (Montreal), P Cossette (Montreal), N Giard (Montreal), J Saint-Hilaire (Montreal), A Bouthillier (Montreal), D Nguyen (Montreal)*

Chers collègues,

Bienvenue au 45^e congrès de la Fédération des sciences neurologiques du Canada. Le contenu éducatif du congrès reflète, aujourd'hui plus que jamais, les besoins en matière de perfectionnement professionnel continu indiqués par les membres de la FSNC, tel que déterminés lors de nos différentes évaluations. Parmi les éléments ou les sujets proposés en réponse à la rétroaction par les participants, on peut citer :

1. Le congrès du Réseau canadien contre les accidents cérébrovasculaires se déroulera immédiatement avant le congrès de la FSNC, du 6 au 8 juin 2010.
2. Des séances de révision sur certains sujets, conçues pour les résidents ainsi que pour les non-résidents qui souhaitent actualiser leurs connaissances sur le sujet en question. En 2010, les sujets abordés sont l'épilepsie et la chirurgie neurovasculaire. De nouveaux sujets seront choisis chaque année.
3. Les cours sur les maladies neuromusculaires et sur les céphalées sont de retour au programme, ainsi que le cours de neuro-oncologie, de retour pour la première fois depuis 2006.
4. Une fois encore, le nombre de résumés présentés a été très élevé; attendez-vous donc à des présentations sous forme de mini-plateforme ou de plateforme de qualité supérieure, dans un format qui s'améliore constamment.
5. Le docteur James Orbinski sera le conférencier éminent invité de cette année.

Pendant ce congrès, vous aurez des occasions :

1. D'établir des réseaux avec vos collègues, vos mentors et vos amis.
2. De rafraîchir votre pratique grâce aux connaissances et aux aptitudes supplémentaires que vous apprendrez.
3. De stimuler votre réflexion.
4. D'accumuler des crédits de maintien du certificat de section 1.

Veuillez nous dire ce que vous pensez de nous en remplissant les formulaires d'évaluation des sessions et le formulaire d'évaluation globale du congrès, qui sont disponibles en ligne et dans votre cadeau d'inscription. Il est important que vous nous fournissiez vos commentaires afin que nous puissions continuer à nous améliorer et à mieux répondre à vos besoins en matière de perfectionnement professionnel.

Cordialement,



George Elleker
Président
FSNC



Michael Hill
Président
Comité du programme scientifique

Veuillez consulter les sites suivants afin d'obtenir davantage d'informations sur le congrès et sur la province de Québec.

www.cnsfederation.org

www.bonjourquebec.com

Comité exécutif de la FSNC

Le comité exécutif supervise les affaires de l'organisme, prend des décisions au nom du conseil entre ses réunions plénières et agit à titre d'intermédiaire entre le conseil et le président-directeur général. Le président, deux vice-présidents et le président-directeur général de la FSNC (qui n'ont pas le droit de vote) siègent au comité exécutif.

George Elleker
président de la FSNC

Garth Bray
vice-président de la FSNC

Derek Fewer
vice-président de la FSNC

Dan Morin
président-directeur général de la FSNC

Comité du programme scientifique et comité du perfectionnement professionnel

Le comité du programme scientifique et le comité du perfectionnement professionnel est responsable de planifier tous les aspects touchant les programmes scientifiques en vue du congrès annuel de la FSNC, ce qui représente une activité d'apprentissage accréditée approuvée pour les crédits de section I, tels que définis par le Collège royal des médecins et chirurgiens du Canada. Le comité supervise et coordonne les cours de formation du congrès, les colloques et les ateliers élaborés conjointement par le secteur, l'approbation des abrégés, la structure du programme ainsi que les objectifs et les programmes éducatifs à court et à long terme.

Dr Michael Hill (*président, CPS*)

Dr Robert Loch Macdonald
(*vice-président, CPS*)

Dr Colin Chalk (*président, CPP*)

Dr Ron Pokrupa (*vice-président, CPP*)

Dr Cecil Hahn (*CPS*)

Dr Seyed Mirsattari (*CPS*)

Dr Shobhan Vachhrajani (*CPS, CPP*)

Dr George Elleker (*CPS, CPP*)

Dr Jeanne Teitelbaum (*CPS*)

Dr Derek Fewer (*CPS*)

Dr Chris White (*CPS*)

Dr Trevor Steve (*CPS, CPP*)

Dr Eric Massicotte (*CPS*)

Dr Peter Smith (*représentant de l'ACN*)

Dr Michelle Demos (*CPS*)

Dr Vijay Ramaswamy (*CPS, CPP*)

Dr Dhany Charest (*CPP*)

Dr Garth Bray (*CPP*)

Dr Jose Martin del Campo (*CPP*)

Dr Bev Prieur (*CPP*)

Dr Rudolf Arts (*CPP*)

Mr Dan Morin

Mme Lisa Bicek

Mr Brett Windle

RENSEIGNEMENTS D'ORDRE GÉNÉRAL

LIEU DE LA RÉUNION ET INSCRIPTION

SITE DE LA RÉUNION

Centre des congrès de Québec
1000, boul. René-Lévesque Est
Québec, Québec G1R 2B5

INSCRIPTION DES DÉLÉGUÉS ET DES CONFÉRENCIERS - SUR PLACE

Kiosque d'inscription

Centre des congrès de Québec

Le mardi 8 juin	07h00 – 18h30
Le mercredi 9 juin	06h00 – 18h30
Le jeudi 10	07h00 – 18h30
Le vendredi 11 juin	07h00 – 13h30

SITES DES PROCHAINS CONGRES DE LA FÉDÉRATION DES SCIENCES NEUROLOGIQUES DU CANADA

Du 14 au 17 juin 2011	Vancouver, Colombie-Britannique
Du 5 au 8 juin 2012	Ottawa, Ontario

VOUS AVEZ DES QUESTIONS?

Advance Group, gestion de conférences

Attention: Federation des sciences neurologiques du Canada
1444, rue Alberní - Bureau 101
Vancouver, Colombie-Britannique V6G 2Z4
Tél: (604) 688-9655 (poste 2)
Téléc: (604) 685-3521
Courriel: cnsinfo@advance-group.com pour inscription seulement.

Fédération des sciences neurologiques du Canada

709 – 7015 Macleod Trail SW
Calgary, Alberta, Canada T2H 2K6
Tél: (403) 229-9544 Téléc: (403) 229-1661
E-mail: brett-windle@cnsfederation.org

DÉTAILS D'INSCRIPTION

Inscription pour l'événement entier

- comprend toutes les séances du congrès annuel 2010, du mardi 8 juin 2010 au vendredi 11 juin 2010, ainsi que la réception des exposants le mercredi 9 juin 2010.

Les inscriptions pour une journée

- comprennent toutes les séances pour le jour de l'inscription. Remarque : les personnes s'étant inscrites pour un seul jour le mercredi eurent assister à la réception des exposants, le 9 juin 2010.

Insigne d'identité du congrès

- Les délégués doivent porter leur insigne en tout temps afin d'accéder aux cours, aux séances scientifiques et aux soirées du congrès.

ÉVÉNEMENTS MONDAINS

RÉCEPTION DU PROMOTEUR ET DES EXPOSANTS

Mercredi 9 juin 2010 - de 17 h 00 à 19 h 30

Le Centre des congrès de Québec – salon 200AB
Vin et hors d'œuvres. Bar payant. **Insignes nécessaires pour accéder à cet événement.**

AVIS IMPORTANT

Les délégués au congrès 2010 de la FSNC qui s'inscrivent et qui sont hébergés à l'hôtel Hilton de Québec pendant au moins trois nuits consécutives lors du congrès de la FSNC, du 8 au 11 juin, sont admissibles à gagner :

- un séjour gratuit de deux nuits
- un petit déjeuner-buffet pour 2 personnes
- un souper pour 2 personnes au restaurant Allegro de l'hôtel Hilton (menus table d'hôte, aucune consommation alcoolisée).

Le prix doit être utilisé entre le 1er juillet 2010 et le 31 mars 2011. Le prix ne peut pas être échangé contre de l'argent comptant.

Procédure de connexion au réseau Internet sans fil

- Sélectionner le réseau sans fil « Code Centre des congrès ».
- Lancer le navigateur Internet.
- Lire et accepter les termes et conditions en entrant l'un des codes d'accès suivants : AU12N, AU98J, AU42X.
- Pour tout problème de configuration ou de connectivité, le numéro à composer en tout premier lieu est le 1 888 236-8312.

We acknowledge the financial support of the Government of Canada through the Department of Canadian Heritage Official Languages Support Programs Branch.	Nous reconnaissons l'appui financier du gouvernement du Canada par l'entremise du ministère du Patrimoine canadien Direction générale des programmes d'appui aux langues officielles.
	Canadian Heritage Patrimoine canadien

Mardi 8 juin 2010

- 07h45-17h00 **Avancées dans la neurobiologie des maladies**
Salle 206B
- 07h50-17h30 **Revue des notions acquises sur l'épilepsie destinée aux résidents en neurosciences**
Salle 204AB
- 08h00-17h00 **Cours de revue pour résidents en neurochirurgie: maladie neurovasculaire**
Salle 301AB
- 08h30-17h00 **Stratégies visant l'amélioration de la qualité de vie et de la qualité des soins pour les personnes atteintes de SLA**
Quebec Hilton Hotel - Salle Beauport
- 08h30-17h00 **Journée de la neurologie pédiatrique**
Salle 206A
- 12h00-13h30 **Symposium élaboré conjointement (accidents vasculaires cérébraux)**
Salle 2000D
- 18h00-20h00 **Séance vidéo sur l'épilepsie**
Salle 206B
- 18h00-20h00 **Séance du groupe intérêt sur les troubles du mouvement** *Salle 207*
- 18h00-20h00 **Groupe d'intérêt (les céphalées)**
Salle 208A
- 18h00-20h00 **Séance du groupe intérêt sur les maladies neuromusculaires**
Salle 206A

Mercredi 9 juin 2010

- 06h30-08h00 **Symposium élaboré conjointement (les céphalées)** *Salle 204AB*
- 08h00-10h00 **Séance plénière d'ouverture - Progrès scientifique et techniques dans le domaine des neurosciences cliniques** *Salle 200C*
- 10h15-11h45 **Présentations de séance plénière sélectionnées par le président**
Salle 200C
- 12h00-13h30 **Symposium élaboré conjointement (épilepsie)** *Salle 204AB*
- 12h00-13h30 **Symposium élaboré conjointement (douleur neuropathique)** *Salle 205BC*
- 13h30-17h00 **Cours sur les céphalées** *Salle 205BC*
- 13h30-17h00 **Cours sur les accidents vasculaires cérébraux** *Salle 204AB*
- 13h30-17h00 **Chirurgie vasculonerveuse** *Salle 201BC*
- 13h30-17h00 **Cours sur l'épilepsie - La maîtrise de l'épilepsie: de la science fiction à la réalité**
Salle 202
- 13h30-17h00 **Cours de neuro-oncologie**
Salle 203
- 13h30-17h00 **Cours de Sclérose en plaques**
Salle 205A
- 17h00-19h30 **Réception des commanditaires et des exposants**
Salle 200AB

Sauf indication contraire, toutes les sessions ont lieu au Centre des congrès de Québec (CCQ).

CODE DES COULEURS

Assemblée générale annuelle (AGA), Association canadienne de neurologie pédiatrique (ACNP), Journal canadien des sciences neurologiques (Journal), Société canadienne de neurologie (SCN), Société canadienne de neurochirurgie (SCNCH), Société canadienne de neurophysiologie clinique (SCNC), Fondation des sciences neurologiques du Canada (FSNC),

Caractères gras désignent des événements du programme scientifique. Les lettres en noir, des rencontres à caractère commercial ou autre.

Jeudi 10 juin 2010

- 08h30-10h00 **Séance plénière - SCN, ACNP, et SCNC**
Salle 200C
- 08:30-10h00 **Séance plénière - SCNCH**
Salle 204AB
- 10h00-10h15 Pause/Visite de l'exposition
Salle 200AB
- 10h15-12h30 **Séances-plateformes (6 simultanées)**
- SEP *Salle 200C*
- Neurologie générale et démence *Salle 201BC*
- Maladies neuromusculaires et neuro-oncologie *Salle 202*
- Neurologie pédiatrique *Salle 203*
- Prévention et traitement des accidents cérébrovasculaires
I *Salle 204A*
- Rétablissement et réadaptation après un accident
cérébrovasculaire *Salle 205A*
- 12h30-14h00 Dîner/Visite de l'exposition/Mini-plateformes
numériques
Salle 200AB
- 14h00-16h30 **Séances-plateformes (6 simultanées)**
- Colonne vertébrale *Salle 200C*
- Épilepsie *Salle 201BC*
- Neurochirurgie générale et neuroradiologie
Salle 202
- Traumatismes, soins intensifs et neurochirurgie
Salle 203
- Prévention et traitement des accidents vasculaires
cérébraux 2 *Salle 204A*
- Recherche relative aux services de santé pour les
accidents cérébrovasculaires et traitement
d'urgence *Salle 205A*
- 16h30-18h30 Visionnement des affiches numériques et visite
de l'exposition *Salle 200AB*

Vendredi 11 juin 2010

- 08h00-08h15 Rapport du rédacteur en chef du journal et
présentation du Prix Eminent relecteur de
manuscripts *Salle 200C*
- 08h15-08h30 Rapport du CBANHC *Salle 200C*
- 08h30-09h30 **Conférencier émérite invité:**
James Orbinski *Salle 200C*
- 09h30-09h45 Actuellement - tests cliniques canadiens actifs
Salle 200C
- 09h45-10h15 Pause/Visite de l'exposition *Salle 200AB*
- 10h15-12h00 **Tables rondes** *Salle 200C*
- 12h00-13h30 Dîner/Visite de l'exposition/Mini-plateformes
numériques *Salle 200AB*
- 13h30-17h00 **Cours de neuroophthalmologie** *Salle 202*
- 13h30-17h00 **Cours de neuroradiologie interventionnelle -**
Anévrismes difficiles *Salle 201B*
- 13h30-17h00 **Les nouveautés en neurochirurgie**
Salle 203
- 13h30-17h00 **Cours sur les soins de neurologie intensifs**
Salle 204B
- 13h30-17h00 **Cours sur la maladie neuromusculaire**
Salle 204A
- 13h30-17h00 **Cours sur la colonne vertébrale -**
Controverses dans le domaine de la
neurochirurgie de la colonne vertébrale
Salle 201C
- 13h30-17h00 **Les nouveautés en neurologie** *Salle 200C*
- 13h30-17h00 **Cours sur l'EEG** *Salle 205A*

Objectifs d'apprentissage 2010

À la fin du congrès, les délégués auront acquis des connaissances, des aptitudes et des attitudes supplémentaires ou solidifié celles qu'ils possèdent déjà afin d'améliorer les soins de leurs patients atteints de maladies du système nerveux, grâce à ce qui suit :

- En discutant des progrès en matière de maîtrise des troubles neurologiques et neurochirurgicaux aigus et chroniques.
- En discutant de nouvelles observations en matière de troubles neurologiques et neurochirurgicaux.
- En décrivant des avancées dans le domaine des troubles neurologiques et des techniques neurochirurgicales.
- En déterminant les lacunes dans les connaissances qui n'avaient pas été constatées avant la participation au congrès, et en étendant ce perfectionnement professionnel aux soins améliorés des patients une fois le congrès terminé.

Lundi 7 juin 2010

15h00 Réunion du conseil d'administration de la FSNC et du NSFC
Plaines - HH

Mardi 8 juin 2010

07h00-08h15 Réunion du conseil de l'ACNP
Lauzon - HH

12h00-13h00 Réunion des résidents de la SCN
Lauzon - HH

12h00-13h00 Réunion de la section EMG de la SCNC
Portneuf - HH

12h00-13h00 Réunion du conseil de la SCN
Sainte-Foy - HH

12h00-16h00 Comité spécialisé en neurologie du Collège royal
Courville - HH

13h00-14h00 Réunion de la section EEG de la SCNC
Portneuf - HH

16h00-17h30 Réunion du conseil de la SCNC
Portneuf - HH

17h00-18h00 Réunion du conseil de la SCNCH
Sainte-Foy - HH

17h00-18h00 Assemblée générale annuelle de l'ACNP
206A - CCQ

17h30-18h30 Réunion des résidents de la SCNCH
Courville - HH

Mercredi 9 juin 2010

06h45-07h45 Comité de développement international de la SCN
Lauzon - HH

Jeudi 10 juin 2010

07h00-08h00 Assemblée générale annuelle de la société canadienne de la céphalée
Portneuf - HH

07h00-08h00 Réunion du conseil de rédaction du journal de la FSNC
Sainte-Foy - HH

07h30-08h30 Réunion du la FSNC sociétés affiliées
Lauzon - HH

07h30-08h30 Assemblée générale annuelle de la SCNCH
Plaines - HH

09h00-17h00 Réunion du groupe de chercheurs en SEP
Courville - HH

12h45-13h45 Assemblée générale annuelle de la SCN
204A - CCQ

13h30-14h30 Réunion du comité de parrainage de la FSNC
Sainte-Foy - HH

17h00-18h00 Assemblée générale annuelle de la SCNC
Sainte-Foy - HH

17h00-20h00 Réunion du Réseau canadien des cliniques de SEP
Portneuf - HH

17h00-19h00 Réunion du comité de CPS et CPP
204A - CCQ

Vendredi 11 juin 2010

07h00-08h30 Réunion du comité spécialisé en neurochirurgie du Collège royal
Lauzon - HH

12h00-13h30 Réunion du groupe canadien des maladies neuromusculaires
Sainte-Foy - HH

12h00-13h30 Réunion du conseil d'administration de la FSNC et du NSFC
Courville - HH

12h00-13h30 Réunion du groupe de recherche canadien sur les maladies neuromusculaires pédiatriques
Lauzon - HH

12h00-13h30 Réunion du la société canadienne de soins intensifs
Portneuf - HH

Sauf indication contraire, toutes les réunions ont lieu au Hotel Hilton (HH).
Les réunions d'affaires sont commanditées par The Advance Group.

Revue des notions acquises sur l'épilepsie destinée aux résidents en neurosciences Salle 204AB 07h50-17h30

Cette activité éducative bénéficie du soutien généreux de UCB Canada Inc. qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

- Présidents:** Jose Martin Del Campo
- Sommaire de cours:** Une revue détaillée des aspects les plus pertinents de l'épilepsie, d'un point de vue pathophysiologique et thérapeutique.
- Objectifs:** À la fin de cette séance, les participants :
1. Auront passé en revue la neurobiologie de l'épilepsie, y compris les mécanismes liés aux crises épileptiques, le rôle de l'embrasement dans le développement de l'épilepsie et les effets fondamentaux des agents antiépileptiques sur l'épileptogénèse.
 2. Sauront identifier les syndromes d'épilepsie malins et les syndromes d'épilepsie bénins chez les enfants, leurs caractéristiques sur l'EEG et le pronostic clinique.
 3. Pourront décrire les options fondées sur les faits en matière de traitements antiépileptiques, en ce qui concerne leur efficacité, leur profil pharmacocinétique, les interactions médicamenteuses et le risque de réactions indésirables. Les participants pourront également proposer la place dans le traitement pour les agents antiépileptiques émergents, en se basant sur les faits disponibles.
 4. Reconnaîtront les caractéristiques cliniques, les causes sous-jacentes et les courbes d'EEG correspondant à l'état de mal épileptique, et pourront identifier les options conventionnelles et expérimentales en matière de traitement qui permettent de réduire la morbidité et la mortalité.
 5. Discuteront des comorbidités psychiatriques de l'épilepsie, en relation avec l'évolution clinique et le choix de pharmacothérapies.
 6. Pourront distinguer les crises épileptiques réelles de celles ayant une origine physiologique ou psychogénique, du trouble de somatisation et du trouble panique.
 7. Décriront des solutions de rechange au traitement conventionnel par agent anticonvulsivant qui pourraient s'ajouter au plan clinique chez le patient « pharmacorésistant », y compris un régime cétoène, la stimulation du nerf vague et l'acupuncture. Pourront présenter le concept de stimulation cérébrale profonde et les résultats des premières études.
 8. Pourront tenir compte de l'impact des résultats des tomographies par ordinateur, de l'IRM, de l'IRMf, de la spectroscopie RMN, de la MSI, de la tomographie monophotonique d'émission et de la TEP sur l'épilepsie et d'autres anomalies neurologiques pertinentes, en relation avec le diagnostic, le traitement et la planification avant une intervention chirurgicale.
 9. Décriront les options actuelles en matière de chirurgie pour le traitement de l'épilepsie et le rôle du neurologue relativement aux examens avant une intervention chirurgicale.
 10. Pourront développer des plans de traitement appropriée pour les patientes atteintes d'épilepsie, en tenant compte de l'impact des hormones, de la grossesse et du risque d'événement indésirables à long terme, tels que l'ostéoporose.
 11. Décriront les difficultés sur le plan sémiologique qui compliquent le diagnostic d'épilepsie chez les personnes âgées et discuteront des changements pharmacocinétiques du vieillissement qui ont un effet sur la pharmacothérapie clinique.
 12. Pourront évaluer un enfant atteint de crises épileptiques et d'épilepsie en relation avec l'étiologie, le pronostic et le traitement.
- Public visé:** Résidents en neurosciences
- Format d'apprentissage:** Séminaire, Groupe de discussion

**Revue des notions acquises sur l'épilepsie destinée aux résidents en neurosciences
(continu)**

07h50	Introduction <i>Jose Martin del Campo (Toronto, Ontario)</i>
08h00	Qu'est-ce que l'épilepsie? Les mécanismes fondamentaux <i>Warren Blume (London, Ontario)</i>
08h40	L'épidémiologie de l'épilepsie et l'approche de la première crise <i>Jorge Burneo (London, Ontario)</i>
09h20	Pharmacothérapie <i>Alan Guberman (Ottawa, Ontario)</i>
10h00	Pause

Épilepsie chez des populations particulières

10h15	Nouveau-nés <i>Rajesh RamachandranNair (Hamilton, Ontario)</i>
10h35	Bébés et enfants <i>Elizabeth Donner (Toronto, Ontario)</i>
10h55	Adolescents <i>Elizabeth Donner (Toronto, Ontario), Danielle Andrade (Toronto, Ontario)</i>
11h15	Femmes <i>Joseph Bruni (Toronto, Ontario)</i>
11h35	Personnes-âgées <i>Bernd Pohlmann-Eden (Halifax, Nouvelle-Écosse)</i>
12h15	Dîner
13h30	L'imagerie médicale de l'épilepsie <i>Andrea Bernasconi (Montréal, Québec)</i>
14h15	Gestion du patient pharmacorésistant <i>Samuel Wiebe (Calgary, Alberta)</i>
15h00	État de mal épileptique <i>G. Bryan Young (London, Ontario)</i>
15h45	Pause

Comorbidités liées à l'épilepsie

16h00	Psychiatriques <i>Sherese Ali (Toronto, Ontario)</i>
16h30	Crises non épileptiques <i>Alan Guberman (Ottawa, Ontario)</i>
17h00	Cognitives <i>Mary Lou Smith (Mississauga, Ontario)</i>
17h25	Évaluations

Avancées dans la neurobiologie des maladies

Salle 206B 07h45-17h00

Cette activité éducative bénéficie du soutien généreux de Fonds Don Paty de la FSNC-SCN qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

Présidents: Peter Smith, Zelma Kiss

Sommaire de cours: La première partie du cours se penchera sur les concepts fondamentaux et émergents en neurobiologie, ainsi que sur leur relation avec la pratique clinique contemporaine. Les quatre derniers exposés magistraux développeront ces concepts en se concentrant sur les noyaux gris centraux, leur rôle dans les maladies dégénératives et les dyskinésies.

Objectifs: À la fin de cette séance, les participants :

1. Comprendront l'effet des concepts actuels (nouveaux et émergents) de la fonction des cellules gliales, de la neurobiologie moléculaire et de la biostatistique sur la compréhension et le traitement des maladies neurologiques.
2. Sauront expliquer la compréhension actuelle de l'anatomie et de la pharmacologie des noyaux gris centraux et leurs interactions avec le thalamus.
3. Comprendront le rôle des noyaux gris centraux dans les maladies dégénératives et les dyskinésies.

Public visé: Général (y compris les résidents en neurologie / neurochirurgie).

Format d'apprentissage: Séminaire, Groupe de discussion

07h45	Introduction <i>Zelma Kiss (Calgary, Alberta), Peter Smith (Edmonton, Alberta)</i>
08h00	Principes fondamentaux de la biologie des cellules gliales <i>Jasna Kriz (Québec, Québec)</i>
09h00	Principes fondamentaux de la biologie moléculaire : de l'ADN à la thérapie génique <i>Josephine Nalbantoglu (Montréal, Québec)</i>
10h00	Discussion et pause
10h15	Principes de la biostatistique <i>Sam Wiebe (Calgary, Alberta)</i>
11h15	Noyaux gris centraux : vue d'ensemble de l'anatomie <i>Martin Parent (Québec, Québec)</i>
12h15	Pause
13h30	Relations entre le thalamus et les noyaux gris centraux <i>Abbas Sadikot (Montréal, Québec)</i>
14h30	Noyaux gris centraux : pharmacologie et maladies dégénératives <i>Francesca Cicchetti (Québec, Québec)</i>
15h30	Discussion
15h45	Science fondamentale et pertinence clinique des dyskinésies <i>Pierre Blanchet (Montréal, Québec)</i>
16h45	Discussion et évaluations

Cours de revue pour résidents en neurochirurgie: maladie neurovasculaire

Salle 301AB 08h00-17h00

Cette activité éducative bénéficie du soutien généreux de J et J / Codman qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

- Présidents:** J. Max Findlay, Shobhan Vachhrajani
- Sommaire de cours:** Une revue des aspects fondamentaux de l'anatomie, de la physiologie et des états cliniques les plus courants, ainsi que de leur traitement actuel, tels qu'en ont besoin les neurochirurgiens praticiens et les résidents en neurochirurgie.
- Objectifs:** À la fin de cette séance, les participants :
1. seront en mesure de décrire le développement, l'anatomie et la physiologie de la vasculature du système nerveux central.
 2. pourront diagnostiquer de façon efficace les maladies neurovasculaires chirurgicales communes.
 3. connaîtront bien les paradigmes de gestion fondés sur les faits les plus récents concernant les maladies neurovasculaires chirurgicales communes.
 4. seront en mesure d'appliquer les connaissances acquises pour résoudre les problèmes relatifs aux cas neurovasculaires cliniques pouvant être observés dans le cadre d'une pratique neurochirurgicale générale.
- Public visé:** Résidents de 5e année en neurochirurgie, neurochirurgiens praticiens souhaitant revoir les notions de chirurgie neurovasculaire.
- Format d'apprentissage:** Séminaire, Groupe de discussion, Simulation

08h00	Introduction <i>Shobhan Vachhrajani (Toronto, Ontario)</i>
08h10	Embryologie et anatomie <i>J. Max Findlay (Edmonton, Alberta), Gary Redekop (Vancouver, Colombie-Britannique)</i>
09h25	Questions et discussion
09h30	Physiologie <i>Mel Boulton (London, Ontario)</i>
09h55	Questions, discussion et pause
10h15	Maladie de la carotide <i>Cian O'Kelly (Edmonton, Alberta)</i>
10h45	Questions and discussion
10h50	Anévrismes <i>Tim Darsaut, (Edmonton, Alberta), R. Loch Macdonald (Toronto, Ontario), John Wong (Calgary, Alberta)</i>
11h50	Questions et discussion
12h00	Dîner
13h30	Malformations artério-veineuses <i>Julian Spears (Toronto, Ontario)</i>
14h10	Questions et discussion
14h15	Autres malformations vasculaires <i>Robert Willinsky (Toronto, Ontario)</i>
14h55	Questions et discussion
15h00	Aspects médicaux et chirurgicaux des accidents vasculaires cérébraux <i>Ian Fleetwood (Halifax, Nouvelle-Écosse)</i>
15h25	Questions, discussion et pause
15h35	Scénarios d'examens simulés <i>J. Max Findlay, (Edmonton, Alberta), Christopher Wallace (Toronto, Ontario), Genevieve Milot (Québec, Québec)</i>
16h55	Questions et évaluations

Stratégies visant l'amélioration de la qualité de vie et de la qualité des soins pour les personnes atteintes de SLA Salle Beauport, Hilton Hotel 08h30-17h00

- Président:** David Cameron
- Sommaire de cours:** Séances interactives d'une journée avec des patients, des fournisseurs de soins, des professionnels paramédicaux, des neurologues, des physiatres, des agences de soutien communautaire; un examen complet de sujets actuels concernant la SLA, y compris le diagnostic et la recherche, la gestion et la défense des droits.
- Objectifs:** À la fin de ce symposium, les participants sauront :
1. décrire les caractéristiques cliniques et pathophysiologiques actuelles de la SLA.
 2. reconnaître et mettre en pratique des stratégies visant à améliorer l'activité et la qualité de vie des personnes atteintes de SLA.
 3. démontrer leur compréhension des initiatives de recherche et des conclusions des études sur la SLA.
- Public visé:** Patients, fournisseurs de soins, professionnels paramédicaux, neurologues, physiatres et agences de soutien communautaire.
- Format d'apprentissage:** Séminaire, Groupe de discussion
- 08h30 Inscription
- 09h00 **SLA Canada – mandat et activités de recherche**
David Cameron, (Toronto, Ontario)
- Séance 1 : Présentations de séance plénière - Présidées par : Ian Grant (Halifax, Nouvelle-Écosse)**
- 09h10 **Pathogénie et approches d'immunisation passive au traitement**
Jean-Pierre Julien (Québec, Québec)
- 09h35 **Nouvelles du Consortium de la Société canadienne de la SLA et des essais cliniques**
Lorne Zinman (Toronto, Ontario)
- 10h00 Séance de questions et réponses
- 10h20 Pause
- Séance II : Présentations - Présidées par : Charles Kreiger (Vancouver, Colombie-Britannique)**
- 10h40 **Aspects génétiques de la SLA**
Guy Rouleau (Montréal, Québec)
- 11h00 **Soins au terme de la vie pour les patients atteints de SLA**
Wendy Johnston (Edmonton, Alberta)
- 12h00 Séance de questions et réponses
- 12h15 Dîner
- Séance III Séances interactives avec les experts**
- 13h30 **A. Séance francophone : Patients, fournisseurs de soins et professionnels de la santé :**
Modérateurs : David Cameron - SLA Canada (Toronto, Ontario)
Claudine Cook - SLA Québec (Montréal, Québec)
- i) **SLA Québec – programme de services aux clients - présentateurs à déterminer**
- ii) **Présentation clinique – présentateurs à déterminer**
- B. Médecins et chercheurs : Modérateur : Ian Grant (Halifax, Nouvelle-Écosse)**
- i) **Protéines du stress et protéasomes – comment ils mènent au développement de traitements**
Heather Durham (Montréal, Québec)
- ii) **Recherche avec imagerie in vivo**
Jasna Kriz (Québec, Québec)
- 14h30 Pause
- Séance IV - Présidées par : David Cameron (Toronto, Ontario)**
- 14h45 **Traitement de la douleur relative à la SLA**
Angela Genge (Montréal, Québec)
- 15h30 Séance de questions et réponses
- 15h45 Mot de la fin et évaluations
David Cameron (Toronto, Ontario)

Journée de la neurologie pédiatrique

Salle 206A 08h30-17h00

Présidents: Cecil Hahn, Michelle Demos

Sommaire de cours: Cette année, la Journée de la neurologie pédiatrique abordera deux thèmes : la paralysie cérébrale et les concepts émergents relatifs à l'auto-immunité du système nerveux central. Les séances du matin se pencheront sur le thème de la paralysie cérébrale du point de vue de l'épidémiologie, des sciences fondamentales et de la gestion. La séance de l'après-midi, sur les concepts émergents relatifs à l'auto-immunité du SNC, abordera les fondements psychopathologiques, le diagnostic et la maîtrise du syndrome opsoclonus-myoclonus, de la vascularite du SNC et de l'encéphalite auto-immune. Le point saillant des deux séances sera les présentations de cas effectuées par des stagiaires en neurologie pédiatrique de l'ensemble du Canada.

Objectifs: À la fin de cette séance, les participants sauront :

1. acquises grâce à un registre provincial et à des modèles animaux.
2. Maîtriser la spasticité et les troubles du mouvement chez les enfants atteints de paralysie cérébrale.
3. Expliquer les concepts actuels relatifs à l'auto-immunité du système nerveux central.
4. Assurer le diagnostic et le traitement d'enfants atteints du syndrome opsoclonus-myoclonus, de vascularite du SNC et d'encéphalite auto-immune.

Public visé: Neuropédiatres, résidents et moniteurs en neurologie pédiatrique, neuroscientifiques, infirmières en neurologie pédiatrique et autres professionnels paramédicaux qui s'occupent d'enfants atteints de troubles neurologiques.

Format d'apprentissage: Séminaire, Groupe de discussion, Études de cas

08h30	Introduction <i>Cecil Hahn (Toronto, ON), Michelle Demos (Vancouver, Colombie-Britannique)</i>
08h45	Perspectives acquises grâce à un registre provincial sur la paralysie cérébrale <i>Michael Shevell (Montréal, Québec)</i>
09h20	Discussion
09h30	Modèles animaux des lésions cérébrales acquises <i>Jerome Yager (Edmonton, Alberta)</i>
10h05	Discussion et pause
10h30	Spasticité et troubles du mouvement chez les enfants atteints de paralysie cérébrale <i>Chantal Poulin (Montréal, Québec)</i>
11h05	Discussion
11h15	Présentations de cas À CONFIRMER
12h00	Dîner
13h30	Vascularite du SNC et troubles cérébraux inflammatoires <i>Susanne Benseler (Toronto, Ontario)</i>
14h05	Discussion
14h15	Opsoclonus-myoclonus <i>Juliette Hukin (Vancouver, Colombie-Britannique)</i>
14h35	Discussion
15h00	Les encéphalites avec anticorps anti-récepteur NMDA chez les enfants <i>Josep Dalmau (Philadelphie, Pennsylvanie, États-Unis)</i>
15h45	Discussion
16h00	Présentations de cas À CONFIRMER
16h55	Évaluations

Symposium élaboré conjointement (accidents vasculaires cérébraux) Salle 2000D 12h00-13h30

Cet événement est accrédité comme activité d'apprentissage collectif (Section 1) tel que définie par le programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Il a été élaboré conjointement par la Société canadienne de neurologie et Boehringer Ingelheim.

Séance vidéo sur l'épilepsie Salle 206B 18h00-20h00

Président: Richard McLachlan

Sommaire de cours: Une image vaut mille mots. Le cours démontrera l'utilité de la vidéo pour le diagnostic et la classification des crises épileptiques.

Objectifs: À la fin de cette séance, les participants sauront :

1. Distinguer différents types de crises au moyen de la vidéo.
2. Différencier les crises d'autres épisodes.
3. Reconnaître les signes physiques des crises.

Public visé: Résidents, moniteurs et étudiants en médecine, neurologues et neuropédiatres, infirmières et technologues en EEG.

Format d'apprentissage: Groupe de discussion, Études de cas

18h00 **Un cas intéressant**
Jorge Burneo (London, Ontario)

18h30 **La vidéo est utile pour les crises épileptiques chez les enfants**
Lionel Carmant (Montréal, Québec)

19h00 **La sémiologie des crises épileptiques à Saskatoon**
Jose Tellez-Zenteno (Saskatoon, Saskatchewan)

19h30 **Un autre cas intéressant, comme tous les autres**
Richard McLachlan (London, Ontario)

Séance du groupe d'intérêt sur les troubles du mouvement : Salle 207 18h00-20h00

Cette activité éducative bénéficie du soutien généreux de Allergan Inc. qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

Présidents: Alex Rajput, David Grimes

Sommaire de cours: Le groupe d'intérêt comprendra un grand nombre de vidéos et d'observations médicales qui serviront à mettre les délégués à jour concernant une vaste gamme de troubles du mouvement et leur traitement. Les participants seront encouragés à donner leur opinion concernant le diagnostic, les diagnostics différentiels et le traitement des cas présentés.

Objectifs: À la fin de cette séance, les participants :

1. Grâce aux exemples vidéo, connaîtront les dernières informations concernant le diagnostic des troubles du mouvement communs ou rares.
2. Connaîtront les options actuelles en matière de traitements fondés sur les faits et les tendances thérapeutiques concernant la maladie de Parkinson et les autres troubles du mouvement.
3. Connaîtront les options de traitement qui sont actuellement à l'étude.

Public visé: Les résidents, les neurologues généraux et les neurologues spécialisés en troubles du mouvement sont invités à participer aux discussions.

Format d'apprentissage: Groupe de discussion, Études de cas

Séance du groupe d'intérêt sur les céphalées Salle 208A 18h00-20h00

Cette activité éducative bénéficie du soutien généreux de Merck qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

- Président:** Werner Becker
- Sommaire de cours:** Le groupe d'intérêt sur les céphalées commencera par une brève vue d'ensemble des avancées dans le domaine des céphalées au cours de la dernière année. Une discussion détaillée de la maîtrise des céphalées dans le service d'urgence et du diagnostic et de la maîtrise des céphalées attribuées à une baisse de la pression du LCR suivront.
- Objectifs:** À la fin de cette séance, les participants sauront :
1. Discuter des avancées importantes de la dernière année dans le domaine de la maîtrise des céphalées.
 2. Permettre une maîtrise optimale des patients atteints de migraines ou de céphalées qui se présentent en salle d'urgence.
 3. Diagnostiquer et gérer les patients atteints de céphalées secondaires à une baisse de la pression du LCR ou à l'hypovolémie du LCR.
- Public visé:** Neurologues traitant des adultes, neuropédiatres, spécialistes en céphalées, résidents en neurologie/neurochirurgie; toutes les personnes intéressées sont bienvenues.
- Format d'apprentissage:** Séminaire, Groupe de discussion

- | | |
|-------|---|
| 18h00 | Un bref résumé des avancées dans le domaine des céphalées au cours de la dernière année
<i>Werner Becker (Calgary, Alberta)</i> |
| 18h10 | Discussion |
| 18h15 | La maîtrise des céphalées dans le service d'urgence
<i>Elizabeth Leroux (Montréal, Québec)</i> |
| 19h00 | Discussion |
| 19h15 | Le diagnostic et la maîtrise des céphalées attribuées à une baisse spontanée de la pression du LCR
<i>Farnaz Amoozegar (Calgary, Alberta)</i> |
| 19h45 | Discussion |

Séance du groupe d'intérêt sur les maladies neuromusculaires Salle 206A 18h00-20h00

- Président:** Kristine Chapman
- Sommaire de cours:** Il s'agit d'une séance interactive comprenant des discussions en groupe sur des cas de maladie neuromusculaire intéressants et complexes. Des résumés écrits des cas seront remis à la fin. Des idées concernant des études ou des initiatives de collaboration feront peut-être l'objet de discussions.
- Objectifs:** À la fin de cette séance, les participants :
1. Auront discuté de 6 à 8 cas complexes de maladies neuromusculaires.
 2. Auront échangé des idées pour des études ou des initiatives de collaboration concernant les maladies neuromusculaires.
 3. Auront acquis des connaissances concernant les nouveaux développements dans le domaine des maladies neuromusculaires.
- Public visé:** Neurologues, physiatres et résidents qui s'intéressent aux maladies du système nerveux périphérique.
- Format d'apprentissage:** Groupe de discussion, Étude de cas

Symposium élaboré conjointement (les céphalées) Salle 204AB 06h30-08h00

Cet événement est accrédité comme activité d'apprentissage collectif (Section 1) tel que définie par le programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Il a été élaboré conjointement par la Société canadienne de neurologie et Merck.

Séance plénière d'ouverture

Progrès scientifique et techniques dans le domaine des neurosciences cliniques Salle 200C 08h00-10h00

Cette activité éducative bénéficie du soutien généreux de NSFC qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

Sommaire de cours: À la fin de cette séance plénière, les participants auront acquis des connaissances sur les sujets suivants:

1. Avancées récentes dans le domaine de la chirurgie de l'épilepsie pédiatrique.
2. Concepts changeants de la maladie de Parkinson et comment, avec les avancées des traitements et de la détection précoce de la maladie, la nature clinique de la maladie de Parkinson ne correspondra plus au trouble décrit initialement par James Parkinson.
3. Auto-immunité synaptique et nouveaux troubles de la mémoire, de la cognition, du mouvement et psychoses.

Format d'apprentissage: Séance plénière

- | | |
|-------|---|
| 08h00 | Accueil et introduction
<i>George Elleker</i> |
| 08h10 | Conférence Penfield – Avancées récentes dans le domaine de la chirurgie de l'épilepsie pédiatrique : Penfield serait fier
<i>James Rutka (Toronto, Ontario)</i> |
| 08h45 | Conférence Richardson – Pas la maladie de James Parkinson
<i>Anthony Lang (Toronto, Ontario)</i> |
| 09h20 | Conférence Tibbles – Auto-immunité synaptique et nouveaux troubles de la mémoire et de la cognition, troubles du mouvement et psychose
<i>Josep Dalmau (Philadelphie, Pennsylvanie, États-Unis)</i> |

Présentations de séance plénière sélectionnées par le président
Salle 200C 10h15-11h45

Les présentations de séance plénière sélectionnées par le président représentent les meilleurs résumés présentés au cours du congrès en 2010.

Symposium élaboré conjointement (épilepsie)
Salle 204AB 12h00-13h30

Cet événement est accrédité comme activité d'apprentissage collectif (Section 1) tel que définie par le programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Il a été élaboré conjointement par la Société canadienne de neurologie et UCB Canada Inc.

Symposium élaboré conjointement (douleur neuropathique)
Salle 205BC 12h00-13h30

Cet événement est accrédité comme activité d'apprentissage collectif (Section 1) tel que définie par le programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada. Il a été élaboré conjointement par la Société canadienne de neurologie et Pfizer Canada.

Cours sur les céphalées Salle 205BC 13h30-17h00

Cette activité éducative bénéficie du soutien généreux de Merck qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

- Président:** Jonathan Gladstone
- Sommaire de cours:** Ce cours fournira à ses participants une vue d'ensemble de la situation actuelle des médicaments pour les céphalées, combinant l'expertise de neurologues pour adultes, d'un neuropédiatre, d'un neuroradiologue et d'un neurochirurgien. Le cours commencera par une vue d'ensemble des nouveautés en matière de médicaments pour les céphalées. Ensuite, il y aura une séance de discussion des « sujets brûlants », où seront examinés la pathophysiologie des auras et les rapports de recherche émergents dans le domaine des liens entre la migraine, l'aura, l'oestrogène et les accidents vasculaires cérébraux. Nous tournerons ensuite notre attention vers la population pédiatrique et une vue d'ensemble des avancées cliniques et des défis cliniques relativement aux enfants et aux adolescents atteints de céphalées sera présentée. Cela sera suivi de perles cliniques concrètes en matière de neuroimagerie des patients atteints de céphalées. Enfin, la dernière partie de l'après-midi sera consacrée aux options émergentes en matière de traitement neurochirurgical pour les patients atteints de céphalées réfractaires et incapacitantes.
- Objectifs:** À la fin de cette séance, les participants :
1. Comprendront ce qui est nouveau en matière de médicaments pour les céphalées en 2010 et pourront intégrer ces progrès dans leur pratique clinique.
 2. Auront renforcé leur compréhension des concepts actuels relatifs à la pathophysiologie de la migraine et des liens entre la migraine, les auras, les hormones et les risques d'accidents vasculaires cérébraux.
 3. Se sentiront plus à l'aise pour établir un diagnostic et traiter des enfants et des adolescents présentant une gamme de troubles relatifs aux céphalées.
 4. Sauront avoir recours aux progrès récents de la neuroimagerie des céphalées pour les aider à établir un diagnostic pour leurs patients atteints de céphalées.
 5. Comprendront mieux les options émergentes en matière de neurochirurgie pour le traitement des patients atteints de céphalées réfractaires.
- Public visé:** Neurologues, résidents en neurologie, infirmières, neuroradiologues et neurochirurgiens.
- Format d'apprentissage:** Séminaire, Groupe de discussion

13h30	Introduction <i>Jonathan Gladstone (Toronto, Ontario)</i>
13h45	Les nouveautés en matière de médicaments pour les céphalées en 2010 <i>Werner Becker (Calgary, Alberta)</i>
14h05	Discussion
14h20	Sujets brûlants concernant la pathophysiologie des céphalées – migraine, aura et accident vasculaire cérébral – où est le lien? <i>Elizabeth Leroux (Montréal, Québec)</i>
14h40	Discussion
14h55	Perles cliniques concrètes en matière de diagnostic et de traitement des enfants et des adolescents atteints de céphalées <i>Joseph Dooley (Halifax, Nouvelle-Écosse)</i>
15h15	Discussion et pause
15h45	Imagerie du patient atteint de céphalées – que faut-il commander et comment interpréter les résultats? <i>Richard Farb (Toronto, Ontario)</i>
16h05	Discussion
16h20	Options émergentes en matière de neurochirurgie pour le patient atteint de céphalées réfractaires et invalidantes <i>Zelma Kiss (Calgary, Alberta)</i>
16h40	Discussion et évaluations

Cours sur les accidents vasculaires cérébraux

Salle 204AB 13h30-17h00

Cette activité éducative bénéficie du soutien généreux de Boehringer Ingelheim qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

- Président:** Ariane Mackey
- Sommaire de cours:** Fournir une mise à jour de deux sujets choisis liés aux accidents vasculaires cérébraux : La gestion de la sténose carotidienne et la fibrillation auriculaire et la prévention des accidents vasculaires cérébraux
- Objectifs:** À la fin de cette séance, les participants :
1. Sauront choisir la technique d'imagerie médicale de la carotide appropriée pour les patients atteints d'une maladie de la carotide.
 2. Sauront prendre des décisions appropriées concernant la revascularisation de la carotide.
 3. Se seront familiarisés avec les recommandations relatives à la recherche d'arythmies lors d'un accident vasculaire cérébral aigu (télémétrie, Holter).
 4. Seront au fait des derniers développements concernant le traitement préventif approprié des accidents vasculaires cérébraux chez les patients atteints de fibrillation auriculaire.
- Public visé:** Neurologues, neurologues spécialisés en accidents vasculaires cérébraux, résidents en neurochirurgie, neuroradiologues, neurochirurgiens vasculaires et neuroradiologues interventionnels.
- Format d'apprentissage:** Séminaire, Groupe de discussion

- | | |
|-------|---|
| 13h30 | Introduction
<i>Ariane Mackey (Québec, Québec)</i> |
| 13h45 | Angiographie non invasive pour la maladie carotidienne : de la technologie à la pertinence clinique
<i>Daniel Roy (Montréal, Québec)</i> |
| 14h05 | Sténose de la carotide : quand revasculariser?
<i>Jeff Minuk (Montréal, Québec)</i> |
| 14h30 | Sténose de la carotide : l'endoprothèse par rapport à l'intervention chirurgicale. Les résultats CREST et qu'est-ce qui vient après?
<i>Frank Silver (Toronto, Ontario)</i> |
| 14h55 | Discussion du groupe d'experts et pause |
| 15h45 | Accidents vasculaires cérébraux liés à la fibrillation auriculaire : optimisation du diagnostic et prévention
<i>David Gladstone (Toronto, Ontario)</i> |
| 16h05 | RE-LY et Athena : les conclusions?
<i>Theodore Wein (Montréal, Québec)</i> |
| 16h30 | Discussion du groupe d'experts et évaluations |

Cours de chirurgie neurovasculaire Salle 201BC 13h30-17h00

Président: R. Loch Macdonald

Sommaire de cours: Ce cours fournira une mise à jour sur la maîtrise actuelle de certains aspects des maladies neurovasculaires qui sont pertinents sur le plan chirurgical, se concentrant sur la sténose de la carotide, les hémorragies sous-arachnoïdiennes, les hémorragies intracérébrales et les malformations cérébrovasculaires.

Objectifs: À la fin de cette séance, les participants :

1. Expliquer les indications de la sténose de la carotide et ses méthodes de traitement.
2. Décrire certaines techniques de traitement des malformations cérébrovasculaires.
3. Comment gérer les hémorragies sous-arachnoïdiennes et les hémorragies intracérébrales dans l'unité de soins intensifs.
4. Gérer des malformations vasculaires rachidiennes courantes.

Public visé: Résidents en neurochirurgie, moniteurs et membres du corps enseignant.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>R. Loch Macdonald (Toronto, Ontario)</i>
13h45	Sténose de la carotide : indications et maîtrise post-CREST <i>Julian Spears (Toronto, Ontario)</i>
14h05	Discussion
14h20	Malformations artérioveineuses du cerveau : traitement chirurgical <i>Ian Fleetwood (Halifax, Nouvelle-Écosse)</i>
14h40	Discussion
14h55	Mises à jour sur la maîtrise des hémorragies sous-arachnoïdiennes et des hémorragies intracérébrales <i>Stephan Mayer (New York, État de New York, États-Unis)</i>
15h15	Discussion
15h30	Pause
15h45	Malformations vasculaires rachidiennes <i>Mel Boulton (London, Ontario)</i>
16h05	Discussion
16h20	Questionnaire après le cours : comment traiteriez-vous ce patient atteint d'une maladie neurovasculaire? <i>R. Loch Macdonald (Toronto, Ontario)</i>
16h40	Discussion et évaluations

Cours sur l'épilepsie – La maîtrise de l'épilepsie : de la science-fiction à la réalité

Salle 202 13h30-17h00

Cette activité éducative bénéficie du soutien généreux de UCB Canada Inc. qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

- Président:** S. Nizam Ahmed
- Sommaire de cours:** Présenter au public la recherche et la technologie de pointe prometteuses pour une nouvelle génération d'études et de traitements de l'épilepsie.
- Objectifs:** À la fin de cette séance, les participants sauront :
1. Comprendre le rôle potentiel de la nanotechnologie en matière de maladies neurologiques.
 2. Comprendre le rôle et le but d'un laboratoire de neurophysiologie moderne/de la prochaine génération.
 3. Comprendre le rôle de la recherche computationnelle en neuroscience pour la maîtrise de l'épilepsie.
 4. Présenter et renforcer le concept de « stratégies de traitement globales » pour les soins des patients épileptiques.
 5. Comprendre le concept d'interventions chirurgicales minimalement effractives pour l'épilepsie médicalement incurable.
- Public visé:** Neurologues, épileptologues, neurochirurgiens, scientifiques fondamentaux et neurophysiologues.
- Format d'apprentissage:** Séminaire, Groupe de discussion

- | | |
|-------|--|
| 13h30 | Introduction
<i>S. Nizam Ahmed (Edmonton, Alberta)</i> |
| 13h45 | Le rôle potentiel de la nanotechnologie pour les soins de l'épilepsie
<i>Mark Saltzman (New Haven/Yale, Connecticut, États-Unis)</i> |
| 14h05 | Discussion |
| 14h20 | Le rôle et le but d'un laboratoire de neurophysiologie futuriste
<i>G. Bryan Young (London, Ontario)</i> |
| 14h40 | Discussion |
| 14h55 | Des traitements de l'épilepsie haute technologie spécifiques à chaque patient, aux traitements globaux pour tous
<i>Sam Weibe (Calgary, Alberta)</i> |
| 15h15 | Discussion et pause |
| 15h45 | Traitement de l'épilepsie par neurostimulation adaptative
<i>Joelle Pineau (Montreal, Québec)</i> |
| 16h05 | Discussion |
| 16h20 | Interventions chirurgicales minimalement effractives pour l'épilepsie médicalement incurable
<i>Matthew Wheatley (Edmonton Alberta)</i> |
| 16h40 | Discussion et évaluations |

Cours de neuro-oncologie Salle 203 13h30-17h00

Cette activité éducative bénéficie du soutien généreux de Elekta qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.

Président: David Eisenstat

Sommaire de cours: Le cours de neuro-oncologie vous informera des progrès effectués en matière de méthodes thérapeutiques et de diagnostic pour les patients atteints d'un gliome malin. Ce cours intéressera les stagiaires et les praticiens dans les domaines de la neuropathologie, de la neurologie, de la neurochirurgie et de la neurologie pédiatrique.

Objectifs: À la fin de cette séance, les participants sauront :

1. Reconnaître les patients pour lesquels le diagnostic potentiel est un gliome malin et recommander un diagnostic plus poussé et une étude de la stadification.
2. Distinguer les gliomes de faible degré de malignité et les gliomes de degré élevé de malignité, et apprécier les approches de diagnostic moléculaire émergentes.
3. Expliquer la raison d'être des méthodes de traitement chirurgicales, par radiation et médicales (chimiothérapie) actuelles pour les adultes et les enfants atteints d'un gliome malin.
4. Présenter et renforcer le concept de « stratégies de traitement globales » pour les soins des patients épileptiques.
5. Évaluer les stratégies émergentes de traitement multidisciplinaires des gliomes malins chez les adultes et les enfants.

Public visé: Neurologues, neuropédiatres, neurochirurgiens, neuropathologistes, radio-oncologues, oncologues médicaux et oncologues pédiatriques.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>David Eisenstat (Winnipeg, Manitoba)</i>
13h45	La radiothérapie pour les gliomes : d'où venons-nous, où allons-nous et comment nous y rendrons-nous? <i>Arjun Sahgal (Toronto, Ontario)</i>
14h05	Diagnostic moléculaire et neuropathologie des gliomes <i>Stephen Yip (Vancouver, Colombie-Britannique)</i>
14h20	Discussion
14h40	Progrès et controverses dans le domaine de la neuro-oncologie chirurgicale <i>Rolando Del Maestro (Montréal, Québec)</i>
14h55	Discussion
15h15	Thérapies ciblées pour les gliomes malins – la perspective d'un chercheur clinique <i>James Perry (Toronto, Ontario)</i>
15h45	Discussion et pause
16h05	Discussion
16h20	Le passé, le présent et l'avenir des traitements des gliomes malins chez les enfants <i>David Eisenstat (Winnipeg, Manitoba)</i>
16h40	Discussion et évaluations

Cours sur la SEP – Mise à jour à l'intention du professionnel en SEP
Salle 205A 13h30-17h00

Président: Francois Emond

Sommaire de cours: Le but de ce cours à l'intention du professionnel en SEP consiste à discuter de quatre sujets brûlants dans le domaine de la SEP et à présenter des preuves à jour et l'acuité clinique de chacun d'entre eux. Des experts dans le domaine présenteront les nouveautés dans le domaine des essais cliniques, du natalizumab et de la LEMP, les imitateurs de la SEP et l'insuffisance veineuse céphalorachidienne chronique, avec des périodes de discussion qui permettront au public d'interagir directement avec les conférenciers sur ces sujets importants mais controversés.

Objectifs: À la fin de cette séance, les participants :

1. Pourront discuter des différents traitements émergents de la SEP, conformément aux observations tirées des essais cliniques récents ou en cours, et présenter ces traitements à leurs patients.
2. Pourront gérer en toute sécurité les patients traités au Natalizumab conformément aux observations les plus récentes, diagnostiquer tôt un cas éventuel de LEMP et appliquer des principes de maîtrise à jour à cette maladie.
3. Intégreront des « examens de la SEP » recommandés dans leur pratique afin de distinguer avec précision la maladie de ses imitateurs sur des bases cliniques et paracliniques.
4. Discuteront de la manière dont l'hypothèse de l'insuffisance veineuse céphalorachidienne chronique peut être intégrée à la majorité des connaissances psychopathologiques accumulées dans le domaine de la SEP, et discerneront les étapes suivantes de la recherche sur cette entité.

Public visé: Neurologues en SEP, moniteurs en SEP, infirmières en SEP, neurologues s'intéressant à la SEP, résidents sénior en neurologie

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>Francois Emond (Québec, Québec)</i>
13h35	Mise à jour sur les nouvelles thérapies et les essais cliniques <i>Mark S. Freedman (Ottawa, Ontario)</i>
14h05	Discussion
14h20	Mise à jour sur le natalizumab et la LEMP <i>Pierre Duquette (Montréal, Québec)</i>
14h50	Discussion
15h05	Pause
15h20	Défis diagnostiques: imitateurs de la sclerose en plaques <i>François Emond (Québec, Québec)</i>
15h50	Discussion
16h05	Insuffisance veineuse céphalorachidienne chronique : où sont les preuves? Ce qui est à venir <i>E. Mark Haacke (Detroit, Michigan, États-Unis)</i>
16h35	Discussion et évaluations

Séance plénière – Neurologie avec la SCN, l'ACNP et la SCNC Salle 200C 08h30-10h00

Sommaire de cours: À la fin de cette séance plénière, les participants auront acquis des connaissances sur les sujets suivants:

1. Changements de la carte motrice et de la carte sensorielle associés à l'épilepsie.
2. Neuropathies périphériques focales.

Format d'apprentissage: Séance plénière

- 08h30 Accueil et introduction
Lyle Weston
- 08h40 **Conférence Gloor – Changements à la carte motrice et sensorielle avec l'épilepsie : implications pour les comorbidités interictales du comportement**
Cam Teskey (Calgary, Alberta)
- 09h20 **Neuropathies périphériques focales : découvertes des 25 dernières années en 25 minutes**
John Stewart (Vancouver, Colombie-Britannique)

Séance plénière – Neurochirurgie avec la SCNC Salle 204AB 08h30-10h00

Sommaire de cours: À la fin de cette séance plénière, les participants auront acquis des connaissances sur les sujets suivants:

1. Comprendre les mécanismes et la récupération du cerveau humain comateux.
2. La gestion chirurgicale des néoplasmes rachidiens.

Format d'apprentissage: Séance plénière

- 08h30 Accueil et présentation à Charles Tator du prix d'excellence pour l'ensemble des réalisations de la SCNCH
J. Max Findlay
- 08h40 **Dans la boîte noire : pour faire la lumière sur le cerveau humain comateux**
Stephan Mayer (New York, État de New York, États-Unis)
- 09h20 **Maîtrise chirurgicale des néoplasmes rachidiens**
Ziya Gokaslan (Baltimore, Maryland, États-Unis)

Pause/Visite de l'exposition Salle 200AB 10h00-10h15

*Visiter la salle des exposants et de montrer aux entreprises qui soutiennent notre secteur d'activité que leur présence continue et leur soutien financier du Congrès ont une grande importance pour vous!
Que vous ayez eu ou non l'occasion de leur rendre visite, venez dire à nos commanditaires et à nos exposants à quel point vous appréciez leur contribution à votre congrès.*

Séances-plateformes - 6 simultanées 10h15-12h30

SEP	Salle 200C	Modérateur: Mark Freedman
Neurologie générale et démence	Salle 201BC	Modérateur: à confirmer
Maladies neuromusculaires et neuro-oncologie	Salle 202	Modérateur: Mike Nicolle, James Perry
Neurologie pédiatrique	Salle 203	Modérateur: Cecil Hahn
Prévention et traitement des accidents cérébrovasculaires I	Salle 204A	Modérateur: Matthew Hogan
Rétablissement et réadaptation après un accident cérébrovasculaire	Salle 205A	Modérateur: Adam Kirton

Dîner/Visite de l'exposition/Mini-plateformes numériques Salle 200AB 12h30-14h00

Un déjeuner-buffet sera offert dans la salle des exposants

Séances-plateformes - 6 simultanées 14h00-16h30

Colonne vertébrale	Salle 200C	Modérateur: Ramesh Sahjpaul
Épilepsie	Salle 201BC	Modérateur: Seyed Mirsattari
Neurochirurgie générale et neuroradiologie	Salle 202	Modérateur: R. Loch Macdonald
Traumatismes, soins intensifs et neurochirurgie	Salle 203	Modérateur: Jeanne Teitelbaum
Prévention et traitement des accidents vasculaires cérébraux 2	Salle 204A	Modérateur: à confirmer
Recherche relative aux services de santé pour les accidents cérébrovasculaires et traitement d'urgence	Salle 205A	Modérateur: Theodore Wein

Visionnement des affiches numériques et visite de l'exposition Salle 200AB 16h30-18h30

N'oubliez pas d'aller dans la salle des exposants vous présenter aux entreprises qui soutiennent notre secteur d'activité, lorsque vous en aurez l'occasion! Leur contribution à votre congrès nous permet de continuer à proposer le programme de qualité que vous attendez et de maintenir la stabilité des frais d'inscription.

**Rapport du rédacteur en chef du journal et présentation du Prix Eminent
relecteur de manuscripts Salle 200C 08h00-08h15**

Le rédacteur en chef G. Bryan Young présentera son rapport annuel sur le Journal

**Rapport du CBANHC
Salle 200C 08h15-08h30**

Le président Richard Riopelle présentera le rapport annuel du CBANHC

**Conférencier émérite invité
Salle 200C 08h30-09h30**

James Orbinski

Cette activité éducative bénéficie du soutien généreux de la FSNC qui n'a pas participé au choix des conférenciers, du programme ou du contenu de l'activité.



Le docteur James Orbinski, humanitaire canadien et co-fondateur de Dignitas International, a été nommé officier de l'Ordre du Canada en reconnaissance de ses contributions en tant que médecin qui a œuvré pour améliorer l'accès et la prestation des soins de santé dans les pays en développement, ainsi qu'en tant que porte-parole des victimes de guerres, de génocides ou de famines.

L'Ordre du Canada est l'un des honneurs civils les plus importants au pays. Il a été établi afin de souligner les réalisations exceptionnelles, le dévouement à la communauté et le service au pays de toute une vie.

08h30 **Accueil et introduction**
George Elleker

**Essais cliniques canadiens actifs à l'heure actuelle
Salle 200C 09h30-09h45**

- 09h30 **Phase III de l'essai contrôlé randomisé de la minocycline dans les cas de SEP précoce soupçonnée (syndromes isolés cliniquement)**
Luanne Metz (Calgary, Alberta)
- 09h37 **Antagonistes de l'endothéline dans les cas d'hémorragie sous-arachnoïdienne : essais cliniques randomisés CONSCIOUS 2 et 3**
Loch Macdonald (Toronto, Ontario)

Pause/Visite de l'exposition
Salle 200AB 09h45-10h15

C'est votre dernière occasion de visiter la salle des exposants et de montrer aux entreprises qui soutiennent notre secteur d'activité que leur présence continue et leur soutien financier du Congrès ont une grande importance pour vous! Que vous ayez eu ou non l'occasion de leur rendre visite, venez dire à nos commanditaires et à nos exposants à quel point vous appréciez leur contribution à votre congrès.

Signera des livres James Orbinski
Salle 200AB 09h45-10h15

*Après sa conférence, le docteur Orbinski signera son livre intitulé *An Imperfect Offering: Humanitarian Action in the Twenty-first Century*, dans la salle d'exposition. Vous pourrez acheter des exemplaires de ce livre.*

Tables rondes
Salle 200C 10h15-12h00

Présidents: Philippe Major (Montreal, Québec), Martin Savard (Quebec, Québec),
Genevieve Milot (Quebec, Québec)

Objectifs: À la fin de cette séance, les participants :

1. Auront discuté d'études de cas difficiles dans les domaines de la neurologie générale, de la neurochirurgie et de la neurologie pédiatrique.
2. Auront établi un diagnostic ou auront analysé des études de cas difficiles dans les domaines de la neurologie générale, de la neurochirurgie et de la neurologie pédiatrique.

Format d'apprentissage: Groupe de discussion, Étude de cas

Présentateur de Cas SCN - Nicolas Chrestian

Docteur, veuillez modérer votre diagnostic psychiatrique

Présentateur de Cas SCNCH - À CONFIRMER

À CONFIRMER

Présentateur de Cas ACNP

Vol au-dessus d'un nid de coucou

Dîner/Visite de l'exposition/Mini-plateformes numériques
Salle 200AB 12h00-13h30

Un déjeuner-buffet sera offert dans la salle des exposants

Cours de neuroophtalmologie Salle 202 13h30-17h00

Président: William Fletcher

Sommaire de cours: Le cours de neuroophtalmologie 2010 portera sur les problèmes cliniques communs relevant du domaine du neurologue mais qui posent souvent des difficultés sur le plan du diagnostic. Ce cours abordera 5 sujets : l'interprétation des champs visuels, l'ischémie de la rétine et du nerf optique, l'hypertension intracrânienne idiopathique, les maladies de l'orbite et les troubles des mouvements oculaires supranucléaires. Une période de discussion d'une demi-heure à la fin de la séance sera complétée par une présentation de cas intéressants.

Objectifs: À la fin de cette séance, les participants sauront :

1. Interpréter les défauts du champ visuel causés par les maladies neurologiques.
2. Diagnostiquer l'ischémie de la rétine et du nerf optique et la maladie de Horton.
3. Reconnaître et traiter l'hypertension intracrânienne idiopathique.
4. Effectuer des recherches et diagnostiquer des atteintes orbitales présentées au neurologue.
5. Analyser et localiser les troubles des mouvements oculaires supranucléaires.

Public visé: Neurologues généralistes, résidents en neurologie et autres neurologues qui souhaitent augmenter leurs connaissances et leurs compétences en matière de neuroophtalmologie.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>William Fletcher (Calgary, Alberta)</i>
13h35	Les champs visuels pour le neurologue <i>Jason Barton (Vancouver, Colombie-Britannique)</i>
14h00	Discussion
14h05	Hypertension intracrânienne idiopathique <i>Deborah Friedman (Rochester, État de New York, États-Unis)</i>
14h30	Discussion
14h35	L'ischémie oculaire pour le neurologue <i>Edward Atkins (Saskatoon, Saskatchewan)</i>
15h00	Discussion
15h05	Pause
15h20	Les maladies orbitales pour le neurologue <i>Francois Evoy (Sherbrooke, Québec)</i>
15h45	Discussion
15h50	Troubles des mouvements oculaires supranucléaires <i>William Fletcher (Calgary, Alberta)</i>
16h20	Discussion du groupe d'experts et présentations de cas interactives
16h55	Évaluations

Cours de neuroradiologie interventionnelle – Anévrismes difficiles
Salle 201B 13h30-17h00

- Président:** Alain Weill
- Sommaire de cours:** Fournir une mise à jour sur le diagnostic et le traitement endovasculaire des anévrismes complexes et difficiles.
- Objectifs:** À la fin de cette séance, les participants sauront :
1. Définir les anévrismes ayant la forme d'une phlyctène, les diagnostiquer et discuter d'un plan de traitement.
 2. Choisir la meilleure méthode d'imagerie pour diagnostiquer les anévrismes récurrents et discuter de leur traitement.
 3. Discuter des modalités de traitement des anévrismes géants.
 4. Gérer les anticoagulants, les antiagrégants et les agents thrombolytiques dans les cas d'hémorragie.
 5. Critiquer la nouvelle technologie d'endoprothèse de détournement.
- Public visé:** Neuroradiologues, neurochirurgiens vasculaires, neuroradiologues interventionnels et neurologues spécialisés en accidents vasculaires cérébraux qui s'intéressent aux anévrismes.
- Format d'apprentissage:** Séminaire, Groupe de discussion

- 13h30 Introduction
Alain Weill (Montréal, Québec)
- 13h45 **Anévrismes ayant la forme d'une phlyctène : définition, diagnostic et traitement**
Gary Redekop (Vancouver, Colombie-Britannique)
- 14h05 Discussion
- 14h20 **Anévrismes récurrents : diagnostic et traitement**
Robert Willinsky (Toronto, Ontario)
- 14h40 Discussion
- 14h55 **Anévrismes géants : traitements et résultats**
Danna Iancu Gontard (Winnipeg, Ontario)
- 15h30 Pause
- 15h45 **Endoprothèse de détournement : limites et comportement**
Cian O'Kelly (Edmonton, Alberta)
- 16h05 Discussion
- 16h20 **Gestion des anticoagulants, des antiagrégants et des agents thrombolytiques dans les cas difficiles**
Geneviève Milot (Québec, Québec)
- 16h40 Discussion et évaluations

Cours sur les nouveautés en matière de neurochirurgie Salle 203 13h30-17h00

Président: Pascale Lavoie

Sommaire de cours: Ce cours fournira les dernières nouvelles, y compris les nouvelles recommandations cliniques concernant différentes pathologies relevant de la neurochirurgie. Les conférenciers discuteront des dernières preuves scientifiques concernant l'implantation d'endoprothèse vasculaire dans l'artère carotide et la maîtrise des lésions à la moelle épinière, les indications et l'efficacité de la vertébroplastie, les dernières avancées en neuro-oncologie et la maîtrise endoscopique des lésions de la base antérieure du crâne et des structures supra-sellaires.

Objectifs: À la fin de cette séance, les participants :

1. Reconnaîtront les indications concernant l'implantation d'endoprothèse vasculaire dans l'artère carotide.
2. Discuteront de l'efficacité de la vertébroplastie.
3. Seront au courant des nouvelles observations concernant la maîtrise des lésions de la moelle épinière.
4. Seront au courant des dernières avancées en neuro-oncologie.
5. Décriront les indications et les limites de l'approche endonasale endoscopique élargie dans les cas de lésions de la base antérieure du crâne et des structures supra-sellaires.

Public visé: Neurochirurgiens généralistes et résidents en neurochirurgie.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>Pascale Lavoie (Québec, Québec)</i>
13h45	Quoi de neuf en matière de chirurgie de la colonne vertébrale? <i>R. John Hurlbert (Calgary, Alberta)</i>
14h05	Discussion
14h20	Implantation d'endoprothèse vasculaire dans l'artère carotide : les nouvelles preuves <i>Genevieve Milot (Québec, Québec)</i>
14h40	Discussion
14h55	Quoi de neuf en neuro-oncologie? <i>David Macdonald (London, Ontario)</i>
15h15	Discussion
15h30	Pause
15h45	L'approche endonasale endoscopique élargie dans les cas de lésions de la base antérieure du crâne et des structures suprasellaires : indications et limites <i>Fred Gentili (Toronto, Ontario)</i>
16h05	Discussion
16h20	Quoi de neuf en chirurgie de l'épilepsie? <i>Walter Hader (Calgary, Alberta)</i>
16h40	Discussion
16h55	Évaluations

Cours sur les soins de neurologie intensifs Salle 204B 13h30-17h00

Présidents: Jeanne Teitelbaum, Draga Jichici

Sommaire de cours: Grâce à l'utilisation d'observations médicales, les participants obtiendront des informations sur le recours aux tests accessoires en cas de mort cérébrale, du recours approprié à l'hypothermie induite pour différents problèmes neurologiques, sur les manières d'établir un pronostic des résultats après un arrêt cardiaque, comprendront les dernières recommandations en matière de traitement des hémorragies intracrâniennes et des hémorragies sous-arachnoïdiennes, comprendront mieux la surveillance par EEG dans l'unité de soins intensifs et en apprendront davantage sur de nouvelles techniques expérimentales.

Objectifs: À la fin de cette séance, les participants :

1. Auront des informations sur les tests accessoires acceptables à l'heure actuelle utilisés pour la détermination neurologique de la mort cérébrale.
2. Connaîtront les indications, la technique, les complications et les limitations de l'hypothermie induite pour plusieurs troubles neurologiques.
3. Auront des informations sur les observations sur lesquelles sont fondées les recommandations actuelles concernant le pronostic après un arrêt cardiaque.
4. Seront au fait des dernières recommandations concernant le traitement des hémorragies intracrâniennes et des hémorragies sous-arachnoïdiennes, ainsi que les limitations de ces recommandations.
5. Sauront quand et comment appliquer une surveillance continue par EEG dans l'unité de soins intensifs.

Public visé: Neurologues, neurochirurgiens, urgentologues et spécialistes des soins intensifs, ainsi que les résidents dans ces domaines.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>Draga Jichici (Hamilton, Ontario)</i>
13h45	Tests auxiliaires liés à la mort cérébrale <i>Martin Savard (Québec, Québec)</i>
14h05	Discussion
14h20	L'hypothermie induite : quand et comment y avoir recours <i>Draga Jichici (Hamilton, Ontario)</i>
14h40	Discussion
14h55	Pronostic après un arrêt cardiaque <i>G. Bryan Young (London, Ontario)</i>
15h15	Discussion
15h30	Pause
15h45	Les nouveautés en matière d'hémorragies intracrâniennes et d'hémorragies sous-arachnoïdiennes <i>Jeanne Teitelbaum (Montréal, Québec)</i>
16h05	Discussion
16h20	Surveillance continue par EEG dans l'unité de soins intensifs <i>Cecil Hahn (Toronto, Ontario)</i>
16h40	Discussion
16h55	Évaluations

Cours sur la maladie neuromusculaire Salle 204A 13h30-17h00

Présidents: Annie Dionne, Christopher White

Sommaire de cours: Le cours sur la maladie neuromusculaire fournira des mises à jour dans plusieurs domaines. Les conférenciers invités passeront en revue les nouveautés en matière de chirurgie des nerfs périphériques, discuteront des controverses dans le domaine des syndromes canaux, réévalueront les myopathies héréditaires et discuteront des études sur la maladie neuromusculaire pertinentes sur le plan clinique ayant été effectuées l'an passé.

Objectifs: À la fin de cette séance, les participants sauront :

1. Reconnaître les patients le plus susceptibles de bénéficier de chirurgie des nerfs périphériques et expliquer ces bienfaits.
2. Développer une approche des patients qui ont été aiguillés avec des syndromes canaux potentiels rares ou controversés impliquant les nerfs périphériques.
3. Discuter des résultats récents publiés dans les rapports de recherche concernant les patients atteints de maladie neuromusculaire, et les utiliser.
4. Évaluer convenablement les patients atteints de myopathies héréditaires.

Public visé: Neurologues, neurochirurgiens, résidents et spécialistes en électromyographie.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>Christopher White (Calgary, AB), Annie Dionne (Montréal, Québec)</i>
13h35	Nouveautés intéressantes dans le domaine de la chirurgie des nerfs périphériques <i>Rajiv Midha (Calgary, Alberta)</i>
14h05	Discussion
14h15	Syndromes canaux controversés <i>John Stewart (Vancouver, Colombie-Britannique)</i>
14h45	Discussion
14h55	Discussion du groupe d'experts <i>Rajiv Midha (Calgary, Alberta), John Stewart (Vancouver, Colombie-Britannique)</i>
15h10	Pause
15h30	Les myopathies héréditaires : les anciennes connaissances revues <i>Sandrine Larue (Montréal, Québec)</i>
16h00	Discussion
16h15	Nouveautés concernant la maladie neuromusculaire – l'actualité <i>Timothy Benstead (Halifax, Nouvelle-Écosse)</i>
16h45	Discussion et évaluations

**Cours sur la colonne vertébrale – Controverses dans le domaine
de la neurochirurgie de la colonne vertébrale**
Salle 201C 13h30-17h00

*Cette activité éducative bénéficie du soutien généreux de J et J / Depuy Spine / Synthes qui n'a pas participé au choix
des conférenciers, du programme ou du contenu de l'activité.*

- Président:** Eric Massicotte
- Sommaire de cours:** Trois sujets spécifiques feront l'objet d'un débat afin de faciliter les discussions : le cancer métastatique de la colonne vertébrale, les indications en faveur de la décompression et de la stabilisation, le rôle de la fusion instrumentée des cas de spondylolisthésis, et les indicateurs en faveur de l'utilisation d'agents biologiques.
- Objectifs:** À la fin de cette séance, les participants :
1. Pourront discuter des indications en faveur d'une intervention chirurgicale pour le cancer métastatique de la colonne vertébrale.
 2. Apprécieront les avantages du choix du moment pour ces interventions.
 3. Discuteront du recours aux techniques de fusion instrumentées pour la décompression de la colonne lombaire dans les cas de spondylolisthésis.
 4. Discuteront des options en matière d'agents biologiques à la disposition des patients.
- Public visé:** Tous les professionnels de la santé spécialisés en neurosciences.
- Format d'apprentissage:** Groupe de discussion, Études de cas

- | | |
|-------|--|
| 13h30 | Introduction
<i>Eric Massicotte (Toronto, Ontario)</i> |
| 13h35 | Présentation de cas n° 1
<i>Eric Massicotte (Toronto, Ontario)</i> |
| 13h45 | Option de traitement n° 1
<i>Brad Jacobs (Calgary, Alberta)</i> |
| 14h00 | Option de traitement n° 2
<i>David Mercier (Québec, Québec)</i> |
| 14h15 | Discussion |
| 14h40 | Présentation de cas n° 2
<i>Eric Massicotte (Toronto, Ontario)</i> |
| 14h55 | Option de traitement n° 1
<i>Ramesh Sahjpaul (Vancouver, Colombie-Britannique)</i> |
| 15h10 | Option de traitement n° 2
<i>Sean Christie (Halifax, Nouvelle-Écosse)</i> |
| 15h25 | Discussion |
| 15h50 | Présentation de cas n° 3
<i>Eric Massicotte (Toronto, Ontario)</i> |
| 16h05 | Option de traitement n° 1
<i>Ramesh Sahjpall (Vancouver, Colombie-Britannique)</i> |
| 16h20 | Option de traitement n° 2
<i>Eric Massicotte (Toronto, Ontario)</i> |
| 16h35 | Discussion |
| 16h45 | Conclusion du débat et évaluations |

Les nouveautés en neurologie Salle 200C 13h30-17h00

Président: Nicolas Dupré

Sommaire de cours: Ce cours se penchera sur les nouvelles découvertes et les thérapies prometteuses dans le domaine des lésions des nerfs périphériques, des myopathies héréditaires et des maladies neurodégénératives tels que la SLA, les démences frontotemporales, les ataxies héréditaires et les paraparésies spastiques.

Objectifs: À la fin de cette séance, les participants :

1. Pourront amorcer les examens menant au diagnostic d'un patient qui présente une ataxie progressive ou une paraparésie spastique, en fonction des dernières percées sur le plan génétique.
2. Pourront intégrer les connaissances récentes en biologie et en génétique à sa compréhension des démences frontotemporales.
3. Reconnaîtront la façon dont les études actuelles sur la SLA auront une influence sur sa pratique clinique.
4. Comprendront où les études récentes sur les myopathies héréditaires ont permis une meilleure classification de ces entités, et dans quelle mesure les protocoles de recherche actuels seront intégrés à la pratique clinique.
5. Reconnaîtront les patients les plus susceptibles de bénéficier des procédures de réparation des nerfs et comprendront en quoi les dernières découvertes permettent d'améliorer les approches techniques.

Public visé: Neurologues qui s'intéressent à la démence, à la SLA, aux troubles neuromusculaires, à l'EMG, à la neurogénétique et aux maladies neurodégénératives; neuropathologistes; neurochirurgiens qui s'intéressent aux traumatismes et aux lésions des nerfs.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>Nicolas Dupré (Québec, Québec)</i>
13h45	Les nouveautés en neurogénétique <i>Nicolas Dupré (Québec, Québec)</i>
14h05	Discussion
14h20	Les nouveautés en démence frontotemporale <i>Gabriel Leger (Montréal, Québec)</i>
14h40	Discussion
14h55	Les nouveautés sur la SLA <i>Jean-Pierre Julien (Québec, Québec)</i>
15h15	Discussion et pause
15h45	Les nouveautés sur les dystrophies musculaires <i>Jack Puymirat (Québec, Québec)</i>
16h05	Discussion
16h20	Les nouveautés sur la chirurgie et la réparation des nerfs périphériques <i>Line Jacques (Montréal, Québec)</i>
16h40	Discussion et évaluations

Cours sur l'EEG
Salle 205A 13h30-17h00

Président: Seyed Mirsattari

Sommaire de cours: Une analyse de la pathophysiologie, des caractéristiques des ondes et du traitement des anomalies épileptiformes de l'EEG courantes chez les enfants et chez les adultes, et des manières de les distinguer des ondes non épileptiques courantes d'origine métabolique, telles que les ondes trochaïques et les variantes épileptiformes bénignes.

Objectifs: À la fin de cette séance, les participants :

1. Comprendront la pathophysiologie des résultats d'EEG épileptiques courants tels que des pointes épileptiques interictales, des crises épileptiques partielles, des pointes et des ondes généralisées, des crises épileptiques généralisées, des décharges épileptiformes latérales périodiques, des pointes rolandiques et des pointes occipitales.
2. Se seront familiarisés avec la reconnaissance des structures d'anomalies épileptiques courantes, telles que les pointes épileptiques interictales, les crises épileptiques partielles, des pointes et des ondes généralisées, des crises épileptiques généralisées, des décharges épileptiformes latérales périodiques (DELP), des DELP plus, des pointes rolandiques et occipitales bénignes ou malignes, plus des ondes triphasiques et des variantes épileptiformes bénignes.
3. Se seront familiarisés avec l'importance clinique et le traitement des ondes susmentionnées.

Public visé: Résidents en neurologie et en neurochirurgie, neurologues praticiens, technologues en EEG, moniteurs en épilepsie et infirmières du SCN.

Format d'apprentissage: Séminaire, Groupe de discussion

13h30	Introduction <i>Seyed Mirsattari (London, Ontario)</i>
13h45	Pointes épileptiques interictales et crises épileptiques partielles <i>Richard Desbiens (Québec, Québec)</i>
14h05	Discussion
14h20	Ondes triphasiques, ondes et pointes généralisées et crises épileptiques généralisées <i>Charles Deacon (Sherbrooke, Québec)</i>
14h40	Discussion
14h55	Décharges épileptiformes latérales périodiques (DELP) et DELP plus <i>Paolo Federico (Calgary, Alberta)</i>
15h15	Discussion et pause
15h45	Pointes rolandiques et occipitales bénignes et malignes <i>Mary Connolly (Vancouver, Colombie-Britannique)</i>
16h20	Variantes épileptiformes bénignes <i>Seyed Mirsattari (London, Ontario)</i>
16h40	Discussion et évaluations



Don't Forget to Complete the Overall Congress Evaluation Form

The CNSF maintains its 'certification' from the Royal College of Physicians and Surgeons of Canada in part by reviewing our members' perceived and unperceived learning needs. The Overall Congress Evaluation is a vital component of this process and will be used to further develop and enhance all CNSF educational activities, including our Annual Congress.

A summary of the results will be posted on the CNSF's website, www.cnsfederation.org by October 2010. For comments on this survey, please contact Lisa at the CNSF Secretariat office: lisa-bicek@cnsfederation.org. Deadline for completion and submission is July 2, 2010.

Thank you. Your input is vital. - "Certificates of Attendance" will be issued in July upon completion of the online evaluation or return of the hard copy, faxed to 403.229.1661.


N'oubliez pas de remplir le formulaire d'évaluation globale du congrès

La FSNC conserve sa « certification » du Collège royal des médecins et chirurgiens du Canada en partie grâce à l'étude des besoins en matière d'apprentissage perçus et non perçus par nos membres. L'évaluation globale du congrès constitue un élément essentiel de ce processus et servira à développer et améliorer davantage toutes les activités éducatives de la FSNC, y compris notre congrès annuel.

Un résumé des résultats sera publié sur le site Web de la FSNC, à l'adresse www.cnsfederation.org, d'ici le mois d'octobre 2010. Pour faire des commentaires sur ce sondage, veuillez communiquer avec Lisa, au bureau du secrétariat de la FSNC, à l'adresse : lisa-bicek@cnsfederation.org. La date limite pour répondre au sondage et nous le faire parvenir est le 2 juillet 2010.

Merci. Vos commentaires sont essentiels. – Des « certificats de participation » seront émis en juillet à ceux qui auront rempli le formulaire d'évaluation en ligne ou qui nous auront fait parvenir la copie imprimée par télécopieur au 403-229-1661.

Canadian Neurosurgical Society Lifetime Achievement Award Charles H. Tator



Dr. Tator is a professor in the Department of Surgery, at the University of Toronto, and a neurosurgeon at the Toronto Western Hospital. After graduating from the Faculty of Medicine at the University of Toronto in 1961, he trained in research in neuropathology at the University of Toronto and received an MA in 1963 and a PHD in 1965. He completed the Neurosurgery resident training program at the University of Toronto in 1969. He has been Chair of Neurosurgery at the University of Toronto and the Chief of Neurosurgery at Sunnybrook and the Toronto Western Hospitals. He started the first Acute Spinal Cord Injury (SCI) unit in Canada in 1974, and studied the epidemiology, prevention and treatment of acute SCI. He examined the role of surgery and acute spinal cord decompression in clinical and experimental studies. His laboratory research has been aimed at determining the pathophysiology of SCI, especially mechanisms of secondary injury including posttraumatic ischemia. His acute cord clip compression model was the first SCI model in rodents. His current laboratory focus is on stem cell research for regeneration after spinal cord injury.

He has held two research chairs at the University of Toronto, the Dan Family Chair in Neurosurgery and the Campeau Family-Charles Tator Chair in Brain and Spinal Cord Research. In 2000, he received the Order of Canada.

In 1985-86, he was President of the Canadian Neurosurgical Society, and from 2002-2007 he was Chair of the Canadian Brain and Nerve Health Coalition. In 1992, he founded ThinkFirst, Canada, a national brain and spinal cord injury foundation whose mission is to reduce the incidence of catastrophic injuries in Canada. He was President of ThinkFirst from 1992-2007. ThinkFirst is a leader in the promotion of safety for Canada's children and youth and has developed and disseminated targeted injury prevention programs in schools and in sports and recreation.

Dr. Tator, a pioneer "surgeon-scientist", has inspired a generation of neurosurgeons to follow suit, combining the practice of neurosurgery with the pursuit of high quality scientific research into neurosurgical conditions we struggle with daily in the clinic. In Dr Tator's name, the Charles H. Tator Surgeon: Scientist Mentoring Award has recently been established at the University of Toronto.



An investment in research is an investment in hope.

Roche is a leader in the research and development of pharmaceutical and diagnostic solutions that look beyond today's horizons and make a profound difference in people's lives.

Working in partnership with healthcare practitioners from across the country, we have opened the door to countless new possibilities in the discovery, treatment and management of acute and long-term disease.



www.roclicanada.com



We Innovate Healthcare

OUTSMARTING MIGRAINE DÉJOUÉE



CLINICAL CROSSFIRE: EVIDENCE-BASED OPINIONS ON IMPORTANT QUESTIONS RELATED TO MIGRAINE.

CO-DEVELOPED SYMPOSIUM
WEDNESDAY, JUNE 9TH, 2010 • 6:30-8:00 A.M.

PROGRAM CHAIR

WERNER BECKER, MD, FRCPC

PROFESSOR FOR THE DEPARTMENTS OF CLINICAL NEUROSCIENCES AND MEDICINE
DIRECTOR CHAMP PROGRAM, FACULTY OF MEDICINE, UNIVERSITY OF CALGARY

PROGRAM SPEAKERS

SUZANNE CHRISTIE, MD, FRCPC

JACQUES DE LÉAN, MD, FRCPC(C), NEUROLOGIST, M.SC. (NEUROBIOLOGY)
ABEM (AMERICAN BOARD OF ELECTRODIAGNOSTIC MEDICINE)

MAREK GAWEL, M.B.B.CH., MA, MRCP, FRCP

GORDON MACKIE, MD, FRCPC

Migraine diagnosis and management remain a challenge for health care professionals, thus the importance of understanding pathophysiologic factors implicated in migraine attacks. Once the diagnosis is made, health care professionals are then faced with multiple considerations when selecting appropriate and optimal therapy for their patients.

Experts will provide you with their interpretation of the most up-to-date, evidence-based data on important clinical questions related to migraine:

SHOULD TRIPTANS BE FIRST LINE TREATMENT FOR MIGRAINE ATTACKS?

DOES CORTICAL SPREADING DEPRESSION OR A RELATED PHENOMENON INITIATE ALL MIGRAINE ATTACKS?

Please join us, Wednesday, June 9th, 2010 from 6:30-8:00 a.m.
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification activity of the Royal College of Physicians and Surgeons of Canada, and approved by Canadian Neurological Society. This activity is accredited for 1.5 MOC hours.

DÉBAT CLINIQUE : OPINIONS FONDÉES SUR LES PREUVES TOUCHANT DES QUESTIONS IMPORTANTES RELIÉES À LA MIGRAINE.

ACTIVITÉ DE DÉVELOPPEMENT PROFESSIONNEL CONTINU CO-PARRAINÉE
MERCREDI, 9 JUIN 2010 • 6 H 30 – 8 H.

PRÉSIDENT

WERNER BECKER, M.D., FRCPC

PROFESSEUR DÉPARTEMENTS NEUROSCIENCES CLINIQUES ET MÉDECINE
DIRECTEUR PROGRAMME CHAMP, FACULTÉ DE MÉDECINE, UNIVERSITÉ DE CALGARY

CONFÉRENCIERS

SUZANNE CHRISTIE, M.D., FRCPC

JACQUES DE LÉAN, M.D., FRCPC(C), NEUROLOGUE, M.SC. (NEUROBIOLOGIE)
ABEM (AMERICAN BOARD OF ELECTRODIAGNOSTIC MEDICINE)

MAREK GAWEL, M.B.B.CH., MA, MRCP, FRCP

GORDON MACKIE, M.D., FRCPC

Le diagnostic et la prise en charge de la migraine sont un défi pour les professionnels de la santé, d'où l'importance de bien comprendre les facteurs physiopathologiques intervenant dans les crises migraineuses. Une fois le diagnostic posé, les professionnels de la santé doivent considérer un ensemble de facteurs quand vient le moment de choisir l'option thérapeutique optimale pour leurs patients.

Les experts donneront leur avis sur les données probantes les plus à jour touchant des questions importantes reliées à la migraine :

DOIT-ON ADMINISTRER LES TRIPTANS EN PREMIÈRE INTENTION DANS LES CRISES DE MIGRAINE ?

LA DÉPRESSION CORTICALE PROPAGÉE, OU UN PHÉNOMÈNE DU MÊME TYPE, EST-ELLE À L'ORIGINE DE TOUTES LES CRISES MIGRAINEUSES?

Venez assister le : mercredi 9 juin 2010, de 6 h 30 à 8 h.

Cet événement fait partie des activités de DPC collectives agréées (Section 1) telles qu'approuvées par le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada ainsi que la Société canadienne de neurologie. Cette activité donne droit à 1,5 heure de participation au MDC.

This event is co-developed by The Canadian Neurological Society and Merck. / Cette activité a été élaborée conjointement par la Société canadienne de neurologie et Merck.

